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AC   adenylyl cyclase 
ACD  acid, citrate, dextrose 
ADP  adenosine diphosphate 
ATP  adenosine triphosphate 
BAPTA- 1,2-bis (2-aminophenoxy) 
 AM  Ethane-N,N,N,N-tetraacetic 
acid-acetoxymethylester 
BSA  bovine serum albumin 
[Ca2+]i  intracellular Ca2+ concentration 
CaM  calmodulin 
CaMK calcium/calmodulin-dependent kinase 
cAMP  cyclic adenosine monophosphate 
CREB cAMP responsine element binding 
protein 
C-terminus carboxy-terminus 
DMSO  dimethylsulfoxide 
EGTA [ethylenebis(oxyethylenenitrilo)]-
tetraacetic acid 
Epac exchange protein directly activated by 
cAMP 
ERK  extracellular signal-regulated kinase 
DAG  diacylglycerol 
GAP  GTPase-activating protein 
GDP  guanosine diphosphate 
GDS guanine nucleotide dissociation 
stimulator 
GEF  guanine nucleotide exchange factor 
GPCR  G-protein-coupled receptor 
GP   glycoprotein 
GRF  guanine nucleotide releasing factor 
GRP  GRF-related protein 
GST  glutathion S-transferase 
GTP  guanosine triphosphate 
HA   haemagglutinin 
HEPES N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid 
ICAM-1  intercellular adhesion molecule-1 
IP3   inositol 1,4,5-trisphosphate 
IP4BP inositol 1,3,4,5-tetrakisphosphate 
binding protein 
JAK  Janus kinase 
kDa   kilo Dalton 
LDL  low density lipoprotein 
LFA-1  leukocyte function-associated 
molecule-1 
mantGDP 2,3-bis(O)-N-methylantharanoloyl 
guanosine diphosphate 
MAPK  mitogen activated protein kinase 
mSOS  mammalian Son of Sevenless 
N-terminus amino-terminus 
OCS  open canalicular system 
PAF  platelet activating factor 
PAR  protease activated receptor 
PDGF  platelet-derived growth factor 
PGE2  prostaglandin E2 
PGI2  prostaglandin I2 
PH   pleckstrin homology 
PI(3)K  phosphatidylinositol-3OH-kinase 
PIP2 phosphatidylinositol 3,4-diphosphate 
PKA  protein kinase A 
PKB/Akt protein kinase B 
PKC  protein kinase C 
PLA2  phospholipase A2 
PLC  phospholipase C 
PLD  phospholipase D 
P70 S6K p70 ribosomal S6 kinase 
PVDF  polyvinyl difluoride 
RalBP1  Ral-binding protein 1 
RalGPS RalGEFs with PH domain and SH3 
binding motif 
RBD  Ras-binding domain 
RIP   Ral interacting protein 
Rlf   RalGDS-like factor 
RTK  receptor tyrosine kinase 
scr   structurally conserved region 
SDS-PAGE sodium dodecyl sulfate-poly-acrylamide 
gelelectrophoresis 
SERCA sarco/endoplasmic reticulum Ca2+-
ATPase 
SH2   Src homology 2 
STAT signal transducers and activators of 
transcription 
TCR  T-cell receptor 
TK   thymidine kinase 
TPA 2-O-tetradecanoylphorbol-13-acetate 
TxA2  thromboxane A2 
VCAM-1 vascular cell adhesion molecule-1 
VLA-4  very late antigen 4 
vWF  von Willebrand factor 
wt   wild-type 
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I. Rap1 and Ral in signal transduction 
 
 
The Ras family: molecular switches in 
signalling cascades 
 
The Ras superfamily of monomeric GTPases 
Intercellular communication tightly controls 
the behaviour of each individual cell in a human 
being by means of signals like hormones, 
growth factors and cytokines. Cell surface 
receptors enable the cell to monitor its 
environment for the presence of these signals, 
which function as ligands for the receptors. 
Ligand binding results in receptor activation. 
Activated receptors propagate the message to 
the interior side of the cell membrane and 
initiate activation of intracellular signal 
transduction pathways. The intracellular 
signalling machinery regulates cellular 
processes like growth, proliferation, 
differentiation and appropriate gene expression 
profiles. Overactivity or a functional block at 
the level of one of the signalling proteins is 
incompatible with the required tight regulation 
of these cascades. Several diseases are known to 
result from such molecular alterations that 
underly dysregulation of cellular processes, like 
for instance tumour formation or excessive 
bleeding disorders. A first requirement for 
development of therapeutic intervention 
strategies, is to understand the molecular details 
underlying the regulation and mechanisms in 
cellular signalling. Here, the focus will be on 
Ras family members in signal transduction. 
The superfamily of Ras-like small GTPases 
comprises proteins that are divided into 
subfamilies according to structure, sequence 
homology and function (1), Guidebook to the 
Small GTPases, edited by Marino Zerial and 
Lukas A. Huber, Oxford University Press). The 
Sar1/Arf and Rab families are both involved in 
membrane compartmentalisation and vesicular 
traffic (2,-6). The Ran proteins are used for 
transport of proteins and RNAs across nuclear 
pores, mitotic spindle assembly and nuclear 
envelope formation (7-9). The Rho proteins 
mediate organisation of the actin cytoskeleton 
(10,11). The function of the RGK family, 
named after the GTPases Rad and GEM/Kir 
(RGK), is largely unknown, although a 
connection between some of its members and 
the cytoskeleton has been proposed (12,13). The 
Ras family regulates cell proliferation and 
differentiation (14,15). In comparison with 
heterotrimeric G-proteins, the monomeric Ras-
like GTPases have a low molecular mass (20-35 
kDa) and therefore are also referred to as the 
small (or low molecular weight) GTPases.  
 
Ras family members: molecular characteristics 
The behaviour of Ras family members at the 
molecular level is described by the GTPase 
cycle. They either bind GDP or GTP, a 
characteristic that allows them to function as 
molecular binary switches. Conversion to the 
active, GTP-bound state is mediated by guanine 
nucleotide exchange factors (GEFs), which 
catalyse the release of GDP from the 
nucleotide-binding site of the GTPase. As soon 
as GDP is released, GTP enters the binding site, 
as the consequence of relatively high affinity of 
Ras proteins for guanine nucleotides 
(dissociation constant = 10-2 pM in case of Ras) 
in combination with the 10-fold excess of GTP 
(1-10 mM) over GDP in the cytoplasm (16). 
GTP binding induces a conformational change 
after which the effector-binding domain is 
exposed, allowing the GTPase to associate with 
downstream target proteins and generate 
signalling cascades (17-22). Each Ras-like 
protein is supplied with an intrinsic GTP 
hydrolysing activity. The rate at which different 
GTPases hydrolyse bound GTP varies, but is in 
most cases incompatible with the rapid changes 
that are required for proper signalling. However, 
the hydrolysing activity can be strongly 
enhanced by GTPase-activating proteins 
(GAPs) (23), which are able to bind to the 
GTPase and thereby stabilise the GTP-GDP 
transition state (24). Reversion to the GDP-
bound state switches the GTPase off, abolishes 
effector binding and terminates signal 
transduction. Thus, GTPase activity represents 
the coordinated balance between the actions of 
GEFs and GAPs. 
Amino acid changes at positions at or near 
sites of contact with the β- and γ-phosphates of 
the guanine nucleotide (residues 12, 13, 59, 61 
and 63 in H-Ras) lead to reduced intrinsic 
GTPase activity. Mutations that generate 
changes at sites of interaction with the guanine 
base (residues 116, 117 and 119 in H-Ras) 
decrease the affinity of the protein for  
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Figure 1. Ras, the small GTPase 
paradigm. 
Communication signals generated by the 
cell itself (autocrine), neighbouring cells 
(paracrine), or secreted by other cells in 
the blood stream (endocrine) arrive at the 
cell surface where they bind to and activate 
their corresponding receptors. An activated 
receptor transduces the signal to the inte-
rior side of the cell membrane in a recep-
tor-type-specific way, resulting in activation 
of a Ras guanine-nucleotide exchange fac-
tor (GEF). This either involves the second 
messengers calcium and diacylglycerol 
(DAG) or protein complex formation on 
phosphorylated tyrosine residues. An 
active RasGEF catalyses the release of 
GDP out of Ras, that is replaced by GTP. 
In the active, GTP-bound conformation 
Ras is able to interact with effector proteins 
initiating signalling along effector pathways 
and regulation of downstream cellular 
processes. 
 
nucleotides and increase the intrinsic exchange 
rate. These changes all result in a net increase in 
the GTP-bound, active form of the GTPase. 
Genetically, these mutants function as dominant 
active. In addition, mutations that block 
activation of the protein exist. These cause 
inability of the protein to change its 
conformation to the active form. Mutations that 
change residue 17 in H-Ras for instance result 
in a dominant negative version. This is thought 
to result from a constitutive association of the 
GTPase with the exchange factors. Over-
expression of dominant active or negative 
versions of GTPases has been widely used as 
approach to study small GTPases (25).  
The homology in the core effector region of 
the Ras family proteins (amino acids 32-44 in 
H-Ras) is striking and raises concern about 
target specificity. An interaction results from 
association between the GTPase effector 
domain and the Ras-binding domain (RBD) in 
the effector. RBDs share a ubiquitin-like fold 
(26-30). The presence of a number of positively 
charged residues in this tertiary protein structure 
determines successful interaction with the 
negatively charged effector-binding region of 
the small GTPases (31-35). Although Ras, Rap, 
R-Ras and TC21 can indeed bind the same 
effectors, the affinities are different (36-41). 
The amino acid residues flanking the effector 
region contribute to the electrostatic interaction 
between GTPase and effector (14,42). For 
example, changing the residues at position 30 
and 31 in Rap1 into E30D and K31E, similar to 
Ras, results in equal binding affinity between 
Rap1 and Ras for the RBD of RalGDS, one of 
the Ras effectors (34,43,44). In general, one 
GTPase has several effector proteins. 
Discrimination originates from differential 
utilisation of amino acids within the effector 
domain by target proteins. Mutations have been 
defined whereby certain connections are lost, 
while others are still functional (45). 
Small GTPases contain a membrane 
localisation domain at their carboxy (C)-
terminus. Posttranslational modification of the 
C-termini is essential for membrane localisation 
of the Ras proteins and thereby required for 
proper functioning. Moreover, the differences in 
the C-termini may give rise to differential 
membrane localisation and as a consequence 
contribute to effector specificity (reviewed in 
(15)). 
 
The Ras signalling pathway 
In different human tumours, activating 
mutations have been identified at high 
frequency in the founding superfamily member 
Ras (46). For that reason, Ras has received 
much attention and has become a paradigm for 
small GTPase signalling (Figure 1). 
Extracellular signalling molecules bind to their 
transmembrane receptors, which propagate the 
signals in different ways. Either directly or 
indirectly phosphotyrosine docking sites are 
created that serve complex formation between 
the adaptor protein Grb2 and the Ras-specific 
GEF mSOS. This causes mSOS relocalisation to 
Ras-like small GTPases in platelet biology 
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the plasma membrane where it can activate Ras 
(47). Alternatively, activated receptors generate 
the second messengers calcium and 
diacylglycerol (DAG) that regulate GEFs like 
RasGRFs (48) and RasGRPs (49). For Ras, both 
the exchange reaction and GTPase activation 
have been visualised in co-crystallisation 
studies of Ras with the catalytic domain of 
mSOS (16) and of Ras with the catalytic domain 
of p120 RasGAP (24). Ras activation, which is 
(or can experimentally) be mimicked by 
expression of activated Ras mutants (46,50,51), 
gives rise to a number of cellular effects. These 
can be classified as alterations in growth 
control, morphology and attachment, or gene 
expression (21,50,52). They all contribute to the 
oncogenic property of active Ras signalling. In 
part, the molecular mechanisms underlying 
these changes overlap. Members of the Raf 
family (Raf1, A-Raf and B-Raf), 
phosphatidylinositol-3-OH-kinase (PI(3)K) and 
RBD-containing RalGEFs (RalGDS, Rlf and 
Rgl) together with their signalling cascades 
have been established as genuine Ras 
downstream effectors pathways (53,54). 
Obviously, Ras plays an interesting and 
elaborate function in intracellular signal 
transduction. From this point of view, it is 
appealing to speculate on important 
contributions in cell regulation by the closest 
relatives of Ras, namely Ral and Rap proteins. 
 
 
Rap and Ral activity 
 
Rap1 proteins 
Several studies have contributed to the 
discovery and initial characterisation of the Rap 
(Ras-proximate) proteins (55-60). At protein 
level, Rap1A and Rap1B (henceforth also 
collectively referred to as Rap1) are 
approximately 95% identical (only 9 out of 184 
amino acids different), with the major 
difference at the C-terminus (6 amino acids). 
Rap1 shares about 50% overall homology with 
Ras. Strikingly however, their core effector 
regions are nearly identical (54). Rap1 is 
ubiquitously expressed and particularly 
abundant in platelets, neutrophils and brain (61). 
Both Rap1A and B are posttranslationally 
modified at their C-terminus by a 
geranylgeranyl moiety, which mediates 
membrane attachment of the proteins (62-64). 
Rap1 localises to intracellular membranes at the 
perinuclear region (Golgi compartment), 
endocytic and exocytic vesicles and to the 
plasma membrane in fibroblasts (65,66), to 
specific granules in neutrophils (67,68) and to 
secretory vesicles in parotid gland cells (69,70). 
The Rap2 proteins share about 70% homology 
with the Rap1 members at the amino acid level. 
An interesting difference between the two 
groups resides in the core effector domain (Bos 
98). Rap2A and B are 90% identical (18 amino 
acids different), with a predominant difference 
in the C-terminus (61,64,71). As a consequence, 
Rap2A is farnesylated, while Rap2B is 
geranylgeranylated (72-74). 
 
Activation of Rap1 
Rap1 has been implicated in signal 
transduction by the finding that cyclic adenosine 
monophosphate (cAMP) induces an increase in 
GTP-bound epitope-tagged Rap1 (75). So far, 
no antibody is able to immunoprecipitate 
endogenous Rap1. Therefore, activation of 
endogenous Rap1 could not be studied using the 
classical GDP/GTP quantification assay (25). 
This has led to the development of a GTPase 
pulldown assay to monitor activation of 
endogenous GTPases (76-78). Using this assay, 
Rap1 activation has been demonstrated upon 
treatment with a number of extracellular stimuli, 
depending on the cell type (54,79). Receptors 
propagating signals towards Rap1 include 
receptor tyrosine kinases (RTKs), heterotrimeric 
G-protein-coupled receptors (GPCRs; reviewed 
in (80)), immunoreceptors and cytokine 
receptors (76,81-83). Processes like cell 
adhesion, cell density and receptor 
internalisation also play a role in the activation 
mechanism (84,85). In a diversity of cell types, 
like for instance platelets, fibroblasts, 
neutrophils and B-cells, phospholipase C (PLC) 
and several second messengers appeared pivotal 
intermediates in Rap1 activation by 
extracellular ligands (75,76,79,81,82,86). This 
knowledge has sparked off a successful search 
for Rap1 activating factors that are differentially 
regulated by second messengers. 
 
GEFs and GAPs regulating Rap1 
A remarkable variety of GEFs and GAPs 
contribute to the regulation of the Rap1 GTPase 
cycle (79,87) (Figure 2). Among the GEFs, 
different families have recently been discovered  
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Figure 2. Regulation of the 
Rap1 GTPase cycle. 
Stimulus-induced receptor 
signalling may either elevate 
Rap1GTP by promoting the 
action of guanine-nucleotide 
exchange factors (GEFs) or 
by inhibiting (trapping) Rap1 
GTPase-activating proteins 
(RapGAPs). Rap1GEFs are 
controlled by different 
mechanisms in which either a 
second messenger or protein 
complex formation is in-
volved. (PTK: protein tyrosine 
kinases). 
 
 
 
and characterised, which members contain 
binding sites for the second messengers 
calcium, DAG and cAMP. Members of the 
Epac (exchange protein directly activated by 
cAMP, also referred to as cAMP-GEF) family 
contain a cAMP-binding motif that allows 
direct, allosteric activation of the GEF activity 
upon cAMP binding (88-90). Elevation of 
Rap1GTP by calcium and DAG can be 
explained by the action of members of the CD-
GEF (CalDAG-GEF; Cal stands for calcium) 
family, which contain putative calcium- and 
DAG-binding sites (91-94). However, 
consensus about the differential regulation of 
these GEFs by calcium and DAG remains to be 
established (79,87). Regulation of the PDZ-GEF 
family members has not yet been resolved (95-
97). The first RapGEF to be studied in detail 
was C3G (Crk SH3-domain-binding guanine-
nucleotide releasing factor; SH3 stands for Src 
homology region 3 domain). C3G mediates 
activation of Rap1 induced by a mechanism 
involving complex formation with the proto-
oncogene Crk and membrane localisation (98-
104). Since Crk adaptor proteins contain an SH2 
domain, tyrosine kinase-linked receptors are 
able to recruit Crk/C3G complexes by 
phosphorylating tyrosine residues on 
membrane-associated proteins like Cas, Cbl and 
Gab1 (104-108). This is thought to bring C3G 
in close vicinity of Rap proteins. In addition, 
tyrosine phosphorylation of C3G has been 
reported to be involved (109). Other proteins 
have been implicated as GEFs in Rap 
regulation, like Nsp2 (110), but these require 
further characterisation in order to establish 
bona fide RapGEF activity. Strikingly, while the 
RasN17 mutant tightly associates with 
RasGEFs, Rap1N17 does not bind to C3G 
(111). Therefore, RapN17 may not function as a 
dominant-negative mutant in Rap1 signalling in 
the way RasN17 does in the Ras pathway. 
The first family of GAPs for Rap proteins 
contains the members RapGAP I and the amino 
(N)-terminally extended version named 
RapGAP II (112,113). RapGAP II has been 
shown to associate with active Gαi -subunits, 
which results in membrane relocalisation and 
activation of the GAP (113). Rap1GAP can also 
bind Gαo- and Gαz (114,115). The interaction 
with Gαo inhibits GAP activity. Serine 
phosphorylation of RapGAP I by PKA or Cdc2 
has been described, which might allow complex 
formation with other proteins (116-118). A 
second family consists of signal-induced 
proliferation-associated gene 1 (Spa-1) and its 
close homologue E6TP1 (E6 targeted protein 1). 
These proteins are characterised by the presence 
of a PDZ domain (119). E6TP1 was identified 
as a target for degradation by the papilloma 
virus E6 oncoprotein. E6 expression results in 
tumour formation, which suggests a link 
between overactive Rap1 and cell 
transformation. However, the functionality of 
the presumed GAP domain needs to be proven. 
Additional putative RapGAP proteins include 
tuberin, which contains a GAP domain that may 
function towards both Rap1 (120) and Rab5 
(121). Deletions in the tuberin gene cause 
familial tuberous sclerosis, a disease 
characterised by the development of benign 
tumours (122-126). Finally, GAPIP4BP, which 
binds the second messenger inositol 1,3,4,5-
tetrakisphosphate, may function as RapGAP and 
RasGAP (127). 
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The Ral proteins 
The GTPases RalA and RalB are 85% 
identical and predominantly differ in their C-
terminus. They have 58% sequence identity 
with Ras (128-130). Ral and Ras have 
comparable nucleotide binding characteristics 
and low intrinsic GTPase activity (131). The 
Ral proteins are ubiquitously expressed but are 
particularly abundant in brain, testes and 
platelets (132-134). Ral is posttranslationally 
modified by geranylgeranylation (15,135). In 
subcellular localisation studies it has been found 
in plasma membrane (136), endocytotic vesicles 
(130), synaptic vesicles (137) and secretory 
vesicles (138). 
 
Ral activation mechanisms 
An interesting Ras protein connection arose 
when the first identified RalGEF, Ral gunanine 
dissociation stimulator (RalGDS, (139)) was 
found to interact with the GTP-bound form of 
Ras, R-Ras and Rap1 in a yeast two-hybrid 
screen (36,140). Subsequently, the RalGEFs 
RalGDS-like (RGL) and RalGDS-like factor 
were cloned and shown to possess similar 
structural and Ras-binding properties (141-143). 
Together with Rsc these GEFs form the 
RalGDS family of RalGEFs. Rsc is an 
oncoprotein that results from a fusion between 
the yeast Rad23 protein homologue and the C-
terminal region of the RalGEF designated Rgr 
(144). Members of this family are characterised 
by the presence of a Cdc25-like catalytic region 
and a C-terminal RBD. Rgr forms an exception, 
since it lacks this RBD region. While both 
RalGDS and Rlf are ubiquitously expressed 
(41,139), Rgl is predominantly present in brain, 
heart, lung kidney and testis, whereas Rgr is 
mainly present in lung and skin (142,145). The 
involvement of Ral in Ras signalling has been 
firmly established by in vivo proof (reviewed in 
(146)). Upon Ras activation, RalGDS proteins 
are recruited to the plasma membrane. 
Activation of these GEFs requires an intact 
plasma membrane localisation signal in Ras 
(143,147-149). In agreement, membrane 
targeting of RalGDS and Rlf renders them 
constitutively active (143,149).  
In addition, Ras-independent mechanisms 
participate in the regulation of Ral, as for 
instance in response to elevated levels of 
intracellular calcium (150-152) (Figure 3). 
Calcium may regulate Ral by inducing the  
 
 
Figure 3. Regulation of the Ral GTPase cycle. 
Ral activating mechanisms can be classified as Ras-
dependent and -independent. Stimuli that induce 
RasGTP lead to recruitment and activation of the 
RalGEFs containing a Ras-binding domain (RalGDS, Rlf 
and Rgl). Among the Ras-independent pathways are the 
RalGPS proteins, which may be regulated by protein or 
lipid interactions with their proline-rich and pleckstrin 
homology (PH) domains. In addition, a rise in 
intracellular calcium leads to Ras-independent Ral 
activation. This may result from direct association 
between calcium/calmodulin (CaM) and Ral, calcium-
induced Rap1 activation or regulation of RalGDS by 
means of a calcium/calmodulin-dependent kinase 
(CaMK). Additional pathways have been suggested in 
the control of Ral, but these are currently less well 
understood and for that reason not depicted.  
 
binding of calmodulin (CaM) to a CaM-binding 
domain in the C-terminus of RalA (153,154). 
Alternatively, an activated calcium/CaM-
dependent kinase might contribute by 
phosphorylating RalGDS and thereby activate 
the catalytic activity of the GEF (155). Since 
Rap1 is able to associate with the RalGDS 
family members, another explanation may be 
that Rap1 mediates the calcium-induced Ral 
activation. The family of RalGEFs with 
pleckstrin homology (PH) domain and SH3 
binding motif (RalGPS proteins), which consists 
of the splice variants 1A, 1B (also named 
RalGEF2, chapter 2) and 2, also functions 
independent of Ras. The activity of these 
members is regulated by the PH domain and a 
Grb2-binding PXXP motif ((156), chapter2).  
Chapter 1; General introduction 
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Figure 4. Rap1 downstream signalling 
effects. 
Upon activation, Rap1 is supposed to 
interact with effector proteins that 
contain a Ras-binding or Ras-
associating domain. Several candidates 
have been proposed by in vitro and 
over-expression systems, but the 
relevance of these interactions in vivo 
needs to be determined. However, 
requirement for Rap1 activity in a 
diversity of cellular processes has been 
reported, like transcription, 
differentiation, cell adhesion, cell 
polarity, migration and the regulation of 
the intracellular calcium concentration.  
 
Finally, evidence for the involvement of Src-
like kinases, PI(3)K and protein kinase C (PKC) 
has been generated (152) and in addition 
JAK/STAT3/RalGDS (157) and PI(3)K/PDK-1 
(PI 3,4,5-trisphosphate-dependent kinase-
1)/RalGDS (158) pathways have been 
described. Concerning the downregulation of 
RalGTP, different RalGAP proteins have been 
postulated but not cloned (159,160). Other 
RalGEF candidates have been found, namely 
Rab2L (161), And-34 (110), Rgl-2 (162) and 
Rgl-3 (also called RPM) (163), but their activity 
towards Ral needs further proof. 
 
 
Functions of Rap1 and Ral 
 
Rap1 and the Ras effectors 
Rap1 has been identified as the product of a 
gene that could revert oncogenic Ras-induced 
transformation of cells (60). As the core effector 
regions of Ras and Rap1 show striking 
similarity (87), the hypothesis was raised that 
Rap1GTP may interfere in Ras signalling by 
trapping Ras effector proteins out of sight from 
Ras. Indeed, Rap1 has been shown to bind the 
Ras effectors PI(3)K, Raf-B and RalGDS in 
vitro and in over-expression studies 
(36,39,81,143). Many studies have contributed 
to the amount of conflicting results on the 
function of Rap1 in the regulation of the MAPK 
pathway (79,87,164, JM Enserink, submitted). 
Furthermore, the proposed connection of Rap1 
by binding to RalGDS with the upstream 
regulation of the Ral GTPases (146), as has 
been discussed, remains intriguing. Moreover, 
Rap1 has been implicated in cAMP-induced, 
PI(3)K-mediated activation of protein kinase B 
(PKB/Akt) in thyroid cells, indicating that Rap1 
might in addition be able to regulate PI(3)K in 
vivo (165). However, whether these interactions 
between Rap1 and the Ras effectors occur 
between endogenous proteins in vivo remains to 
be determined. 
 
Rap1 in cell adhesion 
In search for a protein function, a 
commonly followed strategy is trying to find 
phenotypes caused by mutations in that protein 
in lower eukaryotes, which are used as genetic 
systems. Investigations in yeast, Dictyostelium 
discoideum and Drosophila melanogaster have 
implicated the Rap relatives in processes 
ranging from bud site selection to cell migration 
and morphogenesis (reviewed in (87)) (Figure 
4). For instance, distribution of adherens 
junctions around the lateral circumference of 
cells within an epithelium was reported to 
require Rap1 in Drosophila (166). In this study, 
cells mutant for Rap1 condensed their adherens 
junctions to one side of the cell, which disrupted 
normal epithelial cell behaviour. In addition, 
Rap1 was found enriched at adherens junctions, 
particularly between divided sister cells. Rap1 
may be linked to adherens junctions by its 
interaction with the multidomain cytoskeletal 
linker protein canoe, the Drosophila orthologue 
of AF-6 (166). This protein interacts with ZO-1 
(167), which in turn associates with the 
adherens junction component α-catenin (168). 
Interestingly, these findings suit with the 
recently discovered exciting link between Rap1 
and integrin-mediated cell adhesion. 
Integrins are heterodimeric cell surface 
receptors that are able to attach to extracellular 
matrix components or adhesion molecules on 
the surface of other cells (169-172). Upon a 
variety of signals, inactive integrins are 
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converted to an active state that has high affinity 
or avidity for ligand, thereby promoting 
attachment to extracellular matrix or other cells. 
One of the first indications for the involvement 
of Rap1 in this process came from the 
observations that over-expressing the RapGAP 
Spa-1 in HeLa cells impaired the attachment to 
fibronectin-coated plates and in 32D 
promyelocytic cells blocked granulocyte 
colony-stimulating factor (G-CSF) to induce 
adhesion to tissue culture dishes (173). In 
addition, dominant-negative C3G blocked 
hepatocyte growth factor (HGF)-induced 
activation of Rap1 and reattachment of 293 cells 
to tissue culture dishes (104). Strong arguments 
have been provided by research using 
haematopoietic cells. Transient over-expression 
of activate Rap1 induces αLβ1-integrin 
(leukocyte function-associated antigen 1; LFA-
1)-mediated cell adhesion in both human T cell 
and mouse pre-B cell leukaemia lines (174-
178). Similar results have been provided using a 
mouse model in which Rap1V12 is expressed in 
the T cell compartment (179). RapN17 
expression inhibited T-cell receptor (TCR)-
induced adhesion and CD31-induced adhesion 
could be blocked by overexpression of RapN17, 
RapGAP and RalGDS-RBD (174). Over-
expressing RapGAP II also decreased the ability 
of WEHI-231 B cells to form phorbol ester-
induced LFA-1-mediated homotypic adhesion 
interactions and decreases adhesion of A20 B 
cells to immobilised intercellular adhesion 
molecule-1 (ICAM-1) (79). Integrin regulation 
by Rap1 does not seem to be restricted to the 
LFA-1 integrin, as Rap1 is also crucial for 
CD31- and cytokine-induced haematopoietic 
cell adhesion depending on the α4β1-integrins 
very late antigen 4 (VLA-4) and VLA-5 
(174,177). The exact mechanism and Rap1 
effectors involved in the activation of integrin-
mediated cell adhesion remain elusive. 
However, inhibition of Rap1 function seems to 
confer a physical restraint on integrins, as 
induction of LFA-1-mediated cell adhesion by 
binding of Mn2+ to extracellular divalent cation-
binding sites or by integrin-activating antibodies 
(KIM185 and TS2/16) is also blocked by Rap1-
inhibitory proteins ((174), chapter 3). The Rap1 
family members R-Ras and H-Ras have also 
been implicated in the regulation of integrins 
(180,181). However, both the mechanisms of 
integrin regulation and the subset of integrins 
regulated may differ. Although RasN17 is also 
able to block TCR- and CD31-induced 
adhesion, CD31 stimulation does not induce 
Ras activation (174). H-Ras requires an intact 
cytoskeleton and is sensitive to inhibitors of 
MAPK, PI(3)K and PLC function, while none 
of these contribute to Rap1-induced adhesion 
(175,182,183). R-Ras can activate both the αmβ2 
integrin (Mac-1) (176) and LFA-1 (174), but not 
VLA-4 (174).  
 
Ral effectors and functions 
As the RalGDS proteins are targets of active 
Ras, it may not be surprising that Ral 
contributes to Ras-mediated cellular effects. 
Indeed, Ral has been demonstrated to function 
in Ras-dependent proliferation (reviewed in 
(145)). Constitutive active RalGEFs have been 
demonstrated to induce enhanced growth 
properties, low serum growth and even 
contribute to tumour invasion and metastasis 
(143,144,184,185). Other reported effects of 
active Ral include anchorage-independent 
growth (186), DNA synthesis (187), 
differentiation (188), inhibition of 
differentiation (189,190) and transcriptional 
regulation (143,191-196) (Figure 5). 
Up to now, several proteins have been 
described to associate with Ral. The first 
identified Ral effector was named Ral-binding 
protein 1 (RalBP1, also called RLIP76 or RIP1) 
(197-199). The interaction with RalBP1 links 
Ral to the small GTPases Rac and Cdc42, since 
RalBP1 harbours GAP activity towards these 
proteins (198). RalBP1 was found to form a 
complex with Pob1 (partner of RalBP1, (200) 
en Reps1 (201)). Ral, complexed with these 
proteins, has been implicated in binding to 
active epidermal growth factor (EGF) receptors 
and, through direct binding to Pob1, the 
recruitment of Epsin and Eps5. These proteins 
have been shown to function in the regulation of 
clathrin-mediated endocytosis of both EGF and 
transferrin receptors (202,203). By this 
mechanism, Ral has been implicated in the 
regulation of ligand-dependent receptor-
mediated endocytosis (204). Phospholipase D 
(PLD) has been described to associate with Ral 
by binding its N-terminus (134,205-207). This 
direct association is not dependent on the 
activation state of Ral and has no effect on PLD 
activity (134). However, Arf was also found to 
associate with the Ral-PLD complex and Arf is  
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Figure 5. Ral downstream signalling 
effects. 
Several proteins have been reported 
to interact with Ral and function as 
effectors. Other proteins have been 
demonstrated to function more 
downstream in Ral-regulated 
signalling pathways (AFX, c-jun). 
Based on these interactions 
supplemented with functional studies 
Ral has been implicated in cellular 
processes that vary from regulation of 
transcription, differentiation, proli-
feration or DNA synthesis, the control 
of the actin cytoskeleton, cell shape 
and migration, and finally events in 
vesicular transport. 
 
 
 
 
able to activate PLD (208,209). Both Arf and 
PLD are involved in vesicle formation and 
endocytosis (210), which again points to a role 
for Ral in the regulation of membrane transport. 
Further proof for this Ral function is provided 
by the recently described interaction between 
RalGTP and Sec5, a subunit of the human 
exocyst complex (211-213). This multi-protein 
complex has been implicated in polarised 
vesicular traffic (214-216) which indeed 
requires proper Ral activity (212). The Ral-Sec5 
interaction may also give rise to Ral-mediated 
filopodia formation (213). The actin filament 
crosslinking protein filamin, also called ABP-
280, has initially been identified to bind to Ral 
in a GTP-dependent fashion in platelets (217-
219). Interestingly, the dominant-negative 
version RalN28 was demonstrated to block 
Cdc42-induced filopodia formation (219). 
Participation of filamin as downstream target in 
the filopodia formation was shown by the 
finding that over-expression of the Ral-binding 
domain of filamin blocked RalA-induced 
filopodia formation in 3T3 cells. Moreover, Ral 
could not induce filopodia formation in filamin-
negative human melanoma cells (219). In 
addition to cross-linking actin filaments, filamin 
forms a docking site for various cell surface 
receptors and certain intracellular proteins 
involved in signal transduction and endocytosis 
(220,221). In conclusion, the Ral interacting 
proteins sofar identified implicate Ral in 
regulating vesicular transport as well as the 
cytoskeleton. Dual participation of several 
binding partners to these processes suggests a 
fine-tuning or integrating function for Ral. 
II. Rap1 and Ral in platelet biology 
 
 
Platelets  
 
Blood platelet as model system to study Rap1 
and Ral signalling 
Blood platelet forms an attractive model 
system to study signal transduction by small 
Ras-like GTPases. First of all, platelets show 
rapid and massive signalling in an all-or-nothing 
fashion. Furthermore, platelets enable one to 
focus on early events, as they lack replication 
and transcription regulation. The Rho family 
members RhoA, Rac1, Rac2 and Cdc42 and the 
Rab family members Rab1, -3B, -4, -6, -8 have 
been detected in platelets (130,222,223). These 
GTPases may contribute to the extensive 
reorganisation of the platelet cytoskeleton and 
the regulated secretion upon activation. In 
addition, platelets contain Ras and Ral proteins 
(130,133,224) and Rap1B expression is even 
particularly high, as it accounts for 0.1% of total 
cellular protein in platelets (62). Moreover, Rap 
and Ral are activated within seconds following 
stimulation with a variety of agonists 
(76,86,151,225-227) and have therefore 
obviously been implicated in the process of 
platelet activation as regulators of platelet 
responses. 
 
Platelet function 
Blood platelets are small, flat, disc-shaped 
and anucleated cell fragments that arise from 
megakaryocytes, a population of cells in the 
bone marrow (textbook: Platelets and their 
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factors, edited by F. von Bruchhausen and U. 
Walter, Springer Verlag Heidelberg). 
Megakaryocyte differentiation is accompanied 
by the appearance of an extensive membranous 
network in their cytoplasm, the demarcation 
membrane. At the time megakaryocytes are 
fully differentiated, cell fragments are shed off 
using this mass of membrane structures and 
enter the blood stream as platelets. They have a 
diameter of 2 to 4 µm and circulate at a number 
of 150,000-300,000 per µl. Platelets contain 
three types of secretory vesicles. The α-granules 
contain, amongst others, adhesive proteins (e.g. 
fibrinogen and von Willebrand Factor (vWF)), 
growth modulators (e.g. platelet-derived growth 
factor (PDGF)) and coagulation factors (e.g. 
factor V). Dense granules contain non-
metabolic ADP and ATP, calcium and 
serotonin. Lysosomal granules contain enzymes 
like cathepsin and β-galactosidase. Peroxisomes 
and mitochondria are also present. The open 
canalicular system (OCS) is formed by 
invaginations of the plasma membrane and 
functions as an export system for secretory 
products. The dense tubular system is thought to 
be a remnant of the megakaryocyte rough 
endoplasmatic reticulum and is the location for 
prostaglandin production and calcium storage. 
A platelet is present in the blood circulation for 
about 8-14 days. Old platelets are removed from 
the blood by the liver, spleen and bone marrow.  
In case injury occurs to a vessel wall, 
platelets get in touch with material present 
underneath the endothelial lining, as for 
instance vWF or collagen. As a consequence, 
platelet function is activated which leads to the 
formation of a haemostatic plug (228). Platelets 
respond robust and very fast. Their shape 
changes within seconds to a spherical 
appearance, which is next converted to an 
irregular, spinny outline with pseudopodia and 
lamellipodia stretching in all directions. 
Regulated secretion and paracrine signalling 
enhance and sustain the ongoing platelet 
response. In addition to the shape change, 
adhesive properties are concomitantly induced 
(229). As a consequence, platelets bind at the 
site of damage to adhesive proteins in the 
injured vessel wall, a platelet clot is built up and 
finally retraction turns the aggregated platelets 
into a wound seal. Hereby the platelets cover 
and close wounds after which bleeding stops 
(230). During this activation process, 
plasminogen activator inhibitor-1 (PAI-1) and 
thromboxane A2 (TxA2) are secreted to decrease 
fibrinolysis and to induce vasoconstriction, 
respectively. Under pathological conditions, 
platelets are involved in thrombosis and 
contribute to atherosclerosis: After adhesion, 
platelets release PDGF and transforming growth 
factor β (TGF-β), which induce proliferation 
and migration of smooth muscle cells. 
 
Platelet adhesion 
The platelet plasma membrane contains a 
diversity of glycoproteins (GPs) that, upon 
platelet activation function in cell-cell and cell-
matrix interactions (229). For instance, GP 
IIb/IIIa, the major platelet integrin αIIbβ3, is a 
calcium-dependent heterodimeric fibrinogen 
receptor (231). Also other ligands for this 
integrin have been reported (232). Glanzmann 
thrombasthenia patients suffer from a severe 
bleeding tendency due to the absence of 
functional αIIbβ3 integrin. In patients with 
Bernard-Soulier-syndrome, the adhesion 
receptor for von Willebrand Factor (vWF), the 
GP Ib-IX-V complex, a member of the leucine-
rich glycoprotein gene family (233,234), is non-
functional, expressed at low levels or even 
absent. 
Strong evidence suggests that platelets 
utilise a multi-step adhesion mechanism 
(235,236). The initial contact of platelets with 
the vessel wall (platelet adhesion) is a complex 
process involving multiple adhesive substrates 
(vWF, collagen, E-selectin) and receptors on the 
platelet surface (GP Ib-IX-V, integrin αIIbβ3 and 
α2β1 and P-selectin) (236,237). Initial platelet 
adhesion is critically dependent on the binding 
of the GP Ib-IX-V complex to immobilised 
vWF, especially under conditions of rapid blood 
flow and thus high shear stress. This receptor-
ligand interaction supports platelet translocation 
and tethering on the surface of endothelial cells 
and at sites of vascular injury (238-240). 
Furthermore, it forms a prerequisite step for 
subsequent integrin-mediated cell arrest, as it 
induces signal transduction leading to activation 
of the platelet and its integrin αIIbβ3 (235,241). 
Once this integrin is activated, it is able to bind 
to vWF through an RGD-containing sequence 
(242) and fibrinogen, resulting in irreversible 
platelet adhesion, spreading and thrombus 
growth (243). This multi-step adhesion 
mechanism may not only be important for 
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platelet-vessel wall interactions, but also for 
platelet aggregation, particularly under high 
shear rates. Platelet aggregation studies using a 
cone-plate viscometer, have demonstrated that 
exposing platelets in suspension to high levels 
of shear stress, induces platelet aggregation 
independent of the addition of an exogenous 
stimulus (reviewed in (238,244)). This shear-
induced platelet aggregation is initiated by the 
binding of soluble vWF to GP Ib-IX-V. This 
interaction not only tethers platelets to one 
another but also triggers platelet activation, 
converting integrin αIIbβ3 from a low- to a high-
affinity receptor which is capable of binding 
fluid-phase adhesive proteins such as soluble 
vWF or fibrinogen (243,245). While high shear 
stress-induced platelet aggregation occurs under 
pathological circumstances, normally occurring 
shear stress also contributes to platelet 
activation and adhesion under physiological 
circumstances (229,240,244). Studies using 
mice lacking vWF, fibrinogen or both have 
demonstrated the central role for vWF in 
promoting platelet-vessel wall and platelet-
platelet adhesive interactions during thrombus 
growth (246). However, the mechanism linking 
the vWF/GP Ib-IX-V interactions to activation 
of αIIbβ3, particularly under shear conditions, 
remains poorly understood. 
 
Platelet signal transduction 
Under resting conditions, platelets are kept 
dormant by inhibitors released from the 
endothelium. Upon vessel wall injury, several 
factors are released that stimulate platelet 
activation. The balance between inhibitory and 
activating signals is maintained by a tightly 
coordinated signal transduction system. This 
discussion on platelet signal transduction will be 
restricted to the major pathways. In general, 
those can be considered as either activating or 
inhibiting platelet function. 
Inhibitory platelet signals generate the 
formation of cAMP. Platelets contain five 
classes of receptors that trigger the production 
of cAMP (247-249). For example, 
prostaglandins (PGs) of the I-type such as 
prostacyclin (PGI2), which is produced by 
endothelial cells and is the most potent platelet 
inhibitor, is recognised by the IP receptor. 
These receptors act on trimeric G-proteins of 
the Gs group, which upon activation stimulate 
adenylyl cyclase (AC) by their α-subunit (250). 
PKA is thought to play an important role in the 
inhibitory mechanisms (251-255). The rise in 
cAMP is counteracted by the action of 3, 5-
cyclic nucleotide phosphodiesterases (256). 
Among the signalling pathways that 
contribute to the rapid platelet action, the 
GPCRs play again a prominent role (229,250). 
The major platelet agonists, α-thrombin, 
platelet-activating factor (PAF), ADP, 
lysophosphatidic acid (LPA) and TxA2, all act 
on serpentine receptors that are coupled to 
different heterotrimeric G proteins on the 
platelet surface. Most platelet agonists function 
through receptors coupled to heterotrimeric G 
protein Gq, the activated subunit of which (Gαq) 
can induce PLC-β (257). PLC-mediated 
hydrolysis of phosphatidylinositol 4,5-
diphosphate (PIP2) generates both DAG 
regulating PKC and inositol 1,4,5- trisphosphate 
(IP3). A subsequent rise in cytosolic calcium is 
sufficient to induce the function of αIIbβ3 and 
triggers platelet activation (229,230). Among 
the different platelet PLC enzymes (258,259), 
the β-forms are regulated by heterotrimeric G 
proteins (259-261), while PLC-γ forms are 
regulated by SH2-mediated protein-protein 
interactions that depend on the state of tyrosine 
phosphorylation (260).  
Interestingly, the most recent studies point 
out that platelet aggregation induced by the 
different agonists results from concomitant 
signalling through both Gq- and Gi-coupled 
receptors (226,227). This concept has initially 
emerged from studies on ADP-induced platelet 
aggregation. ADP binds to both the P2Y 
receptor, coupled to Gq (262,263) and P2Y12, 
coupled to Gi (264,265). Activated P2Y1 
receptor induces PLC, calcium mobilisation and 
platelet shape change (262,263), but is unable to 
trigger aggregation unless Gi-coupled P2Y12 
receptor is concomitantly activated (266). In 
addition, mice deficient in either of these 
receptors fail to aggregate in response to low or 
moderate concentrations of ADP, indicating that 
stimulation of both Gq- and Gi-coupled 
pathways is required for full activation (267-
269). Several reports indicate that this dual 
requirement for full platelet activation is not 
restricted to ADP, but forms a general feature 
for many platelet agonists. This can be either in 
a direct manner, when the agonist functions on 
both Gq- and Gi-coupled receptors as is the case 
for ADP and TxA2 (270), or indirect, as the 
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consequence of secreted ADP or epinephrine, 
which activate receptors coupled to Gi 
(271,272). Inhibition of AC by Gi is an 
important step in agonist-induced platelet 
activation. In vivo namely, platelets are 
continuously kept inactive by exposure to 
prostacyclin, produced by endothelial cells. 
Suppression of cAMP levels is required to 
enable full platelet activation. However, a 
decrease in cAMP alone appears insufficient to 
account for all the roles played by Gi family 
members in the support of platelet activation 
and this is currently under investigation (226). 
Additional receptor types participate in platelet 
regulation, like tyrosine kinase receptors, 
cytokine receptors and glycoproteins (228-230). 
Signalling from ligand-bound GP Ib to 
αIIbβ3 requires intracellular calcium, PI(3)K and 
Rho (273-276). Lateral clustering of GP Ib-IX-
V complexes may be involved in the up-
regulation of the adhesive function of αIIbβ3 
(277). The cytoplasmic domain of GP Ibα is 
known to interact with both filamin (278,279) 
and the signalling adaptor protein 14-3-3ζ 
(278,280,281). The interaction with 14-3-3ζ has 
been proposed to enable GP Ib to transduce 
signals necessary for αIIbβ3 activation (282). The 
interaction of GP Ib with filamin has a 
significant influence on various aspects of 
platelet morphology and GP Ib-IX-V receptor 
function (279,283). This interaction may be 
essential for GP Ib-IX-V anchorage at high 
shear stress (284-286). 
In conclusion, on resting platelets, αIIbβ3 can 
only bind surface-coated fibrinogen. However, 
the platelet agonists described above or 
activation of the GP Ib-IX-V complex initiate 
platelet signal transduction leading to a 
conformational change in αIIbβ3 (inside-out 
signalling). This enables the integrin to bind 
soluble fibrinogen and other ligands by 
increasing its affinity, allowing platelet clot 
formation. Although the initial signalling events 
triggered by platelet agonists have been 
characterised, downstream pathways controlling 
αIIbβ3 control are still elusive. Binding of a 
ligand to αIIbβ3 and attachment of the integrin to 
the cytoskeleton upon platelet aggregation 
initiate so called outside-in signal transduction 
by the integrin (287,288). 
 
 
 
Rap1 and Ral in platelet activation 
 
Rap1 and Ral expression and localisation in 
platelets 
In human platelets, the Rap1B expression 
level exceeds that of other small GTPases 
(including Rap1A) by at least ten fold 
(62,289,290). In platelets, Rap1 has been 
observed predominantly at the plasma 
membrane and associated open canicular 
system, but also at α-granules. Platelet 
stimulation with α-thrombin was found to 
relocalise Rap1 to the canalicular system with 
the secreted α-granules and Rap1 concentrates 
within the pseudopods formed by the plasma 
membrane during activation (291). 
Fractionation studies have described similar 
distribution patterns (292,293). 
RalA and RalB are equally and abundantly 
expressed in platelets (130,133,294,295). Both 
isoforms are membrane-associated due to their 
geranylgeranylation (130). RalA was found 
associated with dense granules of resting 
platelets, vesicles that are secreted during 
platelet activation (296). 
 
Rap1 activity control 
Treatment of human platelets with agents 
like forskolin, PGE2, PGI2 and its analogue 
iloprost, elevate the cAMP level thereby 
reducing platelet responsiveness to activating 
agonists (228). In part this may be due to the 
activation of cAMP-regulated protein kinase A 
(PKA). Targets of this kinase include actin-
binding protein (297), the vasodilator-
stimulated phosphoprotein (VASP) (298), the 
GP Ibβ-chain (299) and thrombolamban (300-
302), which was identified as Rap1B. The 
phosphorylation occurs preferentially at serine 
179. Rap1A, also target for PKA, has only the 
less attractive serine 180 residue (303-305). In 
addition, cyclic guanosine monophosphate 
(cGMP)-dependent protein kinase (PKG) is able 
to phosphorylate the plasma membrane 
associated pool of Rap1B (292,306,307). The 
function of the PKA-mediated phosphorylation 
is unclear (62). However, since the 
phosphorylation site is close to the membrane 
attachment site of Rap, it is likely that 
phosphorylation affects membrane localisation. 
Indeed, the only effect observed so far in vivo 
caused by phosphorylation is an incomplete  
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Figure 6. Mechanisms of Rap1 activation in platelets. 
In platelets, Rap1GTP can be increased by activating receptors coupled to Gi or Gq family members. Epinephrine 
binds and activates α2A adrenergic receptors which induce Rap1GTP via a Gαz-dependent pathway that at least 
partially requires PI(3)K. ADP stimulates both Gi- and Gq-coupled receptors, leading to two pathways of Rap1 
activation: a calcium-dependent route downstream of Gq and a Gi-dependent cascade which is dependent on PI(3)K. 
Thrombin binds to PAR1 and PAR3 in human platelets thereby activating Gq. In addition to the PLC pathway this 
results in release of ADP from dense granules, which in turn stimulates the ADP receptors P2Y1 and P2Y12. Thus, 
thrombin also elevates Rap1GTP through both Gi- and Gq-dependent pathways. Although the exact mechanisms are 
not yet completely understood, Gq-mediated rise in intracellular calcium likely stimulates a CalDAG-GEF. Rap1 
activation by Gi family members appears to be dependent on PI(3)K, but may also involve trapping of some RapGAP 
isoform. 
 
relocalisation of Rap1B to the cytosol (308-
310). 
Several upstream pathways have by now 
been described to contribute to Rap1 activation 
in platelets. Initially, several platelet agonists 
elevating Rap1GTP were found to require PLC-
mediated mobilisation of calcium (76). In 
addition, PKC and PI(3)K were demonstrated to 
play a role in sustained Rap1 activation (86) and 
LDL has been shown to induce Rap1 activation 
dependent on p38 MAPK and phospholipase A2 
(PLA2) activation and consequent TxA2 
formation (225). LDL treatment was in these 
studies not able to initiate platelet aggregation 
and secretion, despite the considerable Rap1 
activation. This implies that Rap1 activation is 
insufficient for the initiation of full platelet 
responses. Recent studies describe that 
stimulation of a Gi-dependent signalling 
pathway (for instance by ADP or epinephrine) 
is necessary and sufficient to induce Rap1 
activation and does not require calcium 
mobilisation (226,227). Instead, Gi-dependent 
Rap1 activation requires PI(3)K activity (226). 
Apparently, activation of Rap1 can be 
accomplished by Gαi- and PI(3)K-dependent 
mechanisms as well as Gq-and calcium-
dependent mechanisms. The earlier observed 
requirement for PKC and PI(3)K in sustained 
Rap1 activation (86) may rely on the Gi-
regulated pathway, induced by PKC-regulated 
secretion of ADP after initial Gq stimulation. In 
Figure 6, upstream pathways leading to Rap1 
activation in platelets are schematically 
summarised.  
GEFs and GAPs regulating Rap1 in 
platelets are currently largely unknown. 
However, the role of calcium and DAG in Rap1 
activation (76,86) suggests the involvement of 
CalDAG-GEF proteins, which is supported by 
experimental evidence (311). Epac is most 
likely not expressed or at least not functional 
(chapter 4). PDZ-GEFs have been were 
recognised in platelet lysates (B. Kuiperij and J. 
de Rooij, personal communication). Rap1GAP 
activity is high in platelets and this does not 
change upon thrombin stimulation; only 
epinephrine was found to reduce Rap1GAP 
activity (312). Two Rap1GAP activities have 
been partially purified from platelet cytosol 
(313) and one of these was demonstrated to 
reside in a 55 kDa protein (64,314).  
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Figure 7. Mechanisms of Ral activation in platelets. 
Ral activation in platelets occurs most likely by Ras-independent processes in which Gq protein-coupled receptor-
mediated intracellular calcium elevation plays an essential contribution. The exact mechanism linking calcium with 
Ral activation is not understood, however several options have been proposed, as indicated. Whether a Gi-regulated 
pathway is involved needs to be investigated. Although RalGEF2 was not found expressed in platelets, the presence 
of other RalGEFs needs to be examined. 
 
Interestingly, this protein is very similar to the 
N-terminus of the 88 kDa membrane-bound 
Rap1GAP I (112,315), which is also expressed 
in platelets (B. Franke, unpublished results). An 
interesting aspect of Rap1 concerns its 
association with the cytoskeleton in activated 
platelets. Upon platelet activation, rapid and 
extensive reorganisation of the actin 
cytoskeleton takes place. An initial breakdown 
of existing structures is followed by the 
formation of an elaborate, strongly 
interconnected F-actin structure (316,317). 
Upon α-thrombin treatment, Rap1 completely 
associated with the actin filaments (318,319). In 
case of other platelet agonists or if aggregation 
is absent, only 20-40% of Rap1 bound to actin 
(319,320). Rap1B and Rap2B association with 
the cytoskeleton induced by vWF involving 
FcγII receptor-mediated protein tyrosine 
phosphorylation has also been demonstrated 
(321). Platelet aggregation was found to 
downregulate Rap1 activity and the 
cytoskeleton-associated fraction of Rap1 was in 
the inactive state (86). Moreover, Rap1GAP I 
was also observed to associate with the 
cytoskeleton in thrombin-stimulated platelets 
(B. Franke, unpublished results). Although these 
observations are interesting and may form a 
mechanism for Rap1 activity downregulation, 
the function of the interaction between these 
signalling proteins and the cytoskeleton remains 
obscure.  
 
Ral activity control 
An intriguing relation between Rap1 and 
Ral was found in platelets (146). The proteins 
seemed to be regulated in a coordinated fashion, 
as Ral activation correlated with the activation 
profile of Rap1 instead of Ras. Firstly, this 
clearly implicated Ral in addition to Rap1 in 
platelet activation, suggesting also participation 
of Ral in platelet functions. Interestingly, Ral 
had been proposed to function in secretion 
and/or cytoskeletal organisation. Secondly, this 
formed evidence for Ras-independent ways to 
regulate Ral activity, attracting attention 
towards the upstream activation mechanisms of 
the Ral proteins. Thirdly, the correlation in 
activities together with the known interaction 
between Rap1 and RalGDS suggested a 
function for Rap1 in Ral regulation. 
In platelets, RalGTP is rapidly increased 
upon treatment with α-thrombin, platelet 
activating factor (PAF) or TxA2, all ligands for 
GPCRs (146,225). Activation of Ral by these 
factors requires an increase in the level of 
cytosolic calcium, either by the mobilisation 
from intracellular calcium stores or by the 
induction of a calcium influx. In Figure 7, a 
schematic representation of the Ral activation in 
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platelets is shown. As the RalGDS GEFs can in 
addition to Ras also bind other Ras family 
members (36,41,140,141,322-324), Rap1 has 
been proposed to regulate Ral in platelets (151). 
Binding studies have revealed that the RBD in 
RalGDS has a 100-fold higher affinity for Rap1 
than for Ras or R-Ras in vitro (37). However, in 
Cos7 cells transfected Ras rather than R-Ras or 
Rap1 stimulated RalGDS, Rgl and Rlf exchange 
activity towards Ral (39,142,143). This suggests 
the calcium/calmodulin-pathway leading to Ral 
activation might be most prominent in platelets, 
as also no evidence was found for expression of 
RalGEF2 (chapter 2). Currently it is unknown 
whether Gi-regulated signalling, which leads to 
Rap1 activation, also results in RalGTP 
accumulation.  
 
 
Functions of Rap1 and Ral in platelet 
perspective  
 
Rap and intracellular calcium homeostasis 
An interesting direction concerning the role 
of Rap1 in platelet physiology, originates from 
its connection with the 97 kDa sarco-
/endoplasmic reticulum calcium-ATPase 3b 
(SERCA 3b). SERCA is associated with IP3-
sensitive calcium stores in intracellular 
membranes (325-329). Firstly, several lines of 
research indicate correlated expression of 
SERCA and Rap1 in platelets and other cell 
lines (328,330,331). Interestingly, interaction 
between Rap1 and SERCA 3b in co-
immunoprecipitation experiments has been 
reported, which was abrogated by 
phosphorylation of Rap1 in the membrane 
preparations by the catalytic subunit of PKA 
(327). Rap1, as PKA target, forms the major 
phosphoprotein in antagonist-inhibited platelets. 
Therefore, Rap1 has been connected to the 
PKA-induced removal of calcium from the 
platelet cytosol due to activation of calcium-
ATPases (332-334). Calcium-uptake is 
stimulated by PKA in platelet microsomes 
containing both PKA and Rap1B 
(thrombolamban) (335). In addition, GTPγs, a 
non-hydrolysable GTP analogue, inhibits both 
the calcium-ATPase activity and the 
phosphorylation of Rap1b by the catalytic 
subunit of PKA in membrane preparations of 
platelets (336). One problem for this mechanism 
to occur in vivo however, is raised by the 
finding that PKA-mediated Rap1B 
phosphorylation is a slow process in intact 
platelets (303,308) that lags behind inhibition of 
platelet functions by antagonists, such as 
removal of cytosolic calcium (76,337). 
Furthermore, debate is going on whether 
platelet antagonists induce re-uptake of 
intracellular cytosolic calcium into stores, or 
causes inhibition of mobilisation from these 
stores (338). However, recently also other 
reports point to a role of Rap proteins in the 
regulation of intracellular calcium. A cAMP-
induced Epac-PLC pathway in which Rap2B 
may function was found to increase intracellular 
calcium in HEK293 cells (339). Finally, a 
cAMP-induced calcium increase in human 
megakaryoblast has been reported and the 
involvement of Rap1 was proposed (340). 
 
Rap1 and αIIbβ3 integrin regulation 
As has been described already, Rap1 has 
been implicated in the control of integrin-
mediated cell adhesion. This has raised the 
question whether Rap1 may be able to regulate 
the platelet integrin αIIbβ3 as well. The role of 
Rap1b in αIIbβ3 function was investigated by 
viral transduction of GFP-Rap1 chimeras into 
murine megakaryocytes, which exhibit inside-
out signalling similar to platelets. As a readout 
for integrin affinity, binding of soluble 
fibrinogen was measured. Interestingly, in this 
study solely expression of active Rap1B showed 
no effect, but it augmented thrombin-induced 
fibrinogen binding (311). This effect was 
prevented by inhibition of actin polymerisation. 
The authors proposed Rap1B might regulate 
αIIbβ3 affinity by modulating its interactions 
with the cytoskeleton. With this respect, it is 
interesting to note again the reported 
relocalisation of Rap1 to the actin cytoskeleton 
upon platelet activation (section Rap1 activity 
control). In addition, Rap1 signalling is also 
required for TPA-induced adhesion of DAMI 
human megakaryoblasts to immobilised 
fibrinogen (chapter 5). Although further 
research is required to demonstrate this 
connection in platelets, these studies form initial 
proof for a function of Rap1 in the control of the 
platelet integrin αIIbβ3 and link Rap1 signal 
transduction to one of the most elementary 
processes underlying platelet physiology. 
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Rap1 effector proteins 
Also in platelets Rap1 may interact with 
RBD-containing proteins. The correlation in 
Rap1 and Ral activity in platelets has raised the 
idea that Rap1 may regulate RalGDS (146). 
However, evidence that Rap1 exerts functions 
via on of the Ras effectors in vivo has not yet 
been established. Moreover, expression of 
RalGDS has not even been demonstrated in 
platelets and a calcium pathway without 
contribution of a GEF may be sufficient to 
regulate Ral activity. Among the (putative) 
targets for Ras-like GTPases, proteins containg 
a predicted RBD or Ras-associating (RA) 
domain, several candidates have additional 
domains that allow interaction with the 
cytoskeleton, integrins or adherens junctions, 
like for instance talin and AF-6. Interaction with 
these proteins may explain how Rap1 regulates 
integrins and why Rap1 relocalises to the actin 
cytoskeleton upon platelet activation. However, 
in conclusion, no Rap1 effector protein has been 
established in platelets and this item awaits 
further research.  
 
Ral binding partners and functions 
In contrast to Rap1, for Ral several target 
proteins and binding partners have been 
characterised in the past ten years, as described 
in the section Ral effectors and functions. With 
respect to platelets the nature of these binding 
partners implicates Ral in the regulation of 
vesicular traffic and the actin cytoskeleton. Like 
Rap1, also Ral was observed to associate with 
the cytoskeleton upon platelet activation 
(Franke, unpublished results).  
 
 
III. Conclusions 
 
In conclusion, Rap1 and Ral signal 
transduction pathways are activated upon a 
variety of platelet agonists and inhibited by 
platelet antagonists. This correlation suggests 
the involvement of both GTPases in platelet 
function. By the use of several relevant model 
systems, an augmenting pile of plausible 
possibilities for cellular functions of Rap1 has 
been put forward and this is still in progress. 
Although interaction with Ras effectors remains 
an option, in terms of platelet physiology 
connections with vesicular transport, 
intracellular calcium regulation, cytoskeleton 
and adhesion, which all have only recently 
begun to emerge, are more attractive. In 
addition, Ral has been implicated in the 
regulation of several types of vesicular transport 
and the cytoskeleton. If at any time a reason 
existed to perform functional studies on Rap1 
and Ral in platelets, it is definitely most 
challenging now. 
 
 
IV. Scope of this thesis 
 
We studied both the upstream regulation of 
Ral proteins and downstream functions of Rap1 
in the light of platelet activation. Beside the 
advantages of platelets as a model for signal 
transduction, also a few important 
disadvantages exist. First of all, platelets cannot 
be directly used for genetic studies. 
Transfection experiments are impossible due to 
the lack of the transcription machinery. 
Intervention can only take place by using 
pharmacological inhibitors and activators. 
Moreover, platelets cannot be cultured. 
Therefore, blood donation is required, which 
inevitable increases biological variation due to 
donor variability. As the consequence of these 
restrictions, other models (megakaryocytes, 
lymphocytes and fibroblasts) had to be used as 
well in order to address our research questions. 
We started to investigate the Ras-
independent Ral activation mechanism. In 
chapter 2 the identification and characterisation 
of RalGEF2 is described. This novel RalGEF 
belongs to the family of RalGPS proteins. 
RalGEF2 lacks an RBD domain and its activity 
is independent of Ras signalling. This GEF 
possesses a PH domain that plays a role in its 
membrane localisation and activaty towards 
Ral. However, regulation of RalGEF2 by 
second messengers or complex formation has 
not been identified yet. Next, we focussed on 
cellular effects regulated by Rap1 signal 
transduction. In chapter 3 we describe the 
requirement for Rap1 in integrin-mediated cell 
adhesion induced by either Mn2+ or integrin-
activating antibodies. This Rap1 role was 
demonstrated in a variety of cell types and in 
different combinations of integrin type and 
immobilised integrin ligand. We found that 
active Rap1-induced cell adhesion depends on 
intracellular calcium and calmodulin. We 
propose a facilitating function for Rap1 in the 
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cell adhesion process. In chapter 4 we have 
studied the putative involvement of Rap1 in a 
cAMP-induced PKA-independent signalling 
pathway regulating the intracellular calcium 
regulation in human megakaryocytes. Using a 
cAMP analogue that specifically activates the 
cAMP-regulated RapGEF Epac, we did not find 
evidence for the involvement of endogenous 
Rap1 signalling in calcium homeostasis. 
However, we observed Rap1 activation as the 
consequence of gentle mixing a sample of 
megakaryocytes. Further research revealed that 
in addition to Rap1, several key signal 
transduction pathways are activated in a variety 
of human suspension cell lines, solely due to 
mixing them in a test tube, described in chapter 
5. This may well be the consequence of shear or 
mechanical stress generated by mixing. 
Furthermore, we show that Rap1 is also 
required for TPA-induced αIIbβ3-mediated 
adhesion of DAMI megakaryoblastic cells to 
immobilised fibrinogen. This forms an initial 
indication that Rap1 contributes to the 
regulation of the major platelet integrin. Finally, 
in chapter 6 the implications of our research 
findings are discussed and placed in the context 
of the latest research developments. 
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Ral is a ubiquitously expressed Ras-like small GTPase. Several guanine-nucleotide 
exchange factors for Ral have been identified, including members of the RalGDS 
family, which exhibit a Ras binding domain and are regulated by binding to RasGTP. 
Here we describe a novel type of RalGEF, RalGEF2. This GEF has a characteristic 
Cdc25-like catalytic domain at the N-terminus and a pleckstrin homology (PH) domain 
at the C-terminus. RalGEF2 is able to activate Ral both in vivo and in vitro. Deletion of 
the PH domain results in an increased cytoplasmic localisation of the protein and a 
corresponding reduction in activity in vivo, suggesting that the PH domain functions as 
a membrane anchor necessary for optimal activity in vivo. 
 
 
 
INTRODUCTION 
Ral (RalA and B) is a small GTPase of the 
Ras family implicated in the control of cell 
proliferation (1-7), differentiation (8-10), 
cytoskeletal organisation (11) and vesicular 
transport (12). Ral is activated by a large variety 
of extracellular stimuli (13-15) and one of the 
mechanisms of Ral activation is the direct 
binding of active Ras to Ral-specific GEFs. 
These GEFs, RalGDS, Rgl and Rlf, have a C-
terminal Ras binding domain (RBD) responsible 
for the interaction with RasGTP and an N-
terminal Cdc25-like catalytic domain (5,16,17). 
However, other mechanisms of Ral activation 
occur as well. In platelets and in fibroblasts 
elevation of intracellular calcium levels induce 
Ral activation independently of Ras activation 
(13,18) and in neutrophils phosphatidylinositol-
3-OH-kinase (PI3K) and perhaps Src may 
mediate Ral activation (15). This suggests that 
in addition to RalGDS, Rgl and Rlf, other Ral 
regulatory proteins exist. Indeed, Rsc, a fusion 
protein isolated from a rabbit squamous cell 
carcinoma, has RalGEF activity and appears to 
lack an RBD (19). RalGTP levels are also 
regulated by GTPase activating proteins 
(GAPs), including a high molecular mass 
RalGAP purified from brain and testis and a 43 
kDa RalGAP in human platelets (20,21). 
Finally, Ral A interacts with calmodulin 
(22,23), which may be involved in calcium-
induced regulation of Ral (13,18). 
In addition to proteins that regulate its 
activity, Ral interacts with several other proteins 
which may function as effectors. The active, 
GTP-bound form of Ral associates with RalBP 
(24-26). RalBP is a GAP for Cdc42, a small 
GTPase involved in actin cytoskeleton 
organisation and filopodia formation in 
fibroblasts (27). In addition, RalBP associates 
with Reps1 and POB1, two proteins implicated 
in endocytosis (12,28,29). RalGTP also binds to 
ABP280/filamin1, a cross-linker of actin 
filaments and a scaffold for several other 
proteins. This complex may mediate Cdc42-
induced filopodia formation (11). Finally, Ral 
associates with the small GTPase Arf and 
phospholipase D (PLD) in a nucleotide-
independent manner (30-33). Both PLD and Arf 
have been implicated in many processes, 
including vesicular transport (34-37). All these 
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interactions point to a function of Ral in the 
control of the actin cytoskeleton and processes 
related to this, such as establishing cell polarity, 
migration and vesicular transport (see (38).  
In this paper we describe the identification 
of a novel Ral-specific GEF, RalGEF2. This 
GEF has a characteristic Cdc25-like catalytic 
domain at the N-terminus and a pleckstrin 
homology (PH) domain at the C-terminus. This 
PH domain functions as a membrane anchor 
necessary for optimal activity of RalGEF2 in 
vivo. 
 
MATERIALS AND METHODS 
Plasmids and constructs 
The KIAA0351 cDNA containing the complete coding 
sequence was kindly provided by the Kazusa DNA Research 
Institute. This cDNA was isolated in a random cloning 
strategy (39). A PCR fragment containing RalGEF2 flanked 
by a SalI site at the 5 (primer A: 5-GTCGACTATGTACA-
AGAGGAATGGTCTG-3) and a HpaI site at the 3 
(primerB: 3-CGTTTGGAATACAGTAA-ACTCCAATTG-
ATC-5) end, was subcloned into the pGEM-T vector 
(Promega). This clone was subsequently used to generate HA-
RalGEF2, by introducing a SalI fragment containing 
RalGEF2 into SalI-digested pMT2-SM-HA. Cat-RalGEF2 
(amino acids 1-289), flanked by a SalI site at the 5 end 
(primer A) and a HpaI site at the 3 end (primer C: 3-
CGAGTCTTAGCTTGGTCCTTTACAATTG), and ∆PH-
RalGEF2 (amino acids 1-431), flanked by a SalI site at the 5 
end (primer A) and a HpaI site at the 3 end (primer D: 3-
CTTGAGGCGTCGACACGGTCAATTG-5), were also 
subcloned in pGEM-T. These SalI-HpaI fragments were also 
cloned into SalI-HpaI digested pBluescript in which SalI-NotI 
Rlf-∆RBD-CAAX had been cloned previously to obtain 
RalGEF2 proteins with the C-terminal polybasic sequence 
and CAAX box of K-ras (5). Subsequently, SalI-NotI 
fragments from these clones were isolated and ligated into 
SalI-NotI-digested pMT2-SM-HA to generate HA-cat-
RalGEF2-CAAX (HA-cat-CAAX) and HA-∆PH-RalGEF2-
CAAX (HA-∆PH-CAAX). In addition, cat-RalGEF2 and 
∆PH-RalGEF2 were also isolated as SalI-NotI fragments from 
the pGEM-T constructs and cloned into SalI-NotI digested 
pMT2-SM-HA vector, generating HA-cat-RalGEF2 (HA-cat) 
and HA-∆PH-RalGEF2 (HA-∆PH). From HA-cat-RalGEF2 
the mutants HA-catRalGEF2 L148A and HA-catRalGEF2 
∆SALQS were generated by site-directed mutagenesis. GST-
fusion constructs were made by isolating SalI-NotI fragments 
from the HA-RalGEF2, HA-cat-RalGEF2-CAAX and HA-
∆PH-RalGEF2-CAAX constructs and cloning these fragments 
into XhoI-NotI-digested pGEX-4T3 bacterial expression 
vector, generating respectively GST-RalGEF2, GST-cat and 
GST-∆PH. 
Homology searches 
RalGEF2 was found by searching databases for proteins 
containing Cdc25 catalytic domain homology. RalGEF2 was 
analysed for protein domains using the ISREC ProfileScan 
server (http://www.isrec.isb-sib.ch/software/PFSCAN_form. 
html). The structurally conserved region (scr) sequence was 
defined from a comparison of various Ras and RalGEFs using 
the clustalX (40) alignment program, as was done for the 
alignment of homologous amino acids in the PH domain.  
Cell culture, cell lines and transfection 
A14 (41) and Cos7 cells were grown at 37 °C in DMEM 
(Gibco) supplemented with 10% heat-inactivated (30 min. at 
56 °C) FCS and 0.05% glutamine. For activation studies cells 
were serum starved overnight for at least 16 hours. Cells were 
transfected by the calcium-phosphate method. 
Purification of GST-proteins 
For purification of GST-fusion constructs, protein expression 
was induced in DH5α using 100 nM IPTG for 20 h at room 
temperature. Bacteria were collected and lysed in ice-cold 
PBS containing 1% TX-100 and protease inhibitors. The 
lysates were sonicated three times for 20 seconds and 
centrifuged at 10,000 g for 20 minutes to remove insoluble 
material. GST-fusion proteins were purified from the cleared 
lysate by batch-wise incubation with glutathione-agarose 
beads (Sigma) and after washing the protein was eluted from 
the beads in buffer containing 50 mM Tris pH 7.5, 100 mM 
NaCl, 10 % glycerol and 10 mM glutathione. The eluted 
protein was dialysed for 20 hours in the same buffer without 
glutathione. The purification procedure of the small GTPases 
used in the in vitro experiments is described elsewhere (42-
44). 
Immunoprecipitation and Western blotting  
Western blotting of all protein samples was performed using 
PVDF-membranes. The antiserum used for detecting 
endogenous RalGEF2 was raised against a synthetic peptide 
that consists of the amino acids 543-557 
(KSNRPQVPANLMSFE) of RalGEF2. Other antibodies used 
are anti-HA (12CA5) (45), anti-Ral, anti-Ras and anti-Rap (all 
three from Transduction Laboratories). Anti-RalGEF2 and 
12CA5 were also used to perform immunoprecipitations. 
In vivo activation of small GTPases 
Cells were transiently transfected with HA-tagged versions of 
the small GTPases either alone or in combination with 
RalGEF2, and serum-starved for 20 hours prior to lysis. GTP-
bound forms of the different GTPases were isolated using 
activation specific probes and subsequently quantified, as 
described (13,46,47). For RalGTP the Ral-binding domain of 
RLIP was used, for Ras the RDB of Raf1 and for Rap the 
RBD of RalGDS. 
In vitro activation of small GTPases 
In vitro GEF activity was measured as described (48). Briefly, 
250 nM of purified GTPase, loaded with fluorescently 
labelled 2,3-bis(O)-N-methylantharanoloylguanosinediphos-
phate (mantGDP), was incubated, in the presence of excess 
unlabelled GDP (5mM), with 50 nM of purified GST-cat in 
50 mM Tris pH 7.5, 5 mM Mg2+ and 5 mM DTE at 20°C. 
Release of mantGDP was measured in real-time as a decrease 
in fluorescence using a Perkin-Elmer fluorometer LS50B 
(excitation wavelength 366 nm, emission wavelength 450 
nm). This decrease in fluorescence is caused by quenching of 
released mantGDP by water. In the Ral assay, 0.15 mg/ml 
BSA was added to stabilise the protein. Alternatively, we 
used a reverse assay (49) in which 150 nM RalGDP was 
added to a cuvette containing 100 nM mantGDP either alone 
or in the presence of 50 nM purified GEF protein. Uptake of 
mantGDP results in an increase in fluorescence. 
Subcellular fractionation 
Cells were harvested in lysis buffer (20 mM Hepes, pH 7.4, 5 
mM EGTA, 1 mM sodium vanadate, 1µM leupeptin, 0.1 µM 
aprotinin) and subsequently homogenised through a 23 G 1 
1/4 Microlance syringe. Intact cells and nuclear components 
were removed by a sequential two times centrifugation step at 
6000 rpm for 1 minute (Eppendorf table centrifuge). 
Subsequently, the samples were centrifuged at 100,000 g at 
4ûC for 90 minutes. The supernatant was collected as the 
soluble fraction and the particulate fraction was dissolved in 
buffer containing 1% TX-100, 50 mM Hepes pH 7.5, 50 mM 
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NaCl, 5 mM EDTA, 1 mM vanadate, 1 µM leupeptin and 0.1 
µM aprotinin. Soluble and particulate fractions were analysed 
by SDS-PAGE and immunoblotting. 
 
RESULTS 
A novel Ral guanine-nucleotide exchange 
factor 
In our ongoing search for regulators of Ras-
family members, we found a protein in the 
database from the Kazusa DNA Research 
Institute (KIAA0351) with similarities to 
RasGEFs. A schematic representation of the 
non-coding and coding sequences of KIAA0351 
is presented in Figure 1A. As will be shown 
below, this protein is a GEF for the small 
GTPase Ral, hence we named it RalGEF2, since 
this GEF forms a novel subclass, distinct from 
the RalGEF members which are characterised 
by the presence of the RBD domain (Figure 
1B). RalGEF2 has the characteristic GEF 
domain present in all RasGEFs and shows 
considerable homology to previously described 
RasGEFs, especially in the structurally 
conserved regions scr1, 2 and 3 (data not 
shown). In addition, RalGEF2 has a PH domain 
in its C-terminus that shows highest homology 
to the PH domain in the Drosophila RhoGEF 
Still Life (Sif) (50), and the N-terminal PH 
domains in the RacGEFs Tiam1 and Stef 
(51,52) (Figure 1C). Surprisingly, no Ras 
exchange motif (REM) is present in RalGEF2, 
in contrast to all other Cdc25-like GEFs 
identified so far. 
 
Expression of RalGEF2 
A polyclonal antibody (α-RalGEF2) was 
raised against a C-terminal peptide of RalGEF2. 
This antibody recognised the 60 kD HA-
RalGEF2 protein immunoprecipitated from 
Cos7 cell lysate transiently transfected with 
HA-RalGEF2 using an α-HA-monoclonal 
antibody (Figure 2). A similar-sized protein was 
identified in an α-RalGEF2-immunoprecipitate 
from 293 cells. Both protein bands disappeared 
when the antibody was preincubated with the 
immunising peptide. From this result we 
concluded that α-RalGEF2 recognises RalGEF2 
both in immunoprecipitation and blotting 
experiments. Next, a Western blot containing 
protein samples from various human tissues was 
probed with either α-RalGEF2 or α-RalGEF2 
blocked with peptide. As shown in Figure 2B, 
RalGEF2 expression is rather ubiquitous. It is 
high in brain, heart, kidney, adrenal gland and 
colon, low in pancreas, skeletal muscle, thymus 
and liver, and intermediate in lung and spleen. 
Ubiquitous expression of RalGEF2 was also 
shown using RT-PCR by the Kazusa DNA 
Research Institute (http://www.kazusa.or.jp/ 
huge/gfimage/rt-pcr/html/KIAA0351.html). 
 
RalGEF2 activates Ral both in vivo and in 
vitro 
To investigate which Ras-like GTPase is 
activated by RalGEF2, we incubated GST-cat 
(Figure 3A) with various Ras-like GTPases 
loaded with fluorescent mantGDP. Release of 
guanine-nucleotide bound to Ral was measured 
in real time as decrease in fluorescence. As 
shown in Figure 3B, incubation of Ral-
mantGDP alone already resulted in a decrease 
in fluorescence, indicating that a fraction of the 
protein sample was instable and degraded 
during the incubation. In the presence of GDP 
intrinsic exchange activity is measured. We 
observed a clear increase in exchange when 
GST-cat was added as well, showing that GST-
cat catalyses Ral guanine-nucleotide exchange. 
GST-cat did not affect the exchange rate of 
either Ras or Rap2 (Figure 3C). As an 
alternative assay we used a reverse procedure in 
which binding of mantGDP to Ral results in an 
increase in fluorescence. MantGDP either alone, 
in the presence of GST-cat or in the presence of 
GST-Rlf was incubated and RalGDP was 
added. As shown in Figure 3D, both GST-cat 
and GST-Rlf catalysed guanine-nucleotide 
exchange. Surprisingly, when a shorter version 
of Ral lacking an additional 28 residues at the 
C-terminus was used in the assay, GST-cat 
failed to induce exchange, in contrast to GST-
Rlf. This effect was also observed when 
corresponding Drosophila Ral proteins were 
used (data not shown). To investigate whether 
GST-cat may still bind to Ral, we pre-incubated 
Ral-mantGDP and GST-cat for prolonged 
period of time followed by the addition of GST-
Rlf. GST-cat did not affect the ability of GST-
Rlf to induce exchange (Figure 3E), indicating 
that RalGEF2 fails to interact stably with the C-
terminally truncated protein. From these results 
we conclude that RalGEF2 is indeed a GEF for 
Ral, and that, in contrast to Rlf, RalGEF2 
requires the C-terminal 28 residues of Ral for 
proper interaction.  
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Figure 1. RalGEF2 contains a GEF domain and a PH domain. 
A. Schematic representation of the noncoding and coding sequence in KIAA0351 mRNA and the domains present in 
the predicted protein sequence. UTR, untranslated region; scr 1-3, hyper conserved regions in GEFs for Ras-like 
proteins. Bold type represents the GEF domain, bold and underlined scr1-3 and underlined the PH domain. B. 
Schematic comparison of the five RalGEFs currently identified. Both RalGDS, Rgl and Ral contain in addition to the 
GEF domain, a Ras exchange motif (REM) and a Ras binding domain (RBD). Rgr is a RalGEF that is only found as a 
partner in a fusion protein isolated from a rabbit squamous cell carcinoma (Rsc). The dashed arrow indicates the 
other fusion partner. No mouse or human Rgr sequences have thus far been reported. C. Sequence comparison 
between the PH domain of RalGEF2 and those present in the N-terminal region of the RacGEFs Stef and Tiam-1, 
and Drosophila Still life (Sif ). 
 
 
Subsequently, we analysed whether 
RalGEF2 also activates Ral in vivo. HA-
RalGEF2 was cotransfected with HA-tagged 
RalA in Cos7 cells and Ral activity was 
measured using activation-specific probes. As 
shown in Figure 4A, cotransfection with 
RalGEF2 resulted in a clear activation of Ral. In 
contrast, RalGEF2 displayed only marginal 
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activity for HA-Ras and no exchange activity 
for HA-Rap1 in vivo (Figure 4B and C). From 
this result we conclude that RalGEF2 
selectively activates Ral in vivo. Next, we 
addressed the question whether indeed the GEF 
activity is reponsible for this effect. HA-cat-
CAAX, which is described below, activates 
cotransfected HA-Ral. We made mutants of this 
protein in a region that is fully conserved in all 
human RalGEFs, located in the scr2, in order to 
abolish its catalytic activity. We found that both 
HA-cat L148A and HA-cat ∆SALQS (residue 
146-150) failed to activate HA-Ral (figure 4D). 
From these data we conclude that activation of 
Ral in vivo is directly mediated by the catalytic 
activity of RalGEF2. 
 
 
 
 
 
Figure 2. Expression of RalGEF2 in human tissue. A. 
HA-RalGEF2 was precipitated from lysate of Cos7 cells 
transiently transfected with HA-RalGEF2 using anti-HA 
(12CA5) monoclonal antibody (lane 1), endogenous 
RalGEF2 was precipitated from lysate of 293 cells using 
a polyclonal peptide antibody of RalGEF2 (α-RalGEF2; 
lane 2). Blots were probed with either α-RalGEF2 (left 
panel) or with α-RalGEF2 preincubated with the peptide 
used for immunisation (right panel). H-chain: 
immunoglobulin heavy chain. B. New-born human tissue 
samples were lysed and equal amounts of protein were 
separated by gel electrophoresis. Gels were blotted and 
probed with either α-RalGEF2 (upper panel) or with α-
RalGEF2 preincubated with the peptide used for 
immunisation (lower panel). Lanes represent pancreas 
(p), skeletal muscle (sk), brain (b), skin (s), thymus (t), 
heart (h), kidney (k), liver (li), spleen (sp), lung (lu), 
adrenal gland (ag), colon (c). 
 
Regulatory function of the PH domain 
PH domains commonly interact with 
membrane lipids, in particular phosphorylated 
phosphatidylinositol (PI) lipids. As such, PH 
domains function either as membrane anchor or 
as a regulatory domain that responds to the 
products of PI3K, PI-3,4-P2 or PI-3,4,5-P3. To 
determine whether RalGEF2 responds to PI3K 
signalling, we introduced RalGEF2 in A14 cells 
and stimulated the cells with insulin, a potent 
inducer of PI3K activity (45). However, we did 
not observe any increase in RalGEF2 activity by 
insulin treatment (data not shown). Also other 
stimuli tested, including EGF, endothelin, 
forskolin, ionomycin, LPA and serum failed to 
activate RalGEF2. We therefore investigated 
whether the PH domain is involved in 
membrane localisation of RalGEF2. Cells were 
transfected with HA-RalGEF2 or mutants 
lacking the PH domain (HA-∆PH and HA-cat) 
and the presence of these proteins in the cytosol 
and the membrane-enriched particulate fraction 
was determined. Deletion of the PH domain 
resulted in a clear reduction of the level of 
RalGEF2 in the membrane fraction (Figure 5A), 
indicating that the PH domain is involved in 
membrane localisation of RalGEF2. This 
reduced association to membranes could be 
restored by adding the C-terminal polybasic 
domain and CAAX sequence of K-ras to HA-
∆PH and HA-cat (HA-∆PH-CAAX and HA-cat-
CAAX). This region directs the addition of a C-
terminal isoprenyl group and as a consequnce 
membrane attachment (Figure 5A).  
Next, we investigated whether deletion of 
the PH domain also affects GEF activity in vivo. 
Cells were cotransfected with the various 
RalGEF2 constructs and HA-Ral, and the level 
of RalGTP was determined. Even at lower 
levels of expression (upper panel Figure 5B) 
full length RalGEF2 is much more efficient in 
activating Ral than the mutant lacking the PH 
domain (Figure 5B), showing that the PH 
domain is required for efficient RalGEF2 
activity. The reduced GEF activity of HA-∆PH 
can be restored by the addition of a membrane 
anchor (HA-∆PH-CAAX; Figure 5 C). 
Similarly, addition of the CAAX domain to HA-
cat increased the efficiency of Ral guanine-
nucleotide exchange activity (Figure 5D). From 
these results we conclude that the PH domain of  
RalGEF2 is a membrane targetting sequence 
responsible for efficient RalGEF activity.  
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Figure 3. RalGEF2 specifically activates Ral in vitro. 
A. Coomassie Blue-stained gel, which demonstrates the 
purification result of a fusion protein containing GST and 
the catalytic domain of RalGEF2 (GST-cat; residue 1-
289). M stands for marker. B. 250nM human RalB 
loaded with fluorescent mantGDP was incubated either 
alone to measure stability of the protein (1, open 
circles), with 5 mM GDP to measure the intrinsic release 
(2, closed circles) or with 5 mM GDP and 50 nM GST-
cat (3, open squares). The right panel is a magnification 
of the initial part of the reaction in the left panel, to 
clearly show the rate differences. C. 250 nM H-
Ras.mantGDP (left panel) or 250 nM Rap2.mantGDP 
(right panel) was incubated with either 5 mM GDP (1, 
open circles) or 5 mM GDP and 50 nM GST-cat (2, 
closed circles). D. 100 nM mantGDP was incubated 
either alone (1, open circles), in the presence of 50 (2, 
closed circles) and 100 (3, open squares) nM GST-cat, 
or Rlf (4, closed squares). At the time indicated (arrow) 
150 nM simian Ral loaded with GDP was added. Two 
different RalA proteins were used, one containing 
residue 1-206 (left panel) and one containing residue 1-
178 (right panel). E. 150 nM simian RalGDP (residue 1-
178) was incubated with 100 nM mantGDP either alone 
(1, open circles), or in the presence of 50 nM GST-cat 
(2, closed circles) or 100 nM GST-cat (3, open squares) 
for a prolonged period of time. Subsequently, 50 nM Rlf 
was added (arrow) and incubation continued. 
 
DISCUSSION 
We have identified a novel GEF for the 
small GTPase Ral, RalGEF2. This is a 
ubiquitously expressed protein that is 
particularly abundant in brain, heart, kidney, 
adrenal gland and colon. Previously, four other 
RalGEFs have been identified, including 
RalGDS, Rgl and Rlf. These GEFs have in 
addition to the catalytic region a C-terminal Ras 
binding domain. The most striking characteristic 
of RalGEF2 is its PH domain. This domain is 
most similar to PH domains present in the 
Rho/RacGEFs Tiam1, SIF and Drosophila Still 
life. PH domains may bind to PI lipids, which 
are either constitutively present or which are 
induced by certain stimuli. For instance, the 
product of PI3K, PI-3,4-P2, recruits target 
proteins to the membrane by binding to their PH 
domains (53,54) Via this relocalisation a protein 
is for instance either brought into the vicinity of 
its target or of its activators. However, the fact 
that insulin, a very strong inducer of PI3K, fails 
to activate RalGEF2, suggests that RalGEF2 
activity is not induced by these lipids. Thus, the 
PH domain may serve to constitutively anchor 
RalGEF2 to membranes. Indeed deletion of the 
PH domain results in an increased cytoplasmic 
localisation of the protein and a corresponding 
reduction in the efficiency of Ral activation in 
 
 
vivo. Both membrane localisation and efficient 
GEF activity could be restored by the addition 
of the C-terminal polybasic region and CAAX 
motif of K-ras, which targets proteins to the 
membranes. From these results we conclude 
that the PH domain is predominantly 
responsible for membrane localisation of 
RalGEF2. 
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Figure 4. RalGEF2 specifically 
activates Ral in vivo. 
HA-RalA (A), HA-Rap1 (B) or 
HA-Ras (C) was cotransfected in 
Cos7 cells either alone or in the 
presence of HA-RalGEF2 (0.5, 
1.0, 2.0 and 5.0 µg). A. Upper 
panel shows a Western blot of 
cell lysate incubated with anti-
HA and anti-Ral antisera, lower 
panel shows HA-RalGTP and 
endogenous RalGTP precipita-
ted with RalBD of RLIP and 
identified with anti-Ral anti-
serum. B. Upper panel shows a 
Western blot of cell lysates 
incubated with anti-HA, lower 
panel shows HA-Rap1-GTP pre-
cipitated with RalGDS-RBD and 
identified with anti-HA anti-
serum. In the second and third 
lane the Rap1-specific GEF C3G 
was cotransfected. C. Upper 
panel shows a Western blot of 
cell lysates incubated with anti-
HA, lower panel shows (HA-
)RasGTP precipitated with Raf-
RDB and identified with anti-HA 
antisurum. D. Cos7 cells were transiently transfected with HA-RalA either alone (lane 1), HA-cat (lane 2), HA-cat 
L148A (lane 3) and HA-cat ∆SALQS (residue 146-150; lane 4). Upper panel shows a Western blot of cell lysates 
incubated with anti-HA, lower panel shows HA-RalGTP and endogenous RalGTP precipitated with RalBD of RLIP 
and identified with anti-Ral antiserum. 
 
 
Our failure to induce the activity of 
RalGEF2 by external stimuli may indicate that 
RalGEF2 is a constitutively active GEF, or that 
we have not yet identified the proper stimulus. 
Whereas Ral clearly serves as a downstream 
target of Ras signalling, through the direct 
binding of members of RalGDS, Rgl and/or Rlf 
to activated Ras, it is clear from several studies 
that other pathways are also mediating Ral 
activation. For instance, calcium can activate 
Ral independently of Ras (13,18), while in 
neutrophils as yet unidentified pathways exist 
(15). RalGEF2 may mediate one of these 
pathways. 
RalGEF2 is distinct from the other RalGEFs 
in that it does not have a REM domain. This 
REM domain is thought to play a role in 
stabilising the catalytic domain of Ras-like 
GEFs. Perhaps the PH domain or another region 
serves a similar function. An additional striking 
difference between RalGEF2 and other 
RalGEFs, in particular Rlf, is that RalGEF2 
does not exchange nucleotide in vitro from a 
truncated version of Ral. Apparantly the C-
terminal region of Ral contains amino acids 
essential for the proper binding of the catalytic 
domain of RalGEF2. Whether RalGEF2 directly 
interacts with this region, or if the absence of 
the REM domain is responsible for this 
difference awaits further investigation. 
However, this result clearly indicates that 
RalGEF2 uses a different molecular mechanism 
to release GDP from Ral than Rlf does. 
Ral has been implicated in a variety of 
cellular processes. Most notable is the role of 
Ral in coupling signals from Ras to the 
induction of transcription, such as transcription 
from serum-response elements (5,55) and the 
inhibition of the transcription factor AFX (56). 
These effects may, at least in part, explain the 
effects of Ral-mediated signalling on cell 
proliferation (1-7) and differentiation (8-10). 
However, the mechanism by which Ral 
regulates transcription is unclear. Another 
function of Ral is the regulation of the 
cytoskeleton. This is indicated by the 
association of the active form of Ral with 
RalBP, a GAP for the small GTPase Cdc42, and 
to filamin/ABP280, a protein involved in the 
cross-linking of actin filaments. Indeed, Ral was 
found to mediate Cdc42-induce filopodia 
formation. Finally, Ral has been implicated in  
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Figure 5. PH domain of RalGEF2 is essential for efficient 
membrane localisation and in vivo GEF activity. 
A.NIH-3T3-A14 cells were transiently transfected with either 
HA-RalGEF2, HA-∆PH, HA-∆PH-CAAX, HA-cat or HA-cat-
CAAX. Cells lysates were separated in soluble (s) and 
membrane-enriched particulate (p) fractions. The HA-proteins 
indicated by arrows, were identified by Westernblotting using 
anti-HA. B. Cos7 cells were transiently transfected with HA-
RalA either alone (basal), with HA-RalGEF2 or with HA-∆PH. 
The epitope-tagged proteins, indicated by arrows, were 
identified by Western blotting using anti-HA 12CA5 (upper 
panels). The lower panel shows HA-RalGTP and endogenous 
RalGTP precipitated with RalBD of RLIP and identified with 
anti-Ral antiserum. C. NIH3T3-A14 cells were transiently 
transfected with HA-RalA either alone (lane 1), HA-∆PH-CAAX 
(lane 2), or HA-∆PH (lane 3). Upper panel shows a Western 
blot of cell lysates incubated with anti-HA, lower panel shows 
HA-RalGTP and endogenous RalGTP precipitated with RalBD 
of RLIP and identified with anti-Ral antiserum. Note that for 
unclear reasons HA-∆PH-CAAX resolves as a cluster of bands 
(see also A). D. NIH3T3-A14 cells were transiently transfected 
with HA-RalA either alone (lane 1), HA-∆PH-CAAX (lane 2), or 
HA-∆PH (lane 3). Upper panel shows a Western blot of cell 
lysates incubated with anti-HA, lower panel shows HA-RalGTP 
and endogenous RalGTP precipitated with RalBD of RLIP and 
identified with anti-Ral antiserum. 
 
 
vesicular trafficking. Ral localises in part in 
vesicular membranes and, recently, it was 
shown that Ral, through RalBP and the RalBP-
associated proteins Reps1 and Pob1, is involved 
in the regulation of receptor endocytosis. In 
addition, Ral mediates FcεRI-induced histamine 
secretion (15). It may be that all these effects 
are pleiotropic, resulting from the activation of a 
single pool of active Ral. As a consequence, 
RalGEF2 may be involved in each of these 
processes. Alternatively, the distinct regulatory 
mechanism of RalGEF2 exchange activity, PH 
domain dependent membrane localisation, 
suggests the possibility that compartmentalised 
activation of Ral may regulate distinct functions 
of Ral.  
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In T lymphocytes, the Ras-like small GTPase Rap1 plays an essential role in stimulus-
induced inside-out activation of integrin LFA-1 (αLβ2) and VLA-4 (α4β1). Here we 
show that Rap1 is also involved in the direct activation of these integrins by divalent 
cations or activating antibodies. Inhibition of Rap1, either by RapGAP or the Rap1 
binding domain of RalGDS, abolished both Mn2+- and KIM185 (anti-LFA-1)-induced 
LFA-1-mediated cell adhesion to ICAM-1. Mn2+- and TS2/16 (anti-VLA-4)-induced 
VLA-4-mediated adhesion were inhibited as well. Interestingly, both Mn2+, KIM185 
and TS2/16 failed to induce elevated levels of Rap1GTP. These findings indicate that 
available levels of GTP-bound Rap1 are required for the direct activation of LFA-1 
and VLA-4. Pharmacological inhibition studies demonstrated that both Mn2+- and 
KIM185-induced adhesion, as well as Rap1-induced adhesion, require intracellular 
calcium, but not signalling activity of the MEK-ERK pathway. Moreover, functional 
calmodulin signalling was shown to be a prerequisite for Rap1-induced adhesion. 
From these results we conclude that in addition to stimulus-induced inside-out 
activation of integrins, active Rap1 is required for cell adhesion induced by direct 
activation of integrins LFA-1 and VLA-4. We suggest that Rap1 determines the 
functional availability of integrins for productive binding to integrin ligands. 
 
 
 
INTRODUCTION 
Circulating lymphocytes require a dynamic 
and flexible regulation of their integrin-
dependent adhesive properties. While these cells 
circulate in blood and lymph or migrate through 
tissues, rapid transitions between adherent and 
non-adherent states are required. The leukocyte 
function-associated antigen 1 (LFA-1) (integrin 
αLβ2) is a transmembrane heterodimer 
composed of a unique α subunit (αL or CD11a) 
and a β2 subunit (CD18) that is common to a 
subset of leukocyte integrins. Expressed at the 
cell surface of resting leukocytes, LFA-1 is 
inactive. However, rapid conversion into an 
active state allows the integrin to bind to its 
ligands, intercellular adhesion molecule 1, 2, 
and 3 (ICAM-1, -2 and -3) (1-3). Relevant 
examples of the LFA-1/ICAM-1-mediated 
adhesion include leukocyte-endothelial cell 
interaction to direct lymphocyte homing or 
extravasation (4) and the establishment and 
strengthening of contacts between T cells and 
antigen-presenting cells (APC) (5,6). In 
addition, lymphocytes express VLA-4 (integrin 
α4β1) which binds to vascular cell adhesion 
molecule 1 (VCAM-1) (7). 
The binding of ligand by LFA-1 and VLA-4 
is activated through inside-out signalling (8,9). 
Cytokines, chemokines or other T cell surface 
receptors, such as the antigen-specific T cell 
receptor (TCR) or CD2, lead to the production 
of second messengers and subsequent regulation 
of these integrins. For LFA-1 these signals are 
also generated by stimuli that increase the 
intracellular Ca2+ concentration or by protein 
kinase C (PKC) upon phorbol ester treatment. 
Models explaining the regulation of LFA-1 
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activity incorporate two distinct mechanisms. 
The first postulates modulation of the intrinsic 
affinity of the integrin for its ligand, while the 
second suggests a critical role for increased 
integrin receptor clustering or integrin 
redistribution at the cell surface (avidity 
regulation) (8). In addition to inside-out 
signalling, integrins can be activated directly 
from the outside by divalent cations, like Mn2+ 
or Mg2+ (in the presence of EGTA), which bind 
to the ectodomain (10,11) or after stimulation 
with activating monoclonal antibodies like the 
β2-specific antibody KIM185 (12) and the β1-
specific antibody TS2/16 (13).  
Recently, the small GTPase Rap1 has been 
demonstrated to play a role in TCR-, CD31- and 
cytokine-induced adhesion mediated by LFA-1, 
VLA-4 and VLA-5 (14-16). Overexpression of 
the active mutant RapV12 induced adhesion to 
immobilised ICAM-1 and VCAM-1. TCR- and 
CD31-induced activation of integrins were 
abolished by the introduction of constructs that 
inhibit Rap1 signalling, i.e. Rap GTPase 
activating protein (RapGAP), which lowers the 
level of Rap1GTP, the Rap1 binding domain 
(RBD) of RalGDS, which presumably 
inactivates Rap1 by binding to it and the 
putative dominant negative mutant RapN17 
(15). Interestingly, transgenic mice 
constitutively expressing Rap1A V12 in their T 
cell lineage have been generated (17). 
Expression of active Rap1A in primary T cells 
from these mice is sufficient to induce inside-
out signalling leading to β1 and β2 integrin-
mediated adhesion. In these cells, active Rap1A 
did not modulate integrin affinity, as was 
measured by soluble ICAM-1 binding. 
However, thymocytes expressing Rap1A V12 
showed integrin clustering at the surface, 
pointing to a role for Rap1 in integrin avidity 
modulation. 
In the present study we show that 
overexpression of Rap1 inhibitory signalling 
proteins, RapGAPs and RBD, interferes with 
the ability of Mn2+ and KIM185 to induce LFA-
1-mediated adhesion to ICAM-1, and Mn2+ and 
TS2/16 to induce VLA-4-mediated adhesion to 
VCAM-1. Both divalent cations and the 
activating antibodies do not induce 
accumulation of active Rap1GTP, consistent 
with the notion that they are thought to bypass 
the requirement for intracellular signalling 
events (18,19). This indicates that direct 
activation of integrins does not depend on 
further Rap1 activation. Although TPA-induced 
adhesion (inside-out integrin activation) may 
similarly not require activation of Rap1 (14), we 
demonstrate that it is blocked by inhibition of 
Rap1 signalling. Apparently, both stimulus-
induced inside-out regulation of integrins and 
activation of integrin-mediated cell adhesion by 
cations and integrin-activating antibodies 
require Rap1. Use of pharmacological inhibitors 
reveals that Mn2+-, KIM185-, but also RapV12-
induced LFA-1-mediated adhesion, is critically 
dependent upon intracellular Ca2+ levels, but 
independent of PKC or MEK-ERK signalling. 
Furthermore, RapV12-induced LFA-1-mediated 
adhesion requires calmodulin. We propose that 
Rap1 activity, either basal or induced, regulates 
the functional availability of integrins for the 
adhesion process by or in combination with a 
calcium/calmodulin-dependent mechanism. 
 
 
MATERIALS AND METHODS 
Plasmids and Constructs 
Haemagglutinin (HA)-tagged Rap1, Rap1V12 (HA-RapV12), 
Rap1GAP (HA-RapGAP I), RalGDS-RBD and PDZ-GEF, as 
well as pCAGGS-C3G and pSR-His-tagged Spa1 have 
previously been described (15,20,21). HA-RapGAP II was 
generated by PCR amplification of a 450 bp SalI/XhoI 
fragment including the 30 additional N-terminal amino acids 
of RapGAP II from pCA-RapGAP II (provided by Dr. 
Michiyuki Matsuda, Department of Tumor virology, Research 
Institute for Microbial Diseases, Osaka University, Japan). 
Subsequently, this fragment was subcloned into SalI/XhoI-
digested pMT2-SM-HA-RapGAP I to generate pMT2-SM-
HA-RapGAP II and integrity of the construct was confirmed 
by DNA sequencing. 
Cell Culture, Cell Line and Transfection 
The Jurkat T cell line JHM1 2.2 was provided by Dr. D. 
Cantrell (Imperial Cancer Research Fund, London, UK) with 
kind permission of Dr. A. Weiss (University of California at 
San Francisco, San Francisco, CA). Jurkat T cells were grown 
at 37°C in RPMI 1640 (Gibco Life Technologies, Paisly, UK) 
supplemented with 10% heat-inactivated (30 min. at 56°C) 
foetal bovine serum and 0.05% glutamine, in the presence of 
penicillin and streptomycin. The erythroleukemic K562 cells, 
either wild-type or stably expressing LFA-1, were grown in 
75% RPMI 1640 and 25% IMDM (Gibco Life Technologies) 
supplemented with 10% heat-inactivated foetal bovine serum 
and 0.05% glutamine, in the presence of penicillin and 
streptomycin. The stable transfectants were cultured in the 
presence of 2 mg/ml geneticin, as has been described (22). 
Cells were transiently transfected by electroporation using 35 
µg plasmid DNA. Cells (1.2×107 cells/ml in 0.4 ml complete 
medium) were pulsed at 250 V and 960 µF with 5 µg TK-
luciferase plasmid DNA, construct plasmid as indicated in the 
figure legends and added vector plasmid to keep DNA 
amounts constant. Subsequently, 24 hr. after transfection, 
cells were transferred to serum-free medium and used 42-48 
hr. after transfection.  
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Adhesion Assay 
For adhesion assays, transiently transfected Jurkat cells were 
harvested, washed and resuspended in TSM buffer (20 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) 
at a concentration of 5×105 cells/ml. 96-Well Nunc Maxisorp 
plates were coated overnight at 4°C with goat anti-human IgG 
antibodies (Jackson ImmunoResearch, West Grove, PA; 4 
µg/ml) in sodium bicarbonate buffer (Sigma, St. Louis, MO), 
washed, blocked for 30 min. at 37°C with 1% BSA/TSM, 
followed by incubation for 1 hr. at 37°C with 50 ng/ml 
recombinant ICAM-1 or 2 µg/ml VCAM-1 human IgG Fc 
fusion proteins, depending on the integrin studied. For studies 
on cell adhesion to fibronectin (Sigma, St. Louis, MO), 96-
Well Nunc Maxisorp plates were coated overnight at 4°C with 
1-5 µg/ml fibronectin in sodium bicarbonate buffer, washed 
with TSM and blocked for 30 min. at 37°C with 2% 
BSA/TSM. Poly-L-Lysine (Sigma, St. Louis, MO) was coated 
on plates for 1h. at room temperature as 0.1% w/v solution in 
water. After washing, 50 µl TSM was added per well with or 
without indicated stimuli. Subsequently, 50 µl cell suspension 
was added per well, after which the cells were spun down for 
1 min. at 200 rpm in a Heraeus Sepatech Megafuge 1.0. Cells 
were allowed to adhere for 30 min. at 37°C and non-adherent 
cells were removed with warmed 0.5% BSA/TSM. Adherent 
cells were lysed and subjected to a luciferase assay as 
described previously (23). Expression of transfected 
constructs was confirmed by immunoblotting of total cell 
lysates. Cells bound were calculated and numbers were 
corrected for transfection efficiency and nonspecific effects of 
constructs by measuring luciferase activity of total input cells 
([counts in cells bound/counts in total input cells]×100%). 
Activating anti-integrin β1 and β2 antibodies TS2/16 and 
KIM185 respectively, have been described previously (12,13) 
and were used at 10 µg/ml. Mn2+ was used at 4 mM, TPA 
(Sigma) at 100 ng/ml. Preincubations with the following 
pharmacological inhibitors were performed for 30 min. at 37 
°C: Roche 31-8220 (Calbiochem, La Jolla, CA, 5 µM), GF 
109203X (Biomol, Plymouth, PA, 5 µM), BAPTA-AM 
(Molecular Probes, Eugene, Oregon, USA, 20 µM), PD 98059 
(Sigma, 10 µM), U0126 (Promega, Madison, WI, 10 µM), 
LY294002 (Biomol, 10 µM), wortmannin (Sigma, 100 nM), 
U73122 (1 µM), SK&F96365 (concentration described in 
legend), calmidazolium chloride (10 µM), E6 Berbamine (10 
µM), W-7 (100 µM) (all five from Biomol), calpeptin (Sigma, 
100 µM), KN-93 (Calbiochem, 10 µM) and cyclosporin A 
(Biomol, 200 ng/ml).  
Analysis of Rap1 activation in vivo 
Jurkat cells were serum-starved overnight and resuspended at 
25×106 cells/ml in RPMI without serum. 200 µl of this 
suspension was used per sample. After transfer to Eppendorf 
tubes, cells were left untreated for 15 min. at 37°C. Next, 
Mn2+ (4 mM), KIM185 (10 µg/ml), TS2/16 (10 µg/ml) or 
TPA (100 ng/ml) was added for indicated periods of time. 
Subsequently, cells were lysed for 15 min. at 4°C by the 
addition of ice-cold lysis buffer (10% glycerol, 1% Nonidet 
P40, 50 mM Tris-HCl pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 
1 µM leupeptin, 0.1 µM aprotinin) and lysates were cleared 
by centrifugation at maximal speed in an Eppendorf 
centrifuge for 15 min. at 4°C. The GTP-bound form of Rap1 
was isolated using RalGDS-RBD as an activation specific 
probe and subsequently quantified by Western blotting using 
anti-Rap1 antibody, as has been previously described (24,25). 
Western Blotting  
Western blotting of all protein samples was carried out using 
polyvinylidene difluoride membranes. The antibodies used for 
protein detection are the monoclonal anti-HA (12CA5), 
polyclonal anti-HA (Santa Cruz Biotechnology, Santa Cruz, 
CA), monoclonal anti-Rap1 (Transduction Laboratories, 
Lexington, KY), polyclonal anti-Rap1 (Santa Cruz 
Biotechnology) and anti-phospho-MAPK (Cell Signaling 
Technology, New England Biolabs, Inc., Beverly, MA). 
 
RESULTS 
Inhibition of Rap1 abolishes divalent cation-
induced adhesion to ICAM-1 and VCAM-1 
To determine whether Rap1 is involved in 
Mn2+-dependent activation of LFA-1 we 
measured the effect of Rap1 inhibitory proteins 
on Mn2+-induced adhesion of Jurkat cells to 
ICAM-1, the counter receptor of LFA-1. Cells 
were transfected with RapGAP I, RapGAP II 
(which both lower the level of Rap1GTP) or 
RalGDS-RBD (which can form an inactive 
complex with Rap1GTP) together with a 
luciferase construct to detect transfected cells. 
These cells were subsequently plated on ICAM-
1 in the presence or absence of Mn2+ and after 
30 minutes nonadherant cells were washed 
away, and the percentage of luciferase- positive 
cells attached was measured. In control cells 
transfected with empty vector Mn2+ treatment 
strongly induced adhesion to ICAM-1 (Figure 
1A). In contrast, adhesion induced by Mn2+ was 
blocked in cells transfected with RapGAP I, 
RapGAP II (Figure 1A) or RalGDS-RBD 
(Figure 1B). The ability of Rap1 inhibitory 
proteins to block divalent cation- induced 
integrin adhesion was not limited to LFA-1, as 
RapGAP I and RalGDS-RBD also blocked 
Mn2+-induced adhesion of VLA-4 to VCAM-1 
(Figure 1C). Furthermore, Mg2+/EGTA-induced 
adhesion to ICAM-1 was also blocked by 
RapGAP and RalGDS-RBD (data not shown). 
 
RapGAP proteins act on active Rap1-
induced adhesion 
To confirm the specificity of RapGAP 
proteins in blocking Rap1-dependent adhesion, 
Jurkat cells were transfected with active 
RapV12, or the Rap1 guanine-nucleotide 
exchange factors (GEFs) C3G or PDZ-GEF, to 
activate endogenous Rap1, either alone or in 
combination with RapGAP II (Figure 2A). Like 
in our previous studies, RapV12 strongly 
induced adhesion to ICAM-1, while 
overexpression of C3G or PDZ-GEF resulted in 
a more modest but significant induction of 
adhesion. Cotransfection of cells with RapGAP 
II however, completely blocked adhesion  
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Figure. 1. Inhibition of Rap1 activity abolishes Mn2+-
induced LFA-1- and VLA-4-mediated cell adhesion. 
Inhibition of Rap1 activity by transiently overexpressing 
Rap1-specific GAPs (a, data represent the average 
mean and standard errors of four independent 
experiments, with each experiment performed in 
quadruplicate) or RalGDS-RBD (b, representative 
experiment in quadruplicate) resulted in decreased 
basal adhesion and inhibited cells in their Mn2+-induced 
LFA-mediated adhesion response. Jurkat cells were 
cotransfected with 5 µg pG3-TK luciferase reporter 
plasmid and either empty pMT2-SM-HA vector (vector), 
HA-RapGAP I (RapGAP I) (20 µg), HA-RapGAP II 
(RapGAP II) (20 µg), or HA-RalGDS-RBD (RBD) (10 or 
25 µg), and after 42 hr. the cells were allowed to 
adhere to immobilised ICAM-1 for 30 min. at 37°C. 
Fraction of cells bound was determined by fraction of 
luciferase activity bound. In the bottom panels expression levels of the transfected proteins are shown. c, Inhibition of 
Rap1 activity abolished Mn2+-induced VLA-4-mediated adhesion. Jurkat cells were cotransfected with constructs as 
indicated in a, and the cells were allowed to adhere to immobilised VCAM-1. Results are the average from two 
independent experiments in quadruplicate and indicated as the relative binding to VCAM-1 as compared to vector 
control.  
 
 
induced by RapV12, C3G or PDZ-GEF, 
indicating that RapGAP II inhibited Rap1-
dependent signalling. Precipitation of GTP-
bound transfected Rap1 with GST-RalGDS-
RBD fusion protein (Figure 2B) confirmed that 
transfected RapGAP II catalysed hydrolysis of 
GTP of both wild-type Rap1 and RapV12. 
Together these results show that RapGAP 
overexpression blocks Rap1-induced adhesion 
by decreasing the Rap1GTP amount. We 
conclude that Rap1GTP is required for 
induction of LFA-1 and VLA-4 integrin-
dependent adhesion induced by divalent cations. 
Inhibition of Rap1 blocks adhesion induced 
by β1 and β2 integrin-activating antibodies 
Integrin-mediated cell adhesion induced by 
Mn2+ is proposed to occur by direct interactions 
of these cations with the extracellular domains 
of integrins rather than via intracellular 
signalling pathways. However, Mn2+ might also 
influence other cell surface or intracellular 
signalling proteins. Therefore, we tested the 
effect of Rap1 on cell adhesion induced by the 
monoclonal antibody KIM185. This antibody 
directly and specifically activates LFA-1 
integrin in its ligand-binding capacity (12). 
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Figure 2. Inhibition of active Rap1-
induced adhesion and decrease of 
RapGTP levels by RapGap proteins. 
a, Rap1-specific GEFs induced LFA-
mediated adhesion. Both RapV12- and 
Rap1GEF-induced LFA-1-mediated ad-
hesion could be blocked by cotransfec-
tion of RapGAP II (representative expe-
riment in quadruplicate). Jurkat cells 
were cotransfected with 5 µg pG3-TK 
luciferase reporter plasmid and either 
empty vector, HA-RapV12 (10 µg), 
C3G (10 µg), HA-PDZ-GEF (10 µg), 
HA-RapGAP II (10 µg) or indicated 
combinations of them (10 µg of each 
construct). b, RapGAP II efficiently 
decreased GTP levels of both cotrans-
fected Rap1wt and RapV12. Jurkat 
cells were transfected with empty 
vector, HA-Rap1 or HA-RapV12 alone 
or in combination with HA-RapGAP II 
(amounts of DNA [µg] as indicated in 
the figure). The upper panel shows the 
GTP levels of the Rap proteins 
determined using the pulldown-assay 
(Materials and Methods), the middle 
panel demonstrates the expression of 
HA-RapGAP II in the total lysates and 
the lower panel shows the presence of 
HA-Rap1wt and HA-RapV12 in the total 
lysates. 
 
 
Treatment of Jurkat cells with KIM185 strongly 
induced adhesion to ICAM-1 (Figure 3A). 
Similar to Mn2+, cell adhesion induced by 
KIM185 was completely blocked by 
transfection of either RapGAP I or RalGDS-
RBD. VLA-4-mediated adhesion to VCAM-1 
induced by the activating anti-β1 integrin 
antibody TS2/16 was also completely blocked 
by transfection of cells with either of two 
RapGAPs, RapGAP I or Spa1 (Figure 3B). The 
inhibitory effect of RapGAP on Mn2+- and 
KIM185-induced adhesion to ICAM-1 was also 
observed in the erythroleukemic cell line K562 
stably expressing LFA-1 (22) (Figure 3C). In 
wild-type K562 cells, which only express VLA-
5 (α5β1) as β1 class of integrin (26), RapGAP II 
abolished TS2/16-induced adhesion to 
fibronectin (Figure 3D). Our findings 
demonstrate that Rap1 is required for adhesion 
induced by integrin-activating antibodies.  
 
Blocking Rap1 specifically affects 
integrin/ligand-mediated adhesion 
To show that the Rap1 requirement is 
specific for integrin-ligand binding we tested 
cell adhesion to poly-L-Lysine. No difference in 
cell attachment was observed upon expression 
of Rap1V12 or RapGAP, either in the absence 
or presence of TS2/16 (Figure 4A). We also 
used another approach to demonstrate that 
RapGAP inhibits integrin-ligand-based cell 
binding. Increasing the amount of immobilised 
fibronectin concomitantly increased basal cell 
binding, which could be abolished by 
expression of RapGAP (Figure 4B). 
Interestingly, we observed that higher 
fibronectin densities rescued the inhibitory 
effect of RapGAP on TS2/16-induced adhesion, 
both with K562 and Jurkat cells. Mn2+-induced 
adhesion could still be inhibited by RapGAP II 
at the highest fibronectin concentration used (5 
µg/ml; data not shown). From these results we 
conclude that blocking Rap1 specifically 
inhibits adhesion mediated by integrin-ligand 
binding, but that integrins and processes 
required for adhesion are still functional.  
 
Mn2+-/KIM185-treatment does not activate 
Rap1 
The requirement for Rap1 in Mn2+- and 
antibody-induced integrin-mediated cell 
adhesion suggested the possibility that both  
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Figure 3. Inhibition of Rap1 activity abolishes anti-integrin antibody-induced LFA-1- and VLA-4-mediated cell 
adhesion. a, Inhibition of Rap1 activity by transient expression of either HA-RapGAP I or HA-RalGDS-RBD inhibited 
KIM185-induced LFA-mediated adhesion (representative experiment performed in quadruplicate). b, Transient 
expression of either HA-RapGAP I or Spa1 inhibited TS2/16-induced VLA-4-mediated adhesion (average of two 
independent experiments performed in quadruplicate, normalised to 1 for untreated vector control). c, Transient 
expression of RapGAP II inhibited Mn2+- or KIM185-induced adhesion to ICAM-1 of K562 cells stably expressing 
LFA-1. d, RapGAP abolished TS2/16-induced adhesion of wild-type K562 cells to fibronectin (coated with 1 µg/ml 
concentration). Jurkat and K562 cells with and without stably expressed LFA-1were transfected with 5 µg pG3-TK 
luciferase reporter plasmid and empty pMT2-SM-HA vector (vector), HA-RapV12 (RapV12) (10 µg), HA-RapGAP I 
(RapGAP I) (10 µg), HA-RalGDS-RBD (RBD) (10 µg) or Spa1 (10 µg). After 42 hr. cells were allowed to bind to 
immobilised ICAM-1 (a and c), VCAM-1 (b) or fibronectin (c and d) in the presence and absence of anti-integrin 
antibody KIM185 (a and c), TS2/16 (b and d) or Mn2+ (c).  
 
 
stimuli mediated adhesion via activation of 
Rap1. We therefore tested whether Mn2+, 
KIM185 or TS2/16 were able to induce Rap1 
activation (Figure 5). Cells were stimulated for 
30 minutes, corresponding to the duration of the 
adhesion assay and Rap1GTP was analysed 
using the RalGDS-RBD as activation specific 
probe. No activation of Rap1 was observed with 
Mn2+ (Figure 5A). In contrast, strong activation 
of Rap1 was observed following treatment with 
TPA. Surprisingly, Mn2+ treatment did induce a 
modest and sustained activation of the 
MEK/ERK signalling pathway, as indicated by 
phosphorylation of ERK1 (p44) and ERK2 
(p42) (Figure 5A). Treatment of cells with 
KIM185 (Figure 5B) or TS2/16 (Figure 5C) 
neither increased the Rap1GTP level nor 
induced ERK activation. Thus, although both 
divalent cations and activating anti-integrin 
antibodies stimulate adhesion in a Rap1-
dependent manner, this is not a result of acute 
activation of Rap1. 
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Figure 4. Inhibition of Rap1 activity abolishes 
specifically integrin-ligand-mediated cell adhesion. 
a, Transient overexpression of RapV12 or RapGAP in 
K562 cells in the presence or absence of TS2/16, did 
not affect cell binding to immobilised poly-L-Lysine 
(representative experiment performed in quadruplicate). 
b, Inhibition of cell adhesion induced by increased 
ligand density by transient expression of RapGAP. High 
ligand densities in combination with TS2/16 treatment 
overcame cell adhesion inhibition by RapGAP 
overexpression. The upper panel shows adhesion of 
K562 cells with and without transient expression of 
RapGAP to fibronectin (FN, with indicated 
concentrations in µg/ml used for coating), in the 
presence and absence of TS2/16. In the lower panel a 
similar situation is shown for Jurkat cells (representative 
experiments performed in triplicate). Jurkat cells and 
K562 cells were transfected with 5 µg pG3-TK luciferase 
reporter plasmid and empty pMT2-SM-HA vector 
(vector), HA-RapV12 (RapV12) (10 µg) or HA-RapGAP 
II (RapGAP II) (20 µg). After 42 hr. cells were allowed to 
bind to immobilised poly-L-Lysine (a) or fibronectin 
(plates coated with indicated dilutions of ligand) (b), in 
the presence and absence of anti-integrin antibody 
TS2/16. 
 
Figure 5. Rap1 is not activated by Mn2+ and 
activating anti-integrin antibodies. Jurkat cells were 
unstimulated (basal) or treated for the indicated periods 
of time with either 4 mM Mn2+ (a), the LFA-1 activating 
antibody KIM185 (b) or the VLA-4 activating antibody 
TS2/16 (c). Cells were lysed and RapGTP was 
determined using the RBD pulldown assay. Upper 
panels: RapGTP levels determined by the pulldown 
assay. Middle panels: Total Rap1 in the lysates to 
demonstrate equal input per sample. Lower panels: 
Lysates were analysed for the presence of 
phosphorylated ERK. Treatment for 5 min. with TPA 
(100 ng/ml) was used as a positive control for Rap1 
activation. 
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Inhibition of TPA-induced adhesion by Rap1 
interfering proteins 
The phorbol ester TPA is generally used to 
induce integrin-mediated cell adhesion by a still 
elusive pathway. Therefore, we investigated the  
Figure 6. Effect of inhibiting basal Rap1 signalling 
on TPA-induced inside-out activation of LFA-1-
mediated adhesion. a, Timecourse demonstrating 
RapGTP levels upon TPA treatment (100 ng/ml) for 
indicated periods of time. The upper panel shows 
RapGTP levels. The middle panel shows total Rap1 in 
the lysates to demonstrate equal input per sample. The 
bottom panel demonstrates ERK phosphorylation during 
the timecourse. b, TPA-induced Rap1 and MAPK 
activity in the presence of pharmacological PKC 
inhibitors. After preincubation for 30 min. with either GF 
109203X or Ro 31-8220 (5 µM) cells were treated with 
TPA (100 ng/ml) for 5 min. The upper panel 
demonstrates Rap1GTP levels, the middle panel shows 
the presence of equal amounts Rap1 in each sample, 
and in the bottom panel ERK phosphorylation is shown. 
c, TPA-induced LFA-mediated adhesion to immobilised 
ICAM-1 is dependent on basal Rap1 activity. Jurkat 
cells were transfected with 5 µg pG3-TK luciferase 
reporter plasmid and either empty pMT2-SM-HA vector 
(vector), HA-RapGAP I (20 µg) or HA-RalGDS-RBD (20 
µg) after which binding to immobilised ICAM-1 in the 
presence and absence of TPA (100 ng/ml) was 
analysed (average of 2-3 independent experiments).  
 
possible requirement for Rap1 in TPA-induced 
integrin-mediated cell adhesion as well. 
Treatment of Jurkat cells with TPA resulted in a 
rapid and prolonged activation of Rap1 as well 
as induction of ERK phosphorylation (Figure 
6A). Pretreatment of Jurkat cells with 
pharmacological inhibitors of PKC (Roche 31-
8220 and GF 109203X) inhibited TPA-induced 
activation of both Rap1 and ERK (Figure 6B). 
Although previous studies have provided 
evidence that excludes the requirement for Rap1 
activation in TPA-induced adhesion (14), 
overexpression of RapGAP I or RalGDS-RBD 
blocked TPA-induced adhesion to ICAM-1 
(Figure 6C). Pharmacological inhibition of PKC 
selectively blocked TPA-, but not Mn2+- or 
KIM185- induced adhesion to ICAM-1 (Figure 
7A). These findings show that TPA-induced 
inside-out activation of adhesion requires Rap1 
activity, either basal or induced. 
 
Rap1induced adhesion requires intracellu-
lar calcium and calmodulin 
To study the mechanism by which Rap1 
regulates integrins, we tried to identify common 
elements between RapV12- and Mn2+- or 
activating antibody-induced cell adhesion. 
Several reports have provided strong evidence 
that agonist-induced adhesion in a number of 
heamatopoietic cell types requires influx of 
calcium from extracellular sources (19,27,28). 
Indeed, the calcium chelator BAPTA-AM 
strongly inhibited basal, Mn2+-, TPA- and  
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Figure 7. Involvement of intracellular calcium in 
RapV12-induced LFA-1-mediated cell adhesion. a, 
Effect of PKC inhibitors and the calcium chelator BAPTA-
AM on LFA-1-mediated adhesion to immobilised ICAM-1. 
Jurkat cells were transfected with 5 µg pG3-TK luciferase 
reporter plasmid and empty pMT2-SM-HA vector. The 
next day, cells were serum-starved overnight and 42h 
after transfection cells were pretreated for 30 min. with 
intracellular Ca2+-chelator BAPTA-AM (20 µM) or one of 
the PKC inhibitors Roche 31-8220 (Ro) (5 µM) and GF 
109203X (GF) (5 µM) for 30 min. at 37°C, after which 
binding to immobilised ICAM-1 in the absence and 
presence of Mn2+, TPA or KIM185 was determined. Left 
panel: Fold inductions of cell adhesion to immobilised 
ICAM-1 upon treatment of Jurkat cells with Mn2+, TPA or 
KIM185. Right panel: Percentages inhibition of cell 
binding to ICAM-1 upon treatment with the inhibitors is 
shown (average of 3-6 independent experiments 
performed in quadruplicate). RapV12-induced LFA-1-
mediated adhesion to ICAM-1 could be blocked by b) 
chelation of intracellular calcium with BAPTA-AM (20 µM), c) inhibition of calcium channels with the imidazole 
compound SK&F 96365 (SK&F) (100, 30 and 10 µM) and d) inhibition of calmodulin with calmidazolium chloride 
(CalmC; 10 µM), E6 berbamine (10 µM) and W-7 (100 µM). Jurkat cells were transfected with 5 µg pG3-TK luciferase 
reporter plasmid and either empty pMT2-SM-HA vector (vector) or HA-RapV12 (10 µg). After 42 hr., they were left 
untreated or preincubated for 30 min. with the inhibitors and subsequently cells were incubated for 30 min. at 37°C to 
allow binding to immobilised ICAM-1. Data represent the average of 3 independent experiments performed in 
quadruplicate. 
 
Kim185-induced LFA-mediated adhesion 
(Figure 7A). We therefore examined next 
whether RapV12-induced adhesion also 
displayed a similar requirement. Chelation of 
intracellular calcium with BAPTA-AM strongly 
inhibited both basal and RapV12- induced 
adhesion (Figure 7B). Preincubation of 
RapV12-transfected Jurkat cells with the 
imidazole compound SK&F 96365, which 
inhibits calcium channels in leukocytes and thus 
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lowers intracellular calcium, efficiently blocked 
basal and RapV12-induced adhesion in a dose-
dependent manner (Figure 7C). The calmodulin 
inhibitors W-7, E6 berbamine, and calmidolium 
chloride each blocked RapV12-induced 
adhesion (Figure 7D). From these results we 
conclude that RapV12-induced adhesion, like 
adhesion induced by other stimuli, requires 
calcium signalling.  
 
The MEK-ERK pathway is not involved in 
Rap1-mediated cell adhesion 
We were particularly interested in a possible 
role of the MEK-ERK pathway in Rap1-
mediated cell adhesion, since positive and 
negative regulation of this pathway by Rap1 is a 
predominant effect of Rap1 reported in T 
lymphocytes and other cell types (29-31). To 
measure whether the MEK-ERK pathway 
mediates Rap1-induced adhesion, we used the 
MEK inhibitors PD 98059 and U0126. 
Although both MEK inhibitors completely 
inhibited TPA-induced ERK activation (data not 
shown) they did not affect RapV12- or Mn2+-
induced adhesion (Figure 8). Alternatively, 
Rap1 may mediate cell adhesion by inhibiting 
ERK activation, suggesting that RapGAP might 
inhibit cell adhesion by preventing the 
inactivation of ERK. However, in the presence 
of the two MEK inhibitors, RapGAP II still 
inhibited cell adhesion. From these results we 
conclude that MEK and therefore most likely 
ERK is not involved in Rap1-mediated cell 
adhesion. This is confirmed by recent findings 
that active Rap1 did not interfere with the Ras 
signalling pathway (17). By utilising the PI(3)-
kinase (PI(3)K) inhibitors wortmannin and 
LY294002 and the phospholipase C (PLC) 
inhibitor U73122, we did not find a role for 
PI(3)K or PLC in either RapV12- or Mn2+-
induced adhesion (data not shown).  
 
DISCUSSION 
Previously, we and others have shown that the 
small GTPase Rap1 is required for cytokine-
induced inside-out activation of various 
integrins, including LFA-1, VLA-4 and αMβ2 
(14,15,32,33). In this manuscript we now 
demonstrate that also direct activation of LFA-
1-, VLA-4- and VLA-5-mediated adhesion by 
Mn2+ or integrin-activating antibodies 
(monoclonal KIM185 for LFA-1 and TS2/16 for  
 
 
Figure 8. MEK-ERK pathway is not involved 
in Rap1-mediated cell adhesion to ICAM-1. 
Jurkat cells were transfected with 5 µg pG3-TK 
luciferase reporter plasmid and empty pMT2-
SM-HA vector (vector), HA-RapV12 (10 µg) or 
RapGAP I (20 µg). After 42 hr., cells were 
either left untreated or preincubated with the 
MEK inhibitors PD 98059 (10 µM), or U0126 
(10 µM) for 30 min. at 37°C, after which the 
cells were allowed to bind to immobilised 
ICAM-1 for 30 min. in the presence and 
absence of Mn2+. Data represent the mean and 
standard errors of two independent experiments 
performed in quadruplicate. 
 
VLA-4 and VLA-5) is sensitive to inhibition of 
Rap1 signalling . This is shown by 
overexpression of either Rap-specific GAPs, 
which interfere with Rap1 signalling by 
reducing levels of endogenous GTP-bound 
Rap1, or overexpression of RalGDS-RBD, 
which inhibits Rap1 signalling by binding to 
GTP-bound Rap1 and sequestering it from 
potential effector proteins, in Jurkat and K562 
(Figure 1 and 3). As an assay to monitor 
enhanced integrin function we measured 
binding to immobilised integrin ligands, i.e. 
ICAM-1 for LFA-1, VCAM-1 for VLA-4 and 
fibronectin for VLA-4 and VLA-5. This 
unexpected finding raised the question whether 
the inhibition is due to an integrin-specific 
effect or whether Rap1 affects a general 
requirement for integrin-mediated cell adhesion, 
like cytoskeletal rearrangements and cell 
spreading. However, inhibition of Rap1 
signalling did not affect integrin-independent 
adhesion to poly-L-Lysine (Figure 4A). In 
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addition, inhibition of TS2/16-induced adhesion 
by blocking Rap1 signalling could be rescued 
by increasing the fibronectin concentration 
(Figure 4B). Moreover, inhibitors of actin 
cytoskeleton dynamics, cytochalasin D (14) and 
jasplakinolide (K. de B. unpublished results), 
did not influence RapV12-induced adhesion.  
Basal Rap1 signalling may be sufficient to 
play a role in integrin-mediated adhesion, since 
we have not observed an increase in Rap1GTP 
upon treatment with either Mn2+ or activating 
antibodies (Figure 5). This may imply that Rap1 
only provides a favourable setting for enhanced 
integrin function. In agreement with a 
facilitating function for Rap1 are the recent 
findings that overexpressing Rap1B V12 in 
megakaryocytes itself had no effect, but 
augmented fibrinogen binding to αIIbβ3 induced 
by a PAR4 thrombin receptor agonist (34). In 
addition, we have not observed increased 
adhesion of human megakaryoblasts 
overexpressing active Rap1 to immobilised 
fibrinogen, while we have found inhibition of 
TPA-induced adhesion by RapGAP 
(unplubished results). However, RapV12, as 
well as Rap1-specific GEFs that activate 
endogenous Rap1, are able to induce increased 
integrin-mediated cell adhesion (Figure 2), 
showing that activation of Rap1 is sufficient to 
enhance the function of LFA-1.  
We have also investigated the involvement 
of putative Rap1 effectors in the regulation of 
integrins. Although regulation of the MEK-ERK 
pathway is reported to be a predominant effect 
of Rap1 in T lymphocytes and other cell types 
(29-31), MEK inhibitors neither blocked 
RapV12- nor Mn2+-induced adhesion (Figure 8). 
Interestingly, this issue was recently analysed in 
an in vivo model system (17). In agreement with 
our results, transgenic mice constitutively 
expressing Rap1A V12 in their T cell lineage 
did not demonstrate a modulating role for Rap1 
in the MEK-ERK pathway. Furthermore, 
inhibitors of the proposed Rap1 targets PLC and 
PI(3)K did not interfere with RapV12- or Mn2+-
induced adhesion. However, pretreatment of 
cells with the intracellular calcium chelator 
BAPTA-AM inhibited both basal adhesion and 
RapV12-, Mn2+- or integrin activating antibody-
induced adhesion to a similar extent (Figure 7). 
Utilisation of the SK&F 96365 inhibitor, which 
blocks extracellular calcium channels required 
for leukocyte adhesion, also blocked RapV12-
induced adhesion. This result is compatible with 
recent evidence that extracellular stimuli 
inducing T lymphocyte adhesion via LFA-1, 
such as TCR stimulation and phorbol esters, do 
so by inducing an influx of extracellular 
calcium (28). Although in several studies Rap1 
has been implicated in the regulation of cellular 
calcium levels (35-37), clear evidence is still 
lacking. A recent study demonstrated that 
Rap2b via interaction with PLCε is able to 
regulate intracellular calcium signalling in 
HEK293 cells (38). A large number of calcium 
responsive signalling proteins have been shown 
to regulate integrin-dependent adhesion in 
various cell types, like calpain (28,39,40), 
calmodulin (41), and calcium/calmodulin-
dependent kinase II (42-44). In the case of 
RapV12-induced adhesion, calmodulin is 
required (Figure 7D). However, we could not 
demonstrate a role for calpain, 
calcium/calmodulin-dependent kinase II or 
calcineurin in RapV12-induced integrin 
function (Figure 7). The function of this 
calmodulin requirement is therefore still 
unclear. 
Our results indicate that all stimuli that 
enhance the function of integrins tested, 
including inside-out signalling and direct 
activation, require Rap1. Previously, it was 
reported that the phorbol ester TPA may induce 
integrin activation independent of Rap1 
activation (14). However, we have found that 
overexpression of RapGAPs or RalGDS-RBD 
efficiently blocked TPA-induced adhesion, 
indicating that Rap1-GTP is also required for 
TPA-induced integrin activation. How Rap1 
enhances integrin function is still elusive. Cell 
surface expression of integrins is not affected by 
Rap1 signalling interference (14,15). This 
indicates that Rap1 is involved in the increase in 
integrin function, either by inducing a 
conformational change or by inducing 
clustering of integrins, two nonexclusive modes 
of integrin activation (8,9,45). Importantly, the 
effect of Rap1 on integrin function occurs with 
both β1 and β2 integrins. The most plausible 
explanation for the role of Rap1 is regulation of 
auxillary factors for integrin function. These 
factors may be signalling or structural proteins 
that associate with integrin cytoplasmic tails 
(46). Matsuda and co-workers have utilised 
fluorescent resonance energy transfer (FRET) 
analysis to visualise Rap1 activation in vivo, and 
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have noted that growth factor-induced Rap1 
activation initiates in the perinuclear region 
(47). Perhaps Rap1 influences integrin 
processing, the repertoire of integrin-associated 
proteins that is delivered to surface, or 
modulates membrane microdomain organisation 
(lipid rafts) (48,49) influencing integrin function 
(50).  
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Recently, several studies have provided evidence for a function of the small GTPase 
Rap1 in the regulation of the intracellular calcium homeostasis. Moreover, in human 
megakaryocytes, cAMP-induced increase in intracellular calcium was found to be 
independent of protein kinase A (PKA). We therefore tested the hypothesis that the 
cAMP target Epac, a guanine nucleotide exchange factor (GEF) for Rap1, mediates 
this increase in calcium. For these analyses the synthetic cAMP analogue E-cAMP was 
used. This compound specifically activates Epac both in vitro and in vivo. Here we 
show that in platelets E-cAMP is indeed specific and did not induce typical cAMP-
PKA mediated effects like inhibition of thrombin-induced increase in intracellular 
calcium concentration and inhibition of thrombin-induced Rap1 activation. In 
megakaryocytes, we were unable to demonstrate activation of Rap1 by cAMP or E-
cAMP, indicating that a functional Epac-Rap1 pathway may not exist in these cells. In 
addition, in contrast to forskolin, E-cAMP did not induce an increase in the 
intracellular calcium level. From these results we conclude that the cAMP-induced 
PKA-independent increase in the intracellular calcium concentration in 
megakaryocytes is not mediated by the cAMP-Epac-Rap1 pathway. 
 
 
 
INTRODUCTION 
The small Ras-like GTPase Rap1 (Ras-
proximate) was identified both in a screen for 
proteins related to the small GTPase Ras (1,2) 
and as the cDNA product able to induce flat 
revertants of K-ras-transformed cells (Krev-1) 
(3). Remarkably, in addition to reversion of 
oncogenic transformation Rap1 has been 
implicated in the induction of oncogenic 
transformation in other cell types (4,5). The 
similarity in the effector domains between Ras 
and Rap1 has raised the attractive hypothesis 
that Rap1 may interfere in Ras signalling, 
possibly by interaction with Ras effectors Raf1, 
B-Raf and guanine-nucleotide exchange factors 
(GEFs) for Ral (6-9). Although Rap1 has been 
shown to be able to regulate the extracellular 
signal-regulated kinases (ERKs) both positively 
(10,11) and negatively (12,13), debate is still 
going on about the control of the ERK pathway 
by Rap1 in vivo (14,15, JM Enserink et al., 
submitted). However, compiling evidence 
suggests Rap1 functions in other cellular 
processes. Rap1 has been implicated in platelet 
activation (16), exocytosis (17), differentiation 
(18,19) and regulation of integrin-mediated cell 
adhesion (15,20-24). Moreover, in lower 
eukaryotes, Rap1 orthologues contribute to 
processes related to the establishment of cell 
polarity (reviewed in (14)) and the regulation of 
adherens junction positioning and cell adhesion 
(25). 
Rap1 can be activated in various cell types 
with a plethora of stimuli (16,26-30). Different 
signalling pathways contribute to Rap1 
activation, depending on the receptor and the 
cell type. In general, the second messengers 
calcium, diacylglycerol (DAG) and cyclic 
adenosine monophosphate (cAMP) are used in 
the upstream control. Four families of guanine-
nucleotide exchange factors (GEFs) have been 
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characterised that regulate the activation of 
Rap1. The first, C3G, may regulate tyrosine 
kinase-induced Rap1 activation through the 
adapter proteins Crk and Cbl (29,31,32). 
Second, the Epacs, which are directly regulated 
by cAMP (33,34). Members of the third, the 
CD-GEF family, contain calcium- and DAG-
binding domains and show different GTPase 
specificities (35-37). Evidence exists which 
indicates differential regulation of these 
members by calcium and DAG (J. de Rooij, 
unpublished results). Finally, the PDZ-GEFs, 
which have so far not been connected to 
upstream activators ((38), H.B. Kuiperij et al. 
submitted). 
Rap1 has been connected to signal 
transduction initiated by intracellular calcium 
(Ca2+i). An increase in the intracellular calcium 
concentration ([Ca2+]i ) was demonstrated to be 
necessary and sufficient to activate Rap1 in 
platelets (16). Interestingly however, Ca2+i 
might not only function upstream from Rap1, as 
independent studies suggest a role for Rap1 in 
the regulation of [Ca2+]i. First, evidence has 
been provided for a cAMP-regulated 
Phospholipase-C-ε (PLC-ε)- calcium signalling 
pathway that is mediated by Rap2B (39). 
Secondly, Rap1 has been suggested to function 
in Ca2+i homeostasis in platelets. Rap1 and the 
97 kDa sarco-/endoplasmic reticulum Ca2+-
ATPase (SERCA), that is associated with 
inositol 1,4,5-trisphosphate (IP3)-sensitive Ca2+-
stores in intracellular membranes linked to the 
plasma membrane, interacted in co-
immunoprecipitation experiments. This 
interaction dissociated upon phosphorylation of 
Rap1 in the membrane preparations by the 
catalytic subunit of PKA (40). GTPγS, a non-
hydrolysable GTP analogue, was found to 
inhibit both SERCA activity and the 
phosphorylation of Rap1b by the catalytic 
subunit of PKA in membrane preparations of 
platelets (41). Moreover, the expression of 
SERCA and Rap1 in platelets and various other 
cell lines seem to correlate (42,43). Finally, 
immature human megakaryocytes have been 
demonstrated to respond upon iloprost- or 
forskolin-induced cAMP production with an 
increase in [Ca2+]i, which is insensitive to the 
PKA inhibitor H-89 (44). In this latter study, 
Rap1 activity was reported to parallel the [Ca2+]i 
increase induced by cAMP-elevating 
treatments, suggesting the involvement of the 
Epac-Rap1 pathway. 
We have addressed the question whether the 
cAMP-regulated Epac-Rap1 signalling pathway 
controls [Ca2+]i in megakaryoblasts. We 
therefore used E-cAMP, a cAMP analogue that 
activates Epac with a 30-100 times higher 
affinity as compared to PKA (JM Enserink et 
al., submitted). This tool enabled us to focus 
specifically on the downstream effects of 
cAMP-initiated signalling mediated by the 
Epac-Rap1 cascade. In the present study we 
show that treatment of MEG-01 cells with E-
cAMP did not result in increased [Ca2+]i. 
Moreover, we did not find evidence for a 
functional cAMP-Epac-Rap1 signalling 
pathway to exist in MEG-01 cells. From these 
results we conclude that the cAMP-Epac-Rap1 
pathway in not involved in cAMP-mediated 
regulation of intracellular calcium.  
 
 
 MATERIALS AND METHODS 
Materials 
Fura-2-acetomethylester (Fura-2/AM) and α-thrombin were 
from Sigma (St. Louis, MO, USA. Forskolin was purchased 
from Calbiochem (San Diego, Ca, USA) while 8-Bromo-
cAMP and E-cAMP were from Biolog Life Science Institute. 
Cell Culture and Cell Line 
The MEG-01 cell line was grown at 37°C in RPMI 1640 
(Gibco Life Technologies, Paisly, UK) supplemented with 
20% heat-inactivated (30 minutes at 56°C) foetal bovine 
serum. OVCAR cells were cultured in RPMI 1640 supple-
mented with heat-inactivated10% foetal bovine serum. Both 
cell lines were grown in the presence of 0.05% glutamine, 
penicillin and streptomycin, in a humidified atmosphere with 
5% CO2. Prior to stimulation, cells were serum-starved 
overnight. 
Platelet Isolation 
Donors claimed not to have taken any medication during the 
preceding 10 days. After informed consent was obtained, 
freshly drawn venous blood from healthy volunteers was 
collected into 0.1 volume of 130 mM trisodium citrate. 
Citrated blood was centrifuged (150×g, 15 minutes at 20°C) 
and subsequently the platelet-rich plasma was supplemented 
with prostaglandin I2 (10 ng/ml) and ACD (2.5 g tri-sodium 
citrate, 1.5 g citric acid and 2.0 g D-glucose in 100 ml dH2O) 
for acidification to pH 6.5 and centrifuged again (330×g, 15 
minutes at 20°C). 
Measurement of Calcium Responses 
Platelet-rich plasma was supplemented with 3 µM Fura-2/AM 
and incubated for 45 minutes at 37°C in the dark. Next, the 
platelet-rich plasma was supplemented with ACD for acidifi-
cation to pH 6.5 and centrifuged (330×g, 15 minutes at 20°C). 
Platelets were resuspended in Hepes-Tyrode (HT) buffer (145 
mM NaCl, 5 mM KCl, 0.5 mM NaH2PO4, 1 mM MgSO4, 1 
mM CaCl2, 10 mM Hepes and 0.1% (w/v) glucose) pH 6.5, to 
a concentration of 2×109 and stored at room temperature in 
the dark. Immediately before [Ca2+]i measurement, the platelet 
suspension was diluted 10 times in prewarmed (37°C) HT 
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buffer (pH 7.4) and GRGDS peptide (100 µM) was added to 
prevent platelet aggregation. MEG-01 cells were pelleted (5 
minutes, 125×g, 20°C) and resuspended in HT buffer pH 7.4 
supplemented with 0.1% (w/v) BSA, at a concentration of 
5×105 cells/ml. Next, Fura-2/AM was added to a final concen-
tration of 3 µM and cells were loaded for 1 hour at 37°C in 
the dark. Subsequently, cells were spun down, resuspended in 
HT-buffer without BSA to a final concentration of 1.6×106 
cells/ml and stored at room temperature in the dark. 
Immediately before analysis of [Ca2+]i, the cells were 
resuspended in prewarmed (37°C) HT-buffer at 2×105 
cells/ml. Measurements were performed at 37°C under mild 
stirring (50 rpm) on a Hitachi F-4500 fluorescence 
spectrophotometer (Hitachi Ltd., Tokyo, Japan). Fura-2 
fluorescence was measured at 340 nm (F1) and 380 nm (F2) 
excitation and 510 nm emission wavelength. Measurements, 
calibrations and calculations were performed as described 
previously (44). 
Analysis of Rap1 activation using an activation-specific 
probe 
MEG-01 cells were resuspended at 5×106 cells/ml in RPMI 
without serum. 200 µl of this suspension was used per 
sample. After transfer to eppendorf tubes, cells were left 
untreated or preincubated with an inhibitor as indicated in the 
Results section for 30 minutes at 37°C. Next, a stimulating 
agent was added after which samples were mixed gently and 
incubated for indicated periods of time. Subsequently, cells 
were lysed for 15 minutes at 4°C by the addition of ice-cold 
lysis buffer (10% glycerol, 1% Nonidet P40, 50 mM Tris-HCl 
pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 1 µM leupeptin, 0.1 
µM aprotinin) and lysates were cleared by centrifugation at 
maximal speed in an Eppendorf centrifuge for 15 minutes at 
4°C. The GTP-bound form of Rap1 was isolated using 
RalGDS-RBD as an activation specific probe and 
subsequently quantified by Western blotting using anti-Rap1 
antibody, as has been described previously (16,45,46). 
Determination of PKA Activity 
Analysis of PKA activity in platelets and MEG-01 cells upon 
indicated treatments was carried out by using the mobility-
shift of VASP on Western blot as a readout (47). This is 
caused by PKA-mediated phosphorylation on Ser 157. 
Alternatively, phosphorylation of CREB (cAMP responsive 
element binding protein) was used as read-out for PKA 
activity. 
Western Blotting 
Western blotting of all protein samples was carried out using 
polyvinylidene difluoride membranes. The antibodies used for 
protein detection are the rabbit polyclonal anti-Rap1 (Santa 
Cruz Biotechnology, CA, USA) and goat polyclonal anti-
VASP (Santa Cruz Biotechnology). The secondary goat-anti-
rabbit-HRP antibody was from Santa Cruz Biotechnology and 
rabbit-anti-goat-peroxidase was purchased from DAKO 
(Glostrup, Denmark).  
 
 
RESULTS 
E-cAMP does not inhibit thrombin-induced 
increase in [Ca2+]i in platelets 
Previous studies have demonstrated that 
treatment with the stable derivative of 
prostacyclin, iloprost, or forskolin results in a 
simultaneous accumulation of cAMP and 
[Ca2+]i in the immature megakaryoblastic cell 
line MEG-01. These signalling events were 
accompanied by an increase in the Rap1GTP 
level (44). Surprisingly, the rise in [Ca2+]i was 
insensitive to the PKA inhibitor H-89, pointing 
to a possible role for the cAMP-regulated Rap1-
specific GEF Epac. To investigate whether 
indeed Epac mediates cAMP-induced calcium 
increase, we made use of a recently developed 
cAMP analogue, E-cAMP, that activates Epac 
efficiently while it has a strongly reduced effect 
on PKA (JM Enserink et al., submitted). To first 
test the specificity of this compound we used 
platelets, which are extremely sensitive to 
cAMP-PKA-mediated inhibition, including 
inhibition of thrombin-induced calcium 
mobilisation (see Figure 1A and B). Pre-
treatment with 0.1 mM E-cAMP for a similar 
period of time did not affect the thrombin-
induced calcium response (Figure 1C), showing 
that PKA is not activated. Only at higher 
concentrations (0.3 mM) E-cAMP resulted in a 
partial inhibition of thrombin-induced [Ca2+]i 
(Figure 1D). From these results we conclude 
that E-cAMP at concentrations up to 0.1 mM 
does not induce PKA-mediated signalling to 
inhibit thrombin-induced increase in [Ca2+]i. 
 
E-cAMP does not affect Rap1 activation in 
platelets 
We next investigated the effect of E-cAMP on 
Rap1 activation in platelets. As shown 
previously (16), Rap1 is very rapidly activated 
by thrombin and this activation is completely 
abolished by forskolin-induced cAMP 
formation (Figure 2A). Again, E-cAMP was 
unable to inhibit thrombin-induced Rap1 
activation, stressing our conclusion that E-
cAMP does not activate PKA. Whereas cAMP-
PKA clearly inhibits Rap1 activation, it may 
still be possible that cAMP-Epac activates 
Rap1. However, treatment of platelets with E-
cAMP did not induce Rap1 activation (Figure 
2B). To show that indeed E-cAMP is able to 
induce Rap1 activation, we treated OVCAR 
cells with E-cAMP as a control. As shown in 
Figure 2C, treatment with E-cAMP resulted in a 
clear Rap1GTP accumulation. Treatment with 
8-Br-cAMP activated both Rap1 and induced 
phosphorylation of CREB, an indirect read-out 
for PKA activity. Together, these findings 
indicate that E-cAMP used at concentrations up 
to 0.1 mM neither activates PKA nor Rap1 in 
platelets. 
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Figure 1. Effect of E-cAMP on platelet [Ca2+]i responses. A, Thrombin-induced elevation of [Ca2+]i in platelets. B, 
Inhibition of thrombin-induced [Ca2+]i elevation in platelets by a forskolin pre-treatment. C, Platelets neither increased 
[Ca2+]i upon 0.1 mM E-cAMP nor was thrombin-induced [Ca2+]i elevation inhibited by a pre-treatment with 0.1 mM E-
cAMP. D, Used at 0.3 mM, E-cAMP pre-treatment resulted in a partial inhibition of the thrombin-induced rise in 
[Ca2+]i. Platelets were freshly isolated after which they were loaded with Fura-2-AM. Subsequently, Ca2+ responses 
induced by thrombin (1 U/ml), either in the absence (A) or presence (B) of forskolin (40 µM) or E-cAMP (C, 0.1 mM 
and D, 0.3 mM) were measured in the presence of 1 mM extracellularly added Ca2+.  
 
E-cAMP neither induces Rap1 activation nor 
Ca2+ mobilisation in megakaryocytes 
In addressing the question whether E-cAMP can 
induce Rap1 activation in the megakaryoblastic 
MEG-01 cell line as previously reported for 
cAMP (44), we noticed that gentle mixing the 
MEG-01 cells already induced Rap1 activation 
(see Chapter 5). In case we controlled for this 
effect and gently mixed the untreated samples 
as well, we did not observe an increase in Rap1 
activation after stimulation with either forskolin 
(Figure 4) or with E-cAMP (data not shown). 
Despite many attempts we were unable to find 
conditions to avoid mix-induced Rap1 
activation, and therefore we could not measure 
whether cAMP can induce Rap1 activation in 
these cells. Forskolin was still able to signal and 
to induce phosphorylation of vasodilator-
stimulated phosphoprotein (VASP), a read-out 
for PKA activity (47), in MEG-01 cells (Fig. 
3B). As expected, E-cAMP did not induce 
phosphorylation of VASP. 
Next, we measured the effect of forskolin 
and E-cAMP on [Ca2+]i in MEG-01 cells. 
Stimulation with forskolin resulted in a small 
increase in [Ca2+]i (Figure 3A) as previously 
reported (44). However, addition of E-cAMP 
did not generate a calcium response (Figure 
3B), while [Ca2+]i could be elevated by 
thrombin. From these results we conclude that 
the Epac-Rap1 pathway is unlikely to mediate 
cAMP-induced calcium increase.  
 
 
DISCUSSION 
Previously, treatment with iloprost or forskolin 
was shown to concomitantly elevate [Ca2+]i and 
the RapGTP level in MEG-01 cells, both in a H-
89-insensitive manner (44). These observations 
suggested the involvement of the Epac-Rap1 
signalling pathway in the regulation of [Ca2+]i. 
In the present study, we have investigated 
whether indeed cAMP-Epac-Rap1 signalling 
plays a role in cAMP-induced rise in [Ca2+]i in  
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Figure 2. Rap1 activity and VASP phosphorylation 
are not affected by E-cAMP in platelets. A, Pre-
treatment of platelets with E-cAMP does not block 
thrombin-induced accumulation of Rap1GTP. Platelets 
were left untreated or preincubated (10 minutes, 37°C) 
with either E-cAMP (0.1 mM) or forskolin (40 µM), which 
was followed by thrombin stimulation (1 U/ml) for the 
indicated periods of time. Next, platelets were lysed and 
RapGTP was determined using the RBD pulldown 
assay. B. E-cAMP does not activate Rap1 in platelets. 
Isolated platelets were left untreated (basal) or 
stimulated with 0.1 mM E-cAMP for the indicated 
periods of time, after which Rap1 activation was 
measured. thrombin (1 U/ml) was used as a positive 
control for Rap1 activation. C, Treatment with E-cAMP 
activates Rap1 but not PKA. OVCAR cells were treated 
for 15 minutes with 0.1 mM E-cAMP. Cells were lysed 
after which Rap1 activity was analysed using GST-
RalGDS-RBD coupled to glutathion-agarose beads to 
pulldown Rap1GTP. Phosphorylation of CREB in 
corresponding cell lysates was determined as a read-
out for PKA activity using a phosphospecific CREB 
antibody. As a control, cells were treated with 0.1 mM 8-
Bromo-cAMP for 15 minutes, followed by a similar 
analysis.  
 
immature megakaryocytes. We used a cAMP 
derivative, indicated as E-cAMP, which when 
used between 10 and 100 µM, binds and 
activates the cAMP-regulated Rap1-specific 
GEF Epac and does not affect PKA (JM 
Enserink et al., submitted). Indeed, in platelets 
E-cAMP did not inhibit thrombin-induced  
 
 
Figure. 3. Effect of E-cAMP treatment on Rap1 
activation and VASP phosphorylation in MEG-01 
cells. A, Mixing a sample of resting MEG-01 cells 
induces accumulation of Rap1GTP. Stimulation with 
forskolin (40 µM) did not have additional effect on the 
Rap1 activation. MEG-01 cells were serum-starved 
overnight and the next day resuspended in fresh, 
serum-free medium. Samples (1×106 cells in 200 µl) 
were distributed in reaction tubes, after which these 
were placed in a 37°C waterbath in order to let the cells 
rest for 30 minutes. Next, samples were left untreated 
(basal), gently mixed (5 times upside-down) or 
stimulated with forskolin followed by gentle mixing, after 
which they were incubated for indicated periods of time. 
Subsequently, cells were lysed and Rap1GTP was 
determined using the activation-specific probe assay. B, 
Treatment of platelets with E-cAMP does not induce 
VASP phosphorylation. Platelets were left untreated or 
were stimulated with either forskolin (40 µM) or E-cAMP 
(0.1 mM) for 1 minute. Next, platelets were lysed using 
Laemmli sample buffer and phosphorylation of VASP 
was determined by a mobility shift assay. 
 
[Ca2+]i elevation or Rap1 activation, effects 
strongly inhibited by cAMP (Figure 1 and 2). E-
cAMP treatment also did not elevate [Ca2+]i or 
the Rap1GTP level. Similarly, in MEG-01 cells 
E-cAMP treatment neither induced a rise in 
[Ca2+]i nor Rap1 activation (Figure 3 and 4). 
From these results we conclude that that the 
cAMP-Epac-Rap1 is not involved in the 
regulation of [Ca2+]i. 
Our finding that cAMP does not induce 
Rap1 activation in MEG-01 cells is in contrast 
with previous results (44). However, we noted 
that mild disturbance of MEG-01 already results 
in a considerable Rap1 activation. This could be 
the explanation for the controversy, but it also 
implies that cAMP does induce Rap1 activation, 
but that due to the effect of mixing on Rap1 
activation a small increase is undetectable. 
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Figure. 4. Effect of E-cAMP treatment on [Ca2+]i in 
MEG-01 cells. A, MEG-01 cells respond upon forskolin 
with an increase in [Ca2+]i. B, E-cAMP did not generate 
a Ca2+ response although a clear rise in [Ca2+]i could be 
evoked, demonstrated here by a thrombin treatment. 
MEG-01 cells were loaded with Fura-2-AM after which 
[Ca2+]i was monitored in the presence of 1 mM 
extracellular Ca2+. Responses upon (A) forskolin (40 
µM) or (B) E-cAMP (0.1 mM) followed by thrombin 
(1U/ml) were determined. In the case of E-cAMP 
treatment a representative of duplicate observations 
with similar results is shown.  
 
Unfortunately, at this moment no antibodies are 
available that are able to detect endogenously 
expressed Epac (J.R. de Rooij, personal 
communication). However, using PCR we were 
able to demonstrate Epac mRNA (data not 
shown). Irrespective whether the cAMP-Epac-
Rap1 pathway does operate in MEG-01 cells, in 
contrast to forskolin, E-cAMP did not induce an 
increase in [Ca2+]i. We therefore conclude that 
the cAMP-Epac-Rap1 pathway does not 
mediate the cAMP-induced PKA-independent 
increase in [Ca2+]i. Interestingly, the cAMP 
derivative Sp-5,6-DCL-cBIMP, which is able to 
induce both PKA and Epac activation (J.R. de 
Rooij, personal communication), did not elevate 
[Ca2+]i in MEG-01 cells (44). This points to the 
involvement of another cAMP target in the 
regulation of cAMP-induced [Ca2+]i increase. 
This pathway, including the cAMP-target is still 
elusive, but cAMP-regulated ion channels may 
be good candidates (48). 
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The small GTPase Rap1 is activated by a large variety of stimuli and functions in the 
control of integrin-mediated cell adhesion. Here we show that in human 
megakaryocytes and several other commonly used haematopoietic cell lines, like K562, 
Jurkat and THP-1, shear stress induced by gently tumbling of the samples induces 
Rap1 activation rapidly and strongly. Inhibitors that have previously been shown to 
affect Rap1 activation in human platelets, like the intracellular calcium chelator 
BAPTA-AM and various PKC inhibitors, could not block this shear stress-induced 
activation. Also inhibition of actin cytoskeleton dynamics did not influence this 
activation of Rap1, suggesting that this activation is mediated by cell surface receptors. 
Human platelets, however, were refractory to this shear stress-induced activation of 
Rap1. To determine the consequences of Rap1 activation we measured adhesion of 
megakaryocytes to fibrinogen, which is mediated by the integrin αIIbβ3, in the presence 
of inhibitors of Rap1 signalling. Introduction of both Rap1GAP and RalGDS-RBD in 
the megakaryoblastic cell line DAMI strongly reduced basal adhesion to immobilised 
fibrinogen. This inhibition was partially rescued by the phorbol ester TPA, but not by 
α-thrombin. From these results we conclude that in megakaryocytes mix stress induces 
Rap1 activation that controls αIIbβ3-mediated cell adhesion. 
 
 
 
INTRODUCTION 
The small GTPase Rap1 is a molecular 
switch that cycles between an inactive GDP and 
active GTP-bound conformation. The protein 
can be activated by a plethora of stimuli (1-6), 
indicating that Rap1 activation is a common 
event in signalling. In general Rap1GTP 
accumulation is induced by second messengers, 
like cAMP, calcium ions and diacylglycerol and 
a number of guanine nucleotide exchange 
factors (GEFs) have been identified to mediate 
this activation (7). In human platelets Rap1 is 
abundantly expressed and is rapidly activated by 
a large variety of agonists, including a 
thrombin, thromboxane A2, epinephrine, platelet 
activating factor, ADP and the phorbol ester 
TPA (1). At least two different signalling 
pathways are involved in this activation, one 
mediated by Gq, phospholipase C (PLC) and 
calcium and one mediated by protein kinase C 
(PKC) and phosphatidylinositol 3-kinase 
(PI(3)K) (1,8-10). In platelets, Rap1 activation 
is rapidly inhibited by agents that increase the 
intracellular cAMP concentration, like for 
instance prostaglandin I2 (1). Activation of 
Rap1 is prior to platelet activation, suggesting a 
key role of Rap1 in this process. After platelet 
activation, Rap1 relocalises to the actin 
cytoskeleton (8,11,12). In the control of Rap1 in 
platelets, RapGAP, which can interact with 
active alpha subunit of the heterotrimeric G-
protein Gz, plays a role as well (13).  
Rap1 has been implicated in a variety of 
cellular functions including the control of the 
Raf-MEK-ERK pathway, although this result is 
questioned (7,14). More recently, in a variety of 
haematopoietic cell lines Rap1 was found to be 
involved in the regulation of integrin-mediated 
cell adhesion. Rap1 controls T-cell receptor-, 
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CD31- and CD98-induced activation of αLβ2 
(15-19), but is also required for Mn2+- or 
activating antibody-induced αLβ2-mediated 
adhesion (20). In macrophages Rap1 regulates 
αMβ2-mediated phagocytosis (19,21) and in a 
variety of cell types Rap1 was found to regulate 
β1-integrins as well (20,22). The mechanism of 
this activation is still unclear and may involve 
an increase in both integrin clustering and 
integrin affinity. In Drosophila, Rap1 was found 
to control cell polarity (23) and to regulate the 
even distribution of adherence junctions (24).  
The role of Rap1 in the regulation of 
integrins with β1 or β2 subunits raised the 
question whether Rap1 may regulate the 
activation of integrin αIIbβ3. Proper control of 
this integrin forms a key step in platelet 
adhesion and aggregation. Since platelets are 
not suitable for genetic interference studies, we 
have chosen human megakaryocytes, platelet 
precursor cells expressing αIIbβ3. In these 
studies we noted that these cells are highly 
sensitive to mild disturbances, like tumbling 
tubes to mix added growth factors. This stress-
induced effect was observed in several other 
haematopoietic cell lines as well. In addition we 
observed that inhibition of Rap1 strongly 
reduced cell adhesion to fibrinogen, the counter 
receptor of αIIbβ3. This inhibition was partially 
rescued by treatment with the phorbol ester 
TPA, but not by α-thrombin. From these results 
we conclude that in megakaryocytes shear stress 
is a mechanism to activate Rap1 and that Rap1 
is involved in the control of αIIbβ3-mediated cell 
adhesion to fibrinogen.  
 
 
MATERIALS AND METHODS 
Materials 
The following stimuli and inhibitors were used at 
concentrations indicated, unless stated otherwise: 8-Bromo-
cAMP (Biolog Life Science Institute, 1 mM), forskolin (ICN, 
20 µM) BAPTA-AM (Molecular Probes, Eugene, Oregon, 
USA, 25 µM), Roche 31-8220 (Biomol, Plymouth, PA, USA, 
5 µM), GF 109203X (Biomol, Plymouth, PA, 5 µM), 
staurosporin (Sigma, 200 nM), jasplakinolide (Molecular 
Probes, 5 µM), cytochalasin D (Biomol, 5 µM), latrunculin A 
(Molecular probes, 5 µM), latrunculin B (Molecular Probes 5 
µM), LY294002 (Biomol, 10 µM), wortmannin (Sigma, 100 
nM), H-89 (Biomol, 10 µM), PP1 (Biomol, 50 µM), genistein 
(Biomol, 100 µM), SB 203580 (Biomol, 10 µM), rapamycin 
(Biomol, 10 nM), thrombin (Sigma, 1U/ml), TPA (Sigma, 
100 ng/ml). 
 
 
Cell culture, cell lines and transfection 
MEG-01 cells (25) were grown at 37°C in RPMI 1640 (Gibco 
Life Technologies, Paisly, UK) supplemented with 20% heat-
inactivated (30 min. at 56°C) fetal bovine serum. DAMI cells 
(26) were grown in IMDM supplemented with 10% heat-
inactivated horse serum. CHRF-288-11 cells (27) were 
cultured in Fischers medium enriched with 20% heat-
inactivated horse serum. The Jurkat T cell line JHM1 2.2 was 
provided by Dr. D. Cantrell (Imperial Cancer Research Fund, 
London, UK) with kind permission of Dr. A. Weiss 
(University of California at San Francisco, San Francisco, 
CA). These Jurkat cells were grown as has been described 
earlier (15). AZU II cells were kindly provided by Dr. M. van 
de Wetering, Department of Immunology, University Medical 
Center Utrecht, The Netherlands). They were grown in RPMI 
1640 supplemented with 10% foetal calf serum. The 
erythroleukemic K562 cells, a gift from Dr. C.G. Figdor, were 
grown in 75% RPMI 1640 and 25% IMDM (Gibco Life 
Technologies) supplemented with 10% heat-inactivated foetal 
bovine serum. THP-1 cells were kindly provided by Dr C.J. 
Heijnen (Department of Immunology, University Medical 
Centre Utrecht, The Netherlands) and were maintained like 
the Jurkat cells, but in the presence of 4×10-4 % mercapto-
ethanol. All cell types were cultured in the presence of 0.05% 
glutamine, penicillin and streptomycin, in a humidified 
atmosphere with 5% CO2. For electroporation, DAMI cells 
(1.2×107 cells/ml in 0.4 ml complete medium) were pulsed at 
250 V and 960 µF with 5 µg TK-luciferase plasmid DNA, 
construct plasmid as indicated in the figure legends and added 
vector plasmid to keep DNA amounts constant. Subsequently, 
24 hrs after transfection, cells were transferred to serum-free 
medium and used 42-48 hrs after transfection. The constructs 
used for electroporation have been described previously (20). 
Platelet Isolation 
Donors claimed not to have taken any medication during the 
preceding 10 days. After informed consent was obtained, 
freshly drawn venous blood from healthy volunteers was 
collected into 0.1 volume of 130 mM trisodium citrate. 
Citrated blood was centrifuged (150×g, 15 minutes at 20°C) 
and subsequently the platelet-rich plasma (PRP) was 
supplemented with prostaglandin I2 (10 ng/ml) and ACD (2.5 
g tri-sodium citrate, 1.5 g citric acid and 2.0 g D-glucose in 
100 ml dH2O) for acidification to pH 6.5 thereby preventing 
platelet activation during further isolation. Next, platelets 
were purified from PRP by centrifugation (330×g, 15 min at 
20°C). The platelet pellet was resuspended in HEPES-tyrode 
buffer (10 mM HEPES, 137 mM NaCl, 2.68 mM KCL, 0.42 
mM NaH2PO4, 1.7 mM MgCl2, 11.9 mM NaHCO2, pH 7.4) 
containing 5 mM D-glucose at 2×108 platelets/ml. 
Mixing-induced shear stress 
Cells were incubated overnight in serum-free medium. Next, 
cells were resuspended at 5×106 cells/ml (MEG-01) 10×106 
cells/ml (DAMI, CHRF-288-11) or 25×106 cells/ml (Jurkat, 
AZU II, K562, THP-1) in medium. 200 µl of cell suspension 
or 500 µl of platelet suspension (2×108 platelets/ml) in 
eppendorf tubes was incubated in a 37°C waterbath for 30 
minutes. A Sample was mixed gently, i.e. five times up and 
down and incubated at 37°C for the indicated periods of time. 
Subsequently, cells were lysed for 15 min. at 4°C by the 
addition of ice-cold lysis buffer (10% glycerol, 1% Nonidet 
P40, 50 mM Tris-HCl pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 
1 µM leupeptin, 0.1 µM aprotinin) and lysates were cleared 
by centrifugation at maximal speed in an Eppendorf 
centrifuge for 10 minutes at 4°C.  
Measurement of Rap1, Ras and Ral activation 
The GTP-bound form of Rap1 was isolated using RalGDS-
RBD as an activation-specific probe and quantified by 
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Western blotting using anti-Rap1 antibody, as has been 
described previously (1). Similarly, RasGTP and RalGTP 
were determined using Raf1RBD and RalBP as activation-
specific probes (28,29). 
Adhesion assay 
Adhesion assays were performed and analysed as has been 
extensively described (15). Briefly, cells were transiently 
transfected with a luciferase expression contruct in the 
presence or absence of additional expression constructs as 
indicated. Cells were harvested, washed and resuspended in 
TSM buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM 
CaCl2, 2 mM MgCl2) containing 0.5% BSA at a concentration 
of 5×105 cells/ml. Coating of 96 well plates was performed as 
described previously (20) with some minor modifications. 
Greiner Microlon 96 well plates that had been coated 
overnight at 4°C with different concentrations of fibrinogen 
(Chromogenix AB, Mölndal, Sweden) in sodium bicarbonate 
buffer (50 µl per well) were washed with TSM buffer and 
blocked for 30 minutes at 37°C with 5% BSA/TSM. After 
washing the plate again with TSM, 50 µl 0.5% BSA/TSM 
was added to each well containing a stimulating agent or not. 
Subsequently, 50 µl cell suspension was added per well, after 
which the cells were spun down for 1 minute at 200 rpm in a 
Heraeus Sepatech Megafuge 1.0. Cells were allowed to 
adhere for 30 minutes at 37°C and non-adherent cells were 
removed with warmed 0.5% BSA/TSM. Adherent cells were 
lysed and subjected to a luciferase assay as described 
previously (30). Expression of transfected constructs was 
confirmed by immunoblotting of total cell lysates. Cells 
bound were calculated and numbers were corrected for 
transfection efficiency and nonspecific effects of constructs 
by measuring luciferase activity of total input cells ([counts in 
cells bound/counts in total input cells]×100%). 
Western blotting  
Western blotting of all protein samples was carried out using 
polyvinylidene difluoride membranes. The antibodies used for 
protein detection are the rabbit polyclonal anti-Rap1 (Santa 
Cruz Biotechnology, CA), anti-Ras (Transduction 
Laboratories). Phosphospecific antibodies against ERK1 and 
2, PKB/Akt substrate and S6 were all purchased from Cell 
Signalling. 
 
RESULTS 
Shear stress-induced Rap1 activation 
In our analysis of Rap1 activation in MEG-
01 cells, we noted that elevated Rap1GTP levels 
already occurred in the absence of the 
stimulating agents, solely due to the gentle 
mixing procedure. This effect was rapid as it 
occurred within 30 seconds after tumbling the 
tube and was sustained for at least 5 min (Figure 
1A). Addition of the phorbol ester TPA, a 
strong inductor of Rap1 in platelets, did not or 
hardly induce a further activation of Rap1 (data 
not shown). Also cAMP-elevating stimuli, like 
forskolin, which was previously shown to 
activate Rap1 in MEG-01 cells, did not further 
increase the Rap1GTP level (data not shown). A 
similar mix stress-induced activation was 
observed in a number of other haematopoietic 
cell lines, like K562 (erythroleukemia), Jurkat 
(T lymphocytes), AZU II (B lymphocytes) and 
THP-1 (monocytes) (Figure 1C). Also in two 
other megakaryocytic cell lines, DAMI and 
CHRF-288-11, mix stress induced Rap1 
activation (Figure 1D). This activation was 
neither enhanced nor inhibited by forskolin, an 
activator of adenylate cyclase resulting in 
elevation of the intracellular cAMP level. 
However, TPA has a slight additional effect on 
DAMI cell, and a more pronounced additional 
effect on CHRF-288-11 cells. Importantly, 
mixing-induced shear stress did not induce 
Rap1 activation in platelets (Figure 1D). From 
these results we conclude that in 
megakaryocytes and in a number of other 
haematopoietic cell lines, but not in platelets, 
mild mixing is sufficient to strongly induce 
Rap1 activation. 
To investigate the activation pathway 
responsible for mix stress-induced Rap1 
activation, we investigated the effect of several 
pharmacological inhibitors. Most of the used 
inhibitors were shown in the past to affect 
activation of Rap. In certain cell types, an 
increase in [Ca2+]i was demonstrated to be 
necessary or even sufficient to induce Rap1 
activation and could be blocked by BAPTA-AM 
(1,4). Pre-treatment of MEG-01 cells with a 
combination of BAPTA-AM and EGTA did not 
inhibit shear stress-induced Rap1GTP increase 
(Figure 2A). PKC inhibitors (Roche 31-8220, 
GF 109203X, staurosporine) were described to 
block Rap1 activation in various cell types (4,8) 
(6), however they also did not inhibit shear-
induced elevation of active Rap1 (Figure 2B). 
Also PI(3)K and PKA were implicated in the 
Rap1 activation processes (8,9,14). However, 
inhibitors of PI(3)K activity (LY294002 or 
wortmannin) or PKA (H-89) did not interfere 
with the shear-induced activation (Figure 2C). 
Contribution of src and p38 MAPK was 
proposed (4,14,31), but inhibitors of these 
proteins (PP1/genistein and SB 203580, 
respectively) showed no effect on this stress-
induced Rap1 activation (Figure 2D). 
Apparently, mix stress-induced Rap1 activation 
is not mediated by one of these previously 
described pathways. Finally, we tested whether 
the effect is direct or mediated by changes in the 
actin cytoskeleton. However, no role was found 
for actin cytoskeleton dynamics, as neither actin 
polymer stabilising (jasplakinolide) nor 
dissociating (cytochalasin D, latrunculin A and  
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Figure 1. Activation of Rap1 in a diversity of cell 
types induced by shear stress. A, Serum-starved 
MEG-01 cells were subjected to shear stress as 
described in Materials and Methods and after the 
indicated time points cells were lysed and Rap1GTP 
was determined using the activation-specific probe 
assay. B,. K562, Jurkat, Azu II and THP-1 cells were 
subjected to mixing-induced stress and Rap1 activation 
was measured as in A. C, The megakaryoblastic cell 
lines DAMI and CHRF-288-11 were subjected to mixing-
induced stress as indicated in A. In addition, the cells 
were treated with forskolin (20 µM) and the phorbolester 
TPA (100 ng/ml) for the indicated time points. Platelets 
were either stimulated with α-thrombin (1U/ml) or 
subjected to mixing-induced shear stress and levels of 
RapGTP were determined after the indicated time points 
(b: basal, untreated control). 
 
 
 
 
 
 
 
 
 
 
 
B) agents seemed to affect this Rap1 activation 
(Figure 2E). The effectiveness of the used 
pharmacological inhibitors was tested in parallel 
experiments (data not shown). From these 
results we conclude that mix stress rather 
directly, presumably through a cell surface 
receptor, activates Rap1. 
 
Shear stress-induced activation of Ras and 
phosphorylation of ribosomal protein S6 
To study whether shear stress induces additional 
signal transduction pathways we determined the 
activation of both the small GTPases Ras and 
Ral, and of ERK in MEG-01 cells (Figure 3A). 
Interestingly, Ras was strongly activated, but at 
a later time point than Rap1. Two downstream 
targets of Ras, Ral and ERK were not activated. 
Using a phosphospecific antibody recognising 
phosphorylated targets of protein kinase B 
(PKB) we observed phosphorylation of several 
proteins in lysates of mixed MEG-01 cells 
(Figure 3B). However, we did not find 
activation of PKB itself using phosphospecific 
antibodies (data not shown), but did observe 
phoshorylation of the ribosomal protein S6, 
which is sensitive to the mTOR inhibitor  
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Figure 2. Effect of pharmacological inhibitors on the 
shear stress-induced Rap1 activation. MEG-01 cells 
were serum-starved overnight after which inhibitors 
were added at the indicated concentration 30 min prior 
to the induction of mixing-induced stress. In this period 
cells were kept at 37 °C. Cell were subjected to mixing-
induced stress followed by incubation for indicated 
periods of time (A) or for 1 min (B-E) and Rap1GTP was 
determined. A, Cells were pre-incubated with 25 µM 
BAPTA-AM and 5 mM EGTA. B, Cells were incubated 
with the PKC inhibitors Roche 31-8220, GF 109202X, 
staurosporin or EDTA, used at concentrations as 
indicated. C, Cells were incubated with the PI(3)K 
inhibitors LY294002 (10µM, LY) and wortmannin 
(100nM, W) and the PKA inhibitor H-89 (10 µM). The 
effect of the inhibitors on mixed-induced stress is in 
duplicate. D, Cells were incubated with the src inhibitor 
PP1 (50 µM), the tyrosine kinase inhibitor genistein (100 
µM, G) and the p38MAPK inhibitor SB 203580 (10 µM, 
SB). The effect of the inhibitors on mixed-induced stress 
is in duplicate. E, Cells were incubated with indicated 
concentrations of inhibitors of actin dynamics, i.e. 
jasplakinolide (jaspl), cytochalasin D (cyto D), latrunculin 
A and B (lat A and lat B) (b: basal, untreated control). 
 
 
Figure 3. Shear stress-induced activation of Ras. 
MEG-01 cells were subjected to mixing-induced shear 
stress. A, Effect of mix stress on the activation of Ras, 
Ral and ERK. Activation of Ras and Ral was measured 
using activation specific probes. Activation of ERK was 
measured using a phosphospecific antibody that 
recognises the active form of both ERK1 and ERK2. B, 
Phosphorylated proteins recognised by a phospho-PKB 
substrate-specific antibody. C, Ribosomal S6 protein 
recognised by antibody specific for phosphorylated S6. 
The PI3K inhibitor LY294002 (25 µM) and mTOR 
inhibitor rapamycin (10 nM) were added 30 min prior to 
mixing-induced shear stress as described in the legend 
of Figure 2. (b: basal, untreated control). 
 
rapamycine and the PI(3)K inhibitor LY294002 
(Figure 3C). This suggests that p70 S6 kinase is 
responsible for the phosphorylation of S6.  
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Figure 4. Rap1 involved in αIIbβ3-mediated cell adhesion. DAMI cells were cotransfected with 5 µg pG3-TK 
luciferase reporter plasmid and either empty pMT2-SM-HA vector (vector), HA-RapGAP I (RapGAP I) (20 µg) or HA-
RalGDS-RBD (RBD) (20 µg). After 42 hrs, the cells were allowed to adhere to immobilised fibrinogen for 30 minutes 
at 37°C. The percentage of cells bound was determined by fraction of luciferase activity bound, as described in the 
Materials and Method section. 96-well plates were coated with the indicated concentration of fibrinogen. Where 
indicated, the cells were treated with α-thrombin (1 U/ml) or TPA (100 ng/ml). 
 
Interestingly, shear stress-induced activation of 
p70 S6 kinase was previously demonstrated 
(32). From these results we conclude that mix 
stress induces activation of several signalling 
pathways one of which is the activation of 
Rap1. However, activation of Rap1 appears to 
be a particularly fast response.  
 
Inhibition of Rap1 abolishes αIIbβ3-mediated 
cell adhesion 
In contrast to platelets, which do not bind to 
fibrinogen in the resting state, we observe that 
DAMI cells adhere spontaneously to fibrinogen 
(Figure 4), indicating that the integrin αIIbβ3 is 
(partially) active. To investigate whether Rap1 
is involved in this process, we transfected 
DAMI cells with two different inhibitors of 
Rap1 signalling, i.e. Rap1GAP, which lowers 
the level of Rap1GTP and RalGDS-RBD, which 
binds with high affinity to Rap1GTP. Cells were 
allowed to adhere to 96 well plates coated with 
different concentrations of fibrinogen, the 
counter receptor of αIIbβ3. We observed that the 
concentration dependent adhesion is strongly 
inhibited by Rap1GAP and significantly 
inhibited by RalGDS-RBD, indicating that 
active Rap1 is required for αIIbβ3-mediated cell 
adhesion. Introduction of Rap1V12 had little 
effect on basal level of adhesion, suggesting that 
the endogenous level of Rap1GTP is already 
sufficiently high to support cell adhesion. 
Interestingly, whereas α-thrombin only 
marginally affects basal level of adhesion, TPA 
is a strong inductor of cell adhesion. 
Introduction of Rap1V12 did not significantly 
increase cell adhesion under these conditions. 
The reduction in basal adhesion after expression 
of Rap1GAP and RalGDS-RBD was also 
observed when cells were stimulated with α-
thrombin. However, a much weaker effect of 
Rap1GAP and RalGDS-RBD was observed 
after TPA-induced cell adhesion, showing that 
TPA-induced adhesion is partially independent 
of Rap1.  
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DISCUSSION 
In this paper we show that in a variety of 
haematopoietic suspension cells mixing-induced 
shear stress results in a clear Rap1 activation. 
The presence of additional stimuli, like 
forskolin, TPA or thrombin, did not accomplish 
a clear additional increase in the Rap1GTP 
level. The effect was rather dramatic and even 
observed when cell suspensions were either 
tumbled once up and down or gently stirred 
with a pipet tip. The mechanism by which shear 
stress activates Rap1 is still unclear, despite our 
attemps to find a clue about the initial signalling 
events. We have tried to interfere using a 
variety of inhibitors previously described to 
inhibit Rap1 activation, like inhibitors for PLC, 
PKC and PI(3)K, and chelators of calcium ions. 
We have also tested inhibitors of the 
cytoskeleton or integrin-based cell-cell contacts. 
However, neither of the inhibitors tested so far 
showed an inhibitory effect on the shear stress-
induced Rap1 activation.  
Signalling induced by mixing is probably 
most similar to signalling induced by 
mechanical and shear stress, the first induced by 
changes in cell shape, the second by a fluid 
flow. For both stimuli the receptors that trigger 
the events are still elusive, although cell surface 
receptors and alterations in the cytoskeleton are 
most likely involved (33-37). Both stimuli 
trigger a variety of signalling pathways, 
including the activation of Ras and p70 S6 
kinase, like we observe for mix stress, resulting 
in changes in cell structure and function. 
Previously, activation of Rap1 was observed 
after stretching adherent fibroblastic L 929 cells 
(38). This implies that activation of Rap1 by 
external stress is not restricted to 
haematopoietic suspension cells. 
One of the most prominent effects of active 
Rap1 in mammalian cells is the regulation of 
integrin-mediated cell adhesion. Adhesion 
mediated by integrins containing either β1and β2 
subunits has been shown to be regulated by 
Rap1. This regulation results in an increased 
binding of integrins to soluble ligands or 
increased cell adhesion to immobilised ligands. 
Megakaryocytes, like platelets, express αIIbβ3 
that allows binding to fibrinogen. Interestingly, 
megakaryocytes already adhere to fibrinogen in 
the absence of a stimulus and treatment with α-
thrombin, a very potent activator of αIIbβ3 on 
platelets, did only marginally increase the 
adhesion. This adhesion was dependent on 
fibrinogen and increasing concentration of 
fibrinogen also increased basal and α-thrombin-
induced cell adhesion. Importantly, both basal 
and thrombin-induced cell adhesion was 
inhibited by the introduction of Rap1GAP or 
RalGDS-RBD, inhibitors of Rap1 signalling. 
This shows that Rap1 is required for αIIbβ3-
mediated cell adhesion and suggests that Rap1 
regulates αIIbβ3 activity. The inhibitory effect of 
Rap1GAP and RalGDS-RBD on basal adhesion 
indicates that in resting cells a basal level of 
Rap1 is sufficient to sustain cell adhesion. 
However, considering the stress induced by 
plating cells, it is likely that the basal level of 
Rap1 is elevated by mixing-induced stress and 
thus contributes to αIIbβ3-mediated cell 
adhesion. While this manuscript was in 
preparation, Bertoni et al. reported that Rap1 
regulates the affinity of αIIbβ3 in primary mouse 
megakaryocytes (39). In this study basal 
adhesion was low and insensitive to expression 
of Rap1GAP, whereas α-thrombin strongly 
stimulated cell adhesion, which was further 
augmented by expression of RapV12 and 
inhibited by RapGAP. However, they did not 
measure the level of Rap1GTP in these cells. 
Apparently, these mature megakaryocytes are 
less sensitive to mix stress-induced Rap1 
activation than the DAMI cells, which 
represents a more immature megakaryoblast.  
What could be the reason for cells to 
activate Rap1 in response to extracellular 
applied stress? The most likely explanation 
would be that when cells are subject to forces, 
they respond by increased binding to their 
support. Alternatively, Rap1 regulates integrin 
dynamics to allow cells to respond to shape 
changes without cell rupture. Interestingly, 
Rap1 activation is induced by a large variety of 
stimuli and is thus a very common event. In 
addition, Rap1 appears to modulate all integrins 
thus far tested, indicating that it regulates a 
process required for the activation of all 
integrins. Elucidation of this process is currently 
one of the great challenges in cell biology.  
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Ral and Rap1 in the light of platelet function 
 
A human being consists of billions of cells 
that work together in organs and tissues. For a 
proper organisation, communication between 
these cells is indispensable. Cells send messages 
to each other by means of communication 
signals, for instance hormones. A cell is able to 
receive these signals by specific receptor 
molecules. Once a signal is received, the 
activated receptor passes the message on to 
proteins inside the cell. These proteins in turn 
propagate the signal to other proteins and so on, 
generating protein cascades that transmit the 
signal. Finally, proteins are reached that 
regulate processes underlying cell growth, 
proliferation, differentiation or death, like for 
example the control of which genes are on and 
off. Normally, each individual cell receives 
multiple signal inputs at once and a complex 
network of proteins is needed in order to 
process the messages and to translate them into 
the correct cellular responses that enable the 
desired adaptation in the cellular behaviour. 
This process of receiving, transmitting and 
integrating signals is indicated as signal 
transduction. Small mistakes in these pathways 
may give rise to inappropriate cell reactions and 
thereby underlie several diseases, for example 
uncontrolled cell growth (cancer) or bleeding 
disorders. 
Members of the Ras-like small GTPase 
protein family play an important role in signal 
transduction. These proteins participate in signal 
transduction as molecular switches. This results 
from their characteristic association with either 
the guanine-nucleotide GDP, a conformation in 
which these proteins are inactive, or the 
guanine-nucleotide GTP, the active state. An 
activating signal is propagated to a guanine-
nucleotide exchange factor (GEF) which 
releases GDP from the GTPase, leading to the 
replacement by GTP. In the GTP-bound 
conformation, the GTPase is active and 
transmits the signal further on. Due to the action 
of a GTPase activating protein the GTP is 
hydrolysed, the Ras protein returns to the GDP-
bound, inactive state and signalling is 
terminated. The Ras protein family is 
introduced in chapter 1 of this thesis. The 
studies described in this thesis focus on Ral and 
Rap1, both of which are close relatives of the 
Ras protein. Ras has become notorious, because 
aberrant, persistent Ras signalling due to small 
mutations was found to play a role in several 
types of human cancer (1), demonstrating the 
importance of Ras GTPase signalling. 
The main goal of this thesis was to elucidate 
mechanisms of Rap1 and Ral signalling as they 
occur in platelets. Platelets are anucleate cell 
fragments in the blood circulation and their 
function is to stop bleeding. The behaviour and 
regulation of platelets is described in chapter 1. 
Platelets form an attractive model system to 
study Rap1 and Ral signalling. Ral and Rap1 
are both abundant and rapidly activated upon a 
variety of agonists in human platelets (2-7), 
suggesting regulatory contribution of these 
GTPases to platelet function. Furthermore, due 
to the absence of a nucleus platelets are less 
complex as compared to for instance a 
fibroblast. Elucidating signalling pathways that 
control platelet function enlarges the 
understanding of defects that underlie diseases 
caused by improper platelet behaviour.  
Initially, the Ral activation mechanism in 
platelets was addressed. This research has 
resulted in the characterisation RalGEF2, an 
exchange factor for Ral that is not regulated by 
Ras (chapter 2). In chapter 3, 4 and 5 
investigations on Rap1 signalling and functions 
related to platelet physiology form the central 
theme. 
 
 
Ras-independent Ral activation: 
Identification of RalGEF2 
 
Previous studies on Ral activation have 
established that active, GTP-bound Ras is able 
to recrute and activate Ras-binding domain 
(RBD)-containg RalGEFs and thereby induces 
Ral activation (reviewed in (8)). In platelets 
however, RalGTP elevation occurs upon 
treatment with a diversity of different stimuli in 
a Ras-independent manner. Instead, RalGTP 
accumulation was found to depend on 
intracellular calcium and correlated with Rap1 
activity (3). Initially, a mechanism whereby 
Rap1 regulates the RBD-containing RalGEF 
RalGDS was proposed, but this seemed unlikely 
to occur in vivo (3,9). Alternatively, 
intracellular calcium might fulfil a second 
messenger function in upstream Ral regulation 
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by direct binding to and activation of a Ral-
specific GEF. In search for a novel GEF that 
could account for Ras-independent calcium-
regulated Ral activation in platelets we have 
identified and characterised RalGEF2 (chapter 
2). At the same time, different splice variants of 
RalGEF2 were reported to exist (10). Although 
we clearly have identified a Ras-independent 
factor in the regulation of Ral activity, it is 
unlikely to play a role in platelets. First of all, 
we could not detect protein expression of 
RalGEF2 in blood platelets. In addition, no 
indications exist for regulation of RalGEF2 by 
intracellular calcium. This implies that other 
Ras-independent factors that activate Ral should 
exist. We have performed additional database 
searches, but have not found other putative 
RalGEFs. Alternatively, calcium regulates 
known components in the upstream pathways 
leading to RalGTP accumulation. Indeed, direct 
binding of calcium/calmodulin to Ral thereby 
regulating its activity has been proposed 
(11,12). In addition, calcium/calmodulin-
dependent kinase might regulate RalGDS (13). 
 
 
New insights on Rap1 signalling and 
functions 
 
Rap1 and integrin-mediated cell adhesion 
Recently, Rap1 was found to play a crucial 
role in inside-out regulation of integrin-
mediated cell adhesion (14-18). Expression of 
an activated Rap1 mutant results in increased 
integrin-mediated cell adhesion, while 
expressing proteins that block Rap1 signalling 
(RapGAPs and RalGDS-RBD) inhibit stimulus-
induced cell adhesion, as described in chapter 1. 
Integrins can also directly be activated at the 
outside of the cell. Divalent cations bind to 
defined binding pockets thereby generating the 
high affinity state of the integrin (19). In 
addition, antibodies have been generated that 
associate with the extracellular part of the 
integrin in such a way that they induce the 
conformation in which the integrin displays 
high affinity for its ligand. For example, the 
monoclonal antibody KIM185 activates integrin 
αLβ2 (LFA-1) (20), while TS2/16 increases the 
affinity of α4β1 (VLA-4) and α5β1 (VLA-5) 
(21). Consistent with the notion that divalent 
cations (for instance Mn2+) or these integrin-
activating antibodies induce this high affinity 
state without the requirement for intracellular 
signalling (22,23), treatment with Mn2+ or the 
integrin-activating antibodies does not result in 
activation of Rap1 (chapter 3). This implies that 
Rap1 is not in a linear pathway between 
divalent cations or integrin-activating antibodies 
and the integrin. However, we have shown that 
a block of Rap1 activity inhibits the integrin-
mediated cell response upon treatment with 
these agents (chapter 3). Interestingly, in this 
study, we further demonstrate that induction of 
cell adhesion induced by expression of active 
Rap1 requires in addition to intracellular 
calcium functional calmodulin signalling. 
Adhesion induced by divalent cations or 
activating antibodies also required intracellular 
calcium. This finding suggests that common 
mechanisms underlie both types of integrin 
regulation. In addition we describe that 
stimulus-induced Rap1 activation not always 
enhances integrin-dependent cell adhesion. TPA 
induces a strong and prolonged Rap1 activity in 
Jurkat JHM1 cells, however the effect on cell 
adhesion is only marginally. The data presented 
in this study support a facilitating function for 
Rap1 in the process of integrin-mediated cell 
adhesion. Expression of active Rap1 stimulates 
a mechanism allowing increased adhesion at 
relatively low amounts of immobilised ligand. 
In case Rap1 signalling is severely impaired, 
integrin-mediated adhesion can be established 
by increasing the amounts of immobilised 
ligand in the presence of integrin-activating 
antibody (chapter 3). The Rap1GTP level may 
determine the fraction of a constant integrin 
pool present at the cell surface that is available 
for the adhesion process. At least Rap1 
facilitates the proces of integrin activation. 
Knowing the regulatory Rap1 function in 
integrin-mediated cell adhesion, the question 
raised whether Rap1 also contributes to the 
control of the major platelet integrin αIIbβ3. As 
described in chapter 1, upon platelet activation 
the proper control of αIIbβ3 integrin activity by 
signal transduction mechanisms forms an 
essential aspect for platelet function. We and 
others have demonstrated that, in addition to the 
regulation of integrins αLβ2 (LFA-1), α4β1 
(VLA-4) and α5β1 (VLA-5), Rap1 is required in 
the regulation of the platelet integrin αIIbβ3 in 
megakaryocytes, the cells that develop into 
platelets ((24), chapter 5). Expression of active 
Rap1 in megakaryocytes did not promote αIIbβ3 
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functionality, as measured on soluble fibrinogen 
binding. However, thrombin-induced binding of 
soluble fibrinogen increased as the consequence 
of active Rap1 expression in these cells and was 
inhibited by RapGAP expression (24). We 
observed that megakaryoblastic DAMI cells 
adhere spontaneously to immobilised 
fibrinogen, indicating that in these cells integrin 
αIIbβ3 is at least partially active (chapter 5). This 
adhesion, which was dependent on the 
concentration of fibrinogen coated, could be 
completely abolished by inhibition of Rap1 
signalling, while introduction of Rap1V12 had 
little effect. The block of αIIbβ3-mediated 
adhesion by inhibition of Rap1 was partially 
rescued by a TPA treatment, indicating that 
TPA-induced adhesion is partially independent 
of Rap1 in these cells. Together, these findings 
again illustrate that Rap1 not directly induces 
increased integrin functionality but fulfils a 
facilitating function. 
 
Mechanism of integrin regulation by Rap1 
The mechanism by which integrins bind to 
their ligands is complex (reviewed in (25,26)). 
In the currently held view, integrins can be 
regulated by increasing the ligand-binding 
affinity, by clustering at the cell surface 
impeding their lateral diffusion in the plasma 
membrane, by relieve of a restraint and by 
induced association with the cytoskeleton. 
Receptor-induced signalling that gives rise to an 
increase in the intrinsic affinity of an integrin 
heterodimer for its ligand is denoted inside-out 
activation. In this situation, the cytoplasmic 
integrin domain may be modified in such a way 
that a conformational change in the extracellular 
integrin domain is brought about. For instance, 
this could be either phosphorylation or 
association with cytoskeletal proteins. However, 
receptor-induced cell adhesion often results 
from increased integrin avidity. Increased 
avidity is the result of multiple simultaneous 
interactions that cooperatively increase the 
binding strength, as is the situation for 
antibodies. Multiple integrin-mediated 
interactions may allow integrin clustering and 
binding of a cell to extracellular matrix 
components or to another cell. However, total 
adhesion strength is limited due to dissociation 
from ligands and lateral diffusion of the 
integrins involved. Immobilising the integrins 
may give rise to stabilisation of these 
interactions. One could think of recruitment of 
the integrins to specialised membrane areas, like 
for instance lipid rafts (27), or anchoring the 
integrins to the cytoskeleton. Several proteins 
have been described that associate with 
cytoplasmic regions in the integrin and 
consequently couple the integrins to the actin 
cytoskeleton (28-31). Once attached to the 
cytoskeleton, additional signals may regulate 
actin polymerisation, actin-myosin contraction, 
or actin-membrane interactions that could 
promote clustering of the integrins thereby 
increasing their avidity. Rho family GTPases 
have been demonstrated to promote linkage of 
the cytoskeleton to integrins by ezrin, radixin, 
moesin (ERM) proteins and in addition mediate 
actin polymerisation and reorganisation of the 
cytoskeleton (32). 
In an attempt to explain how Rap1 
contributes to integrin regulation, some general 
considerations deserve attention since they 
clearly put some restrictions on the 
oppurtunities. For instance, one needs to take 
into account that it is not clear whether 
Rap1GTP brings about changes in integrin 
clustering or integrin affinity. In mouse T cells, 
expression of active Rap1 induced clustering of 
LFA-1 and did not increase affinity of this 
integrin as measured by soluble ligand binding 
(18). In contrast, other studies report affinity 
modulation of LFA-1 by Rap1 in T 
lymphocytes (14), while a combination of both 
affinity and avidity modulation was found in B 
lymphocytes (15). In megakaryocytes, active 
Rap1 did not alter αIIbβ3 affinity, but only 
enhanced the thrombin-induced affinity change 
(24). These findings imply that integrin 
regulation by Rap1 could well be dependent on 
the cell type and the nature of the heterodimer, 
suggesting that it is not one uniform mechanism 
in between Rap1 and the integrins. In that case 
the question remains whether Rap1 couples to 
so many different effector pathways to be able 
to differentially regulate each integrin type. 
Accepting that Rap1 increases the functionality 
of a variety of integrins, a direct mechanism like 
phosphorylation of the integrin or an associated 
protein seems unlikely since a variety of factors 
that induce integrin function require Rap1, but 
do not activate it. For instance, Mn2+-induced 
integrin-mediated adhesion does require Rap1 
but Mn2+ does not induce Rap1 activity (chapter 
3). Furthermore, the presence of Rap1V12 in 
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megakaryocytes hardly or not induced (soluble) 
fibrinogen binding to αIIbβ3 by itself (24) 
(chapter 5). In summary, these findings suggest 
that Rap1GTP is not sufficient to directly 
activate integrins and at least requires the 
involvement of additional factors.  
The results presented in chapter 3 suggest 
that Rap1 determines somehow whether 
integrins can participate in the adhesion process 
or not, which is supported by the finding that 
active Rap1V12 does not alter the affinity of 
αIIbβ3 for fibrinogen by itself, but increases 
thrombin-induced fibrinogen binding in 
megakaryocytes. Most likely, Rap1 facilitates 
integrin function by optimising conditions 
allowing a more active integrin conformation or 
enabling stimuli to induce integrin activation. 
One could think of the recruitment of an 
auxiliary factor involved in proper integrin 
function or fine-tuning of the integrin 
connection with the cytoskeleton. For example, 
Rap1GTP was demonstrated to interact with 
Krit1 (33). This protein was recently reported to 
associate with ICAP-1 (34,35), a protein that 
binds to the cytosolic tail of the β1 integrin 
subunit thereby regulating the function of β1 
integrins (36-38). In case Krit1 is bound to 
ICAP-1, it cannot associate with the integrin 
tail. Rap1GTP may titrate away Krit1 allowing 
ICAP-1 to bind the integrin and facilitate its 
function. Of course this would only explain β1 
integrin regulation, while Rap1 also controls 
additional integrin types that do not interact 
with ICAP-1. With respect to the cytoskeletal 
interactions, Rap1 could disrupt an imposed 
cytoskeletal restraint, allowing other factors to 
induce a more active conformation or allowing 
participation of an increased fraction of the 
integrins expressed at the cell surface in the 
adhesion process. Alternatively, Rap1 might 
contribute to the integrin connection with the 
cytoskeleton in such a way that the affinity 
changes or clustering can be brought about. 
Interestingly, several putative Rap1 effector 
proteins exist based on the presence of a Ras-
associating domain (RA domain) that possess 
additional protein domains which allow 
interaction with either integrins, associated 
adhesion molecules or the cytoskeleton. For 
instance, talin possesses a band 4.1 domain 
containing a predicted hidden RA domain. Talin 
associates with several β integrin cytosolic tails 
coupling them to the cytoskeleton (39,40). 
Moreover, new insights point to a role for Rap1 
in cell polarisation by regulation of the actin 
cytoskeleton. In Dictyostelium discoideum, 
Rap1 has been implicated in regulation of 
cortical actin-based morphological changes by 
membrane ruffling and the formation of 
lamellipodia (41,42). Furthermore, the yeast 
Rap1 orthologue bud1 recruits polarity-
establishment factors (including the small 
GTPase Cdc42, its GEF Cdc24 and the scaffold 
protein Bem1), controlling thye assembly of the 
actin cytoskeleton for bud formation. The GEF 
and GAP required for Bud1 regulation, Bud5 
and Bud2, respectively, also contribute to this 
process (43,44). A role for Rap1 in localised 
actin cytoskeleton regulation underlying cell 
adhesion is further supported by protein 
complex formation between between Rap1 and 
actin-binding protein AF-6/afadin (45). 
Interestingly, AF-6 localises to tight junctions in 
adherens-based adhesion complexes and is 
thought to connect cell surface adhesion 
molecules to the cortical actin cytoskeleton. In 
addition, AF-6 associates with profilin (45), 
which regulates actin polymerisation (46). In 
Drosophila melanogaster, Rap1 was recently 
demonstrated to regulate the proper localisation 
of adherens junctions (47). 
Finally, one should consider the 
intracellular localisation of Rap1. Rap1 is 
membrane-associated and recently stimulus-
induced Rap1 activation was shown to uccur in 
the perinuclear region (48). Localisation in 
membranes other than the plasma membrane 
rules out the opportunity of a direct interaction 
between Rap1 and integrin complexes. In such a 
situation Rap1 could only indirectly facilitate 
integrin activation, for example by modifying 
the plasma membrane lipid composition, cell 
shape, localisation of the integrins in the plasma 
membrane or by regulating the transport of an 
integrin auxiliary factor to the plasma 
membrane. 
In conclusion, although several likely 
possibilities exist to explain the involvement of 
Rap1 in adhesion, the exact mechanisms can 
only be unravelled by the elucidation of the 
Rap1 effector pathways leading to the integrins. 
 
Rap1 in other integrin-mediated cellular 
processes 
New insights with respect to a function of 
Rap1 in the regulation of integrins have paved 
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the way to explore involvement of Rap1 in the 
complete scala of integrin-dependent processes, 
such as morphogenesis, heamotopoiesis, 
migration and tumour invasion. Indeed, Rap1 
functions in agonist-induced, integrin-dependent 
phagocytosis of opsonised particles in 
macrophages (16,49). Interference with Rap1 
activation by overexpression of wild-type (wt) 
or inhibitory Crk and C3G proteins correlates 
with alterations in cellular migratory responses 
to HGF and stromal-cell-derived factor 1 (SDF-
1) (50,51). Genetic analysis in Drosophila 
melanogaster shows a role for Rap1 in both 
morphogenesis and cell migration (52). In 
agreement with these data showing a role for 
Rap1 in migration, overexpressing RapGAP II 
to inhibit Rap1 signalling blocked stromal cell-
derived factor-1 (SDF-1)-induced migration in 
two B cell lines (53). 
 
Rap1 regulating calcium homeostasis 
We have implicated intracellular calcium in 
Rap1-induced adhesion (chapter 3). 
Interestingly, PKA-independent cAMP-induced 
intracellular calcium rise has been described in 
human megakaryocytes (54), suggesting a role 
for the Epac-Rap1 pathway. As described in 
chapter 1, Epac is a RapGEF that is controlled 
by the second messenger cAMP. Furthermore, 
in HEK293 cells a regulating role in the control 
of the intracellular calcium concentration has 
been assigned to Rap2B (55). Moreover, in 
platelets Rap1B associates with the calcium 
transporter SERCA 3B, as described in chapter 
1. Rap1-regulated control of the intracellular 
calcium homeostasis may not only explain why 
active Rap1-induced integrin-mediated adhesion 
is calcium-dependent, but might in addition 
form a possible pathway for the control of Ral 
activity in platelets. As discussed already, Ral 
activation in platelets is Ras-independent, 
requires calcium and correlates with Rap1 
activity. In order to examine a role for the Epac-
Rap1 pathway in the control of intracellular 
calcium in megakaryocyte we made use of a 
synthetic cAMP derivative. This compound was 
recently developed to be able to specifically 
induce Epac-mediated Rap1 signal transduction 
(J.M. Enserink et al., submitted). However, in 
the MEG-01 megakaryoblast cell system we 
have not been able to find evidence in favour of 
cAMP-induced Rap1-mediated intracellular 
calcium elevation (chapter 4). 
Rap1 in mechanical or shear stress-induced 
signalling 
In the blood stream, in addition to several 
agonists, shear or mechanical stress induces a 
variety of biochemical and physical changes in 
cell structure and function. For instance, 
mechanical stress may alter growth and 
differentiation (56-60). Haemodynamic shear 
stress influences regulation of vascular tone and 
diameter, inflammatory responses, haemostasis 
and vessel wall remodelling function (61-64), 
including a time- and position-dependent 
increase in endothelial cell membrane fluidity 
(65) and aligment (60,66,67). Interestingly, 
shear forces have recently been demonstrated to 
promote lymphocyte migration across vascular 
endothelium (68). Circulating lymphocytes need 
to anchor to the luminal side of blood vessels at 
sites of inflammation. In this process, selectins 
play an important role by mediating leukocyte 
tethering and rolling. Subsequent contribution 
of integrins is indispensable for stable cell arrest 
(69). As described in chapter 1, also in platelet 
activation, adhesion and aggregation shear 
stress is considered to play a pivotal role. 
Interestingly, we have found Rap1 activation 
induced by gently mixing MEG-01 human 
megakaryoblast cell suspensions in reaction 
tubes, in the absence of a stimulating agent. 
Surprisingly, we have observed this intriguing 
effect in a variety of additional human 
suspension cells representing different blood 
cell types, like monocytes, B and T 
lymphocytes (chapter 5). We have not been able 
to get a clue about the mechanism generating 
this sensitivity of Rap1 towards mixing, as 
commonly used inhibitors that affect Rap1 
activation in other systems, like PKC and PLC 
inhibitors or calcium chelators (2,5,9,70,71), did 
not affect mixing-induced Rap1 activation. 
However, additional signal transduction events 
are induced as the consequence of mixing 
(chapter 5). Among these, we have identified 
phosphorylation of the ribosomal protein S6, 
which is sensitive to wortmannin and 
rapamycin, suggesting involvement of PI(3)K 
and mTOR pathways. As fluid shear stress has 
been reported to account for p70 S6 kinase 
activation in a PI(3)K-dependent manner 
(72,73), we propose that the mixing-induced 
activation of Rap1 and other signaling proteins 
measured takes place as the result of mechanical 
or shear stress. 
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The consequence of the mixing-induced Rap1 
activation is not only that Rap1GTP elevation in 
these cell types upon different stimuli is easily 
disturbed my gently mixing and therefore 
stimulus-induced Rap1 activation is difficult to 
measure. In addition, it may implicate Rap1 in 
physiological processes regulated by shear or 
mechanical stress. As mentioned already, shear 
plays a role in lymphocyte transendothelial 
migration. It is tempting to speculate on the 
involvement of active Rap1 in this integrin-
mediated process. After initial interaction of 
lymphocytes with the vessel wall, they 
experience shear or mechanical stress from the 
blood flow. As a consequence Rap1 might be 
activated facilitating integrin activation and 
stable arrest at the endothelium. Additional 
shear-induced signalling may regulate cell 
spreading, migration or control of transcription 
and translation in order to prepare the 
lymphocyte for its functions after extravasation 
has occurred. In part, Rap1 could contribute to 
such processes. Several model systems exist to 
explore cellular effects induced by shear or 
mechanical stress in a controlled and 
quantitative fashion, which may be fruitful 
implementing in further research on this 
phenomenon. 
The mixing-induced Rap1 activation 
measured in different human blood cell types 
was under similar experimental settings not 
observed in blood platelets. One explanation 
may be that platelets are only activated at high 
shear stress levels (74,75). High shear stress-
induced activation of the GP Ib-IX-V complex 
triggers activation of platelet integrin αIIbβ3 by 
signalling in which intracellular calcium, PI(3)K 
and Rho have been implicated. As described in 
chapter 1, this integrin fulfils an essential 
function in platelet adhesion and aggregation. 
Upon treatment of platelets with certain 
agonists, a rise in intracellular calcium is 
required and sufficient to induce elevation of 
Rap1GTP (2). It is not unlikely that shear-
induced activation of GP Ib-IX-V induces 
Rap1GTP accumulation that in turn contributes 
to the control of αIIbβ3. In order to examine this 
exciting possibility, it will be of great 
importance to study Rap1 activation in platelets 
in an established, quantitative shear stress 
system. 
 
 
Concluding remarks 
 
The small GTPases Rap1 and Ral are both 
rapidly activated in a diversity of cell types 
upon a variety of stimuli, including platelets, 
which clearly demonstrates a role for these 
proteins in signal transduction. The 
characterisation of a novel Ras-independent 
pathway contributing to the control of Ral 
activity presented in this thesis forms further 
evidence for Ral functions independent of Ras 
effects. Several recent findings have implicated 
Ral in the control of the actin cytoskeleton and 
vesicular transport. Other studies described in 
this thesis contribute to understanding the Rap1 
function in the regulation of integrin-mediated 
cell adhesion in general. With respect to 
platelets, the studies link Rap1 to the control of 
platelet integrin αIIbβ3. This implies Rap1 is 
connected with one of the most elementary 
processes that occur during platelet activation 
that underlies platelet adhesion and aggregation. 
In addition, the results implicate Rap1 in 
mechanical or fluid shear stress-induced 
signalling in different blood cell types. Whether 
Rap1 plays a role in shear stress-induced 
platelet activation requires further examination. 
In conclusion, signal transduction by the Ras 
family members Rap1 and Ral is clearly 
involved in platelet physiology. How these 
GTPases fulfil their functions in platelets needs 
further exploration to enlarge the understanding 
about platelet diseases like bleeding disorders 
and thrombosis. 
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Samenvatting 
 
 
Achtergrond 
 
Een cel is de kleinste eenheid van leven. Het 
menselijk lichaam is opgebouwd uit miljarden 
cellen. Georganiseerd in complexen geven ze 
vorm aan weefsels en organen. Voor het goed 
functioneren daarvan is communicatie tussen 
deze cellen essentieel. Ze beïnvloeden elkaars 
gedrag door het uitzenden van signaalstoffen, 
bijvoorbeeld hormonen of groeifactoren. Via de 
bloedbaan kan een dergelijke boodschap terecht 
komen bij cellen die met behulp van een 
specifieke receptor het signaal ontvangen. Het 
receptor eiwit geeft het bericht door aan een 
volgend eiwitmolecule in de cel. Dit kan 
vervolgens op zijn beurt de boodschap weer 
doorgeven aan andere eiwitten, waardoor een 
hele cascade van eiwitten ontstaat die het 
opgevangen signaal overdragen. Uiteindelijk 
worden eiwitten bereikt die direct 
verantwoordelijk zijn voor het sturen van 
cellulaire processen die ten grondslag liggen aan 
de groei, deling, differentiatie of dood van de 
cel. Een cel kan meerdere signalen tegelijkertijd 
ontvangen en beschikt over een netwerk van 
eiwitten om deze te verwerken, integreren en 
vertalen in de juiste aanpassing in het gedrag. 
Het geheel van biochemische reacties dat 
optreedt in de cel als gevolg van het ontvangen 
van een boodschap wordt signaaltransductie 
genoemd. Functioneert een bepaald eiwit uit 
zon netwerk niet naar behoren, dan kan dit 
afwijkende reacties veroorzaken en leiden tot 
ziektes. 
 
Leden van de Ras-achtige kleine GTPase 
eiwitfamilie spelen een belangrijke rol in de 
signaaltransductie. Ze werken als een soort 
moleculaire schakelaar. Het ontvangen van een 
signaalstof kan via een signaaltransductie 
cascade een Ras eiwit tijdelijk actief maken 
waardoor diverse processen in de cel in werking 
treden. Deze eiwitfamilie is vernoemd naar het 
Ras eiwit, dat als eerste werd ontdekt. Ras kreeg 
bekendheid toen gevonden werd dat kleine 
mutaties in de genetische informatie (het gen) 
die codeert voor dit eiwit tot gevolg hebben dat 
het Ras eiwit voortdurend actief is. Dit kan 
resulteren in het ontstaan van kanker 
(ongecontroleerde celdeling). 
De Ras familieleden Rap1 en Ral worden 
onder andere aangeschakeld in bloedplaatjes op 
het moment dat die een signaal krijgen om hun 
functie te vervullen. Dit suggereert dat Rap1 en 
Ral deelnemen aan de signaaltransductie die de 
daarvoor benodigde processen stuurt. 
Bloedplaatjes komen in grote getale voor in de 
bloedbaan. Ontstaat er ergens in het lichaam een 
beschadiging aan een bloedvat, dan komen er 
signaalmoleculen vrij die ter plaatse aanwezige 
bloedplaatjes activeren. De signaaltransductie in 
die plaatjes heeft als gevolg dat ze van vorm 
veranderen en aan elkaar gaan plakken (adhesie) 
door het actief maken van plakmoleculen 
(integrines) op hun oppervlak. Dit resulteert in 
de vorming van een bloedstolsel en het stelpen 
van de bloeding. Plaatjesactivatie mag alleen 
plaatsvinden als er een wond is. Onder de 
verkeerde omstandigheden kan het leiden tot de 
vorming van een bloedstolsel in een bloedvat 
met in sommige gevallen een infarct als gevolg. 
Kennis en inzicht met betrekking tot de 
signaaltransductie is dus vereist om het 
functioneren van bloedplaatjes (en cellen in het 
algemeen) onder gezonde en zieke 
omstandigheden te begrijpen. De vraagstelling 
voor het hier beschreven promotie-onderzoek 
was op welke manier Ras-achtige kleine 
GTPasen betrokken zijn in signaaloverdracht 
zoals die in bloedplaatjes plaatsvindt. Een 
bloedplaatje heeft echter eigenschappen 
waardoor het voor bepaalde onderzoeksstappen 
niet bruikbaar is. Om die reden zijn diverse 
deelprocessen bestudeerd in andere doch 
relevante celsystemen. 
 
 
Samenvatting 
 
In het eerste hoofdstuk worden de Ras 
eiwitten en hun rol in de signaaltransductie 
belicht. Daarbij gaat de aandacht in het 
bijzonder uit naar hun gedrag in bloedplaatjes 
en de consequenties daarvan voor de 
plaatjesfysiologie. 
Voor het onderzoek beschreven in het 
tweede hoofdstuk heeft het activatie-
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mechanisme van Ral in bloedplaatjes centraal 
gestaan. Uit voorafgaand onderzoek was 
gebleken dat dit niet Ras- maar calcium-
afhankelijk verloopt. Een poging deze calcium-
gestuurde signaleringsroute naar Ral nader te 
definiëren heeft geleid tot de ontdekking van 
een nieuwe Ras-onafhankelijke Ral activator die 
RalGEF2 genoemd is. Dit eiwit bezit een PH 
domein dat zowel een rol speelt in de 
membraanlocalisatie van RalGEF2 als het 
vermogen om Ral te activeren. 
Naast Ral is ook Rap1 een Ras-achtig eiwit 
dat deelneemt aan het activatieproces in 
bloedplaatjes. Hoofdstuk drie biedt nieuw 
inzicht in de functie van Rap1 met betrekking 
tot integrine-gemediëerde celadhesie. Rap1 
activiteit blijkt een voorwaarde te zijn voor dit 
proces wanneer het door divalente cationen of 
integrine-activerende antilichamen aan de 
buitenkant van de cel geïnduceerd wordt. 
Voorheen werd gedacht dat het op deze 
manieren aanzetten tot adhesie onafhankelijk 
was van de situatie in de cel. Het merkwaardige 
is dat behandeling van de cellen met deze 
agentia op zichzelf geen Rap1 activatie tot 
gevolg heeft. Rap1 activatie immers is reeds 
voldoende om integrine-gemediëerde celadhesie 
te bewerkstelligen. Wellicht vervult Rap1 een 
faciliterende taak in deze vorm van integrine-
activatie. 
In hoofdstuk vier wordt de mogelijke rol 
van Rap1 in cAMP-geïnduceerde PKA-
onafhankelijke verhoging van de intracellulaire 
calciumconcentatie onderzocht in humane 
megakaryocyten. Ook in bloedplaatjes is Rap1 
in verband gebracht met de regulatie van de 
intracellulaire calcium homeostase. Met behulp 
van een cAMP analoog die selectief aangrijpt 
op een activatieroute naar het endogeen Rap1 is 
echter vooralsnog geen aanwijzing gevonden 
voor de betrokkenheid van Rap1 in dat proces in 
de megakaryocyten. 
De experimenten in hoofdstuk vijf tonen 
Rap1 activatie aan in diverse bloedcellijnen als 
gevolg van shear stress. Dit effect is gemeten in 
cellijnen die representatief zijn voor T en B 
lymphocyten, megakaryocyten en monocyten. 
Bovendien blijkt Rap1 activiteit nodig te zijn 
voor integrine αIIbβ3-gemediëerde adhesie van 
humane megakaryocyten. Deze bevindingen 
suggereren allereerst een mogelijk verband 
tussen shear stress, Rap1 en de regulatie van 
integrines. Daarnaast koppelen ze Rap1 aan de 
regulatie van het belangrijkste plaatjes-
integrine. De juiste controle over de activiteit 
van integrine αIIbβ3 is onontbeerlijk voor het 
correct functioneren van bloedplaatjes. Daarmee 
is een mogelijke connectie gelegd tussen Rap1 
en een van de meest elementaire processsen van 
de plaatjesactivatie. 
Doel van dit onderzoek is geweest om een 
stap verder te komen in het begrijpen van de rol 
van Ras GTPases in het proces van 
plaatjesactivatie. Kennis en inzicht omtrent de 
signaaltransductieroutes die ten grondslag 
liggen aan de plaatjesregulatie kan leiden tot 
een beter begrip van afwijkend gedrag van 
bloedplaatjes zoals dat optreedt bij ziektes als 
thrombose en atherosclerose. Mogelijkerwijs 
zouden deze moleculaire reacties in zulke 
gevallen bijgesteld kunnen worden middels 
medicinale interventie. 
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